Compound and its use as a CD38 inhibitor
Novel CD38 inhibitor compounds with specific structural modifications address drug-drug interactions and enhance pharmacokinetic properties, improving efficacy in treating CD38-mediated diseases.
Patent Information
- Application Number
- KR1020237040645
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-31
- Filing Date
- 2022-04-28
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2042-04-28
AI Technical Summary
Existing CD38 inhibitors face challenges with drug-drug interactions and suboptimal pharmacokinetic characteristics, limiting their effectiveness in treating CD38-mediated diseases.
Development of novel compounds with specific structural modifications, such as replacing cycloalkyl groups with phenyl groups having one or two carbon atoms replaced by N, enhancing solubility, stability, and reducing drug-drug interactions, thereby improving inhibitory activity and pharmacokinetic properties.
The modified compounds exhibit improved inhibitory activity, longer half-life, higher in vivo exposure, slower metabolism, and better stability, demonstrating superior tolerability in animal studies.
Smart Images

Figure 112023131685834-PCT00628_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a novel compound; a method for producing the compound of the present invention; a pharmaceutical composition comprising the compound of the present invention; and a use and method for treating CD38-mediated diseases by administering the compound of the present invention. In particular, the compound of the present invention can be used as a CD38 inhibitor. Background Technology
[0002] CD38 is a protein composed of 300 amino acids encoded by homologous genes located on chromosomes 4 and 5 in humans and mice, respectively. Within cells, CD38 is generally found to be located on the cell surface, but it can also be detected in intracellular compartments (e.g., endoplasmic reticulum, nuclear membrane, and mitochondria). Structurally, CD38 is a single-stranded glycoprotein with a single transmembrane segment and can function as a type II or type III membrane protein topologically depending on its membrane orientation. In the most common type II orientation, the short amino tail of CD38 faces the cytoplasmic solution, while the catalytic domain of CD38 faces the extracellular environment. A type III orientation, in which the catalytic domain faces the cytoplasmic solution, has also been reported. Given that the enzymatic substrates and products of CD38 are consumed and produced in extracellular or intracellular compartments, these two orientations have functional significance.
[0003] CD38 is nicotinamide adenine dinucleotide (NAD + It catalyzes the synthesis of nicotinamide (NAM) and ADPR using ) as a substrate. NAD + (An essential cofactor regulating energy metabolism) can be converted to cADPR along with the release of NAM. Interestingly, CD38 can also hydrolyze cADPR to ADP-ribose. Therefore, CD38 possesses the enzymatic activities of both ADP-ribosyl cyclase and cADPR hydrolase. Both ADPR and cADPR contain calcium (Ca 2+It acts as a second messenger that controls various cellular functions through mobilization. In addition to its enzymatic function, CD38 may also act as a receptor for CD31. Through the latter interaction, CD38 can act as an adhesion molecule that mediates selectin-like binding between hematopoietic cells and endothelial cells and promotes their migration into tissues.
[0004] CD38 is a ubiquitous protein expressed in various tissues. Expression in non-hematopoietic tissues in both mice and humans includes prostate epithelial cells, pancreatic insular glial cells, smooth muscle cells, retinal tubes, kidneys, intestines, and the brain. However, CD38 is most highly expressed in hematopoietic tissues (e.g., bone marrow and lymph nodes). Within immune cells, CD38 is highly expressed in B cells, macrophages, dendritic cells (DCs), innate lymphocytes (ILCs), natural killer (NK) cells, T cells, neutrophils, and monocytes. However, as observed in transcriptional comparisons between species, CD38 expression levels among these populations may differ between humans and mice.
[0005] Surface markers and the multifunctional enzyme CD38 appear to provide a link between inflammation and age- and disease-related decline in tissue homeostasis, representing important targets for therapeutic interventions. CD38 is expressed primarily in immune cells in response to stimulation by cytokines, endotoxins, and interferons. The expression of the enzyme is regulated by a promoter region containing binding sites for NF-kB, RXR, LXR, and STAT, suggesting that the enzyme plays a crucial role in inflammatory responses. CD38 expression is related to cellular NAD + It significantly reduces levels, altering the availability of substrates for enzymes that regulate cellular homeostasis. Therefore, during infection, aging, or tumorigenesis, the infiltration of CD38-expressing immune cells leads to NAD in the parenchymal tissue or tumor microenvironment. + It has the potential to alter homeostasis; interferes with normal metabolic processes; and impairs tissue integrity.
[0006] The critical role of CD38 in various diseases (including neurodegeneration, neuroinflammation, cancer development, and autoimmune diseases) suggests that targeted inhibition of CD38 is a potential therapeutic approach for treating neurodegenerative diseases, cancer, autoimmune diseases, and other inflammatory diseases. One of the most important strategies targeting CD38 is to develop small molecule inhibitors of CD38 that have demonstrated promising preclinical efficacy.
[0007] The present invention provides novel compounds as CD38 inhibitors. The inventors of the present invention have discovered that some of the compounds disclosed herein (wherein the cycloalkyl (e.g., cyclohexyl) as A3 is replaced with a phenyl having one or two carbon atoms optionally replaced by N (e.g., phenyl, pyridinyl, or pyrimidinyl)) exhibit improved inhibitory activity and improved CYP inhibition, which indicates reduced drug-drug interactions (DDI). As mentioned above, because C in the phenyl as A3 is replaced by N, the obtained compounds exhibit better solubility and better pharmacokinetic (PK) characteristics (including longer half-life, higher in vivo exposure, and slower in vivo metabolism), and these compounds exhibit a superior stability window, as demonstrated by excellent tolerability in animal studies.
[0008] In one embodiment, the present invention provides a compound represented by Formula I or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, and
[0009]
[0010] Formula I
[0011] In the above equation I,
[0012] Al is a halogen; or comprises 1 to 3 heteroatoms selected from N, O, and S, and 1 or 2 C optionally substituted by 1, 2, or 3 halogens. 1-6It is a pentagonal or hexavalent unsaturated monocyclic heterocyclic ring optionally substituted by an alkyl group;
[0013] A2 is ; ; or optionally having one or two carbon atoms replaced by nitrogen is;
[0014] Here, A2 is zero or one -OH; -CN; halogen; C optionally substituted by one, two, or three halogens. 1-6 Alkyl; C 2-6 Alkynyl; C 1-6 Alkoxy; C 3-6 Optionally substituted by a cycloalkoxy, wherein the cycloalkyl group is one carbon atom replaced by O or S; optionally having -NR1R2, wherein R1 and R2 are each independently H, C 1-6 Alkyl, -C(O)C 1-6 Alkyl; and, here It contains 1 to 3 heteroatoms selected from N, O, and S and 1 to 2 C 1-6 It is a 5- or 6-membered saturated or unsaturated heterocyclic ring optionally substituted by an alkyl group;
[0015] A3 is ; C 1-6 Alkyl; -(CHR3) n -C 3-8 Selected from cycloalkyl, where C 3-8 Cycloalkyl groups optionally have one or two carbon atoms replaced by N, O, or S, where n is 0, 1, or 2, and R3 is H or C 1-6 alkyl; or and, where phenyl has one or two carbon atoms replaced by N, k is 0, 1, or 2;
[0016] Here, A3 is -OH; -CN; -OCH2CH2OCH3; -CO-C 1-6 Alkyl; halogen; C optionally substituted by 1-3 halogens, methoxy, or hydroxyl groups1-6 Alkyl; C optionally substituted by NH2, dimethylamino, hydroxy, or carboxy. 1-6 Alkoxy; C 3-6 Cycloalkoxy; or C 3-8 Optionally substituted by zero, one, or two substituents independently selected from cycloalkyl, wherein C 3-8 Cycloalkyls optionally have one or two carbon atoms replaced by N, O, or S, and 1 to 3 halogens, C 1-6 Alkyl, C 1-6 Optionally substituted by an alkyl or hydroxyl group;
[0017] R is H or C 1-6 It is an alkyl.
[0018] In some embodiments, the present invention provides a compound represented by Formula I or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, and
[0019]
[0020] In the above equation I,
[0021] Al is a halogen; or comprises 1 to 3 heteroatoms selected from N, O, and S, and 1 or 2 C optionally substituted by 1, 2, or 3 halogens. 1-6 It is a pentagonal or hexavalent unsaturated monocyclic heterocyclic ring optionally substituted by an alkyl group;
[0022] A2 is ; ; having one or two carbon atoms arbitrarily replaced by nitrogen ; or And, where m is 0 or 1, and if m is 1 and the bond between Y1 and Y2 is a single bond, Y1 and Y3 are each independently CH2, O, S, or NH, and Y2 is C, and if m is 0 and the bond between Y1 and Y2 is a double bond, Y1 and Y2 are each independently CH or N, and Y3 is CH2, O, S, or NH, and if m is 0 and the bond between Y1 and Y2 is a single bond, Y1, Y2, and Y3 are each independently CH2, O, S, or NH;
[0023] Here, A2 is zero or one -OH; -CN; halogen; C optionally substituted by one, two, or three halogens. 1-6 Alkyl; C 2-6 Alkynyl; C 1-6 Alkoxy; C 3-6 Optionally substituted by a cycloalkoxy, wherein the cycloalkyl group is one carbon atom replaced by O or S; optionally having -NR1R2, wherein R1 and R2 are each independently H, C 1-6 Alkyl, -C(O)C 1-6 Alkyl; and, here It contains 1 to 3 heteroatoms selected from N, O, and S and 1 to 2 C 1-6 It is a 5- or 6-membered saturated or unsaturated heterocyclic ring optionally substituted by an alkyl group;
[0024] A3 is ; C 1-6 Alkyl; -(CHR3) n -C 3-8 Selected from cycloalkyl, where C 3-8 Cycloalkyl groups optionally have one or two carbon atoms replaced by N, O, or S, where n is 0, 1, or 2, and R3 is H or C 1-6 alkyl; or and, where phenyl has one carbon atom replaced by N, k is 0, 1, or 2;
[0025] Here, A3 is -OH; -CN; -OCH2CH2OCH3; -CO-C 1-6 Alkyl; halogen; C optionally substituted by 1-3 halogens 1-6 Alkyl; C 1-6 Alkoxy; C 3-6 Optionally substituted by zero, one, or two substituents independently selected from cycloalkoxy;
[0026] R is H or C 1-6 It is an alkyl.
[0027] In some embodiments, the compound is not any of the following:
[0028] 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide;
[0029] N-cyclohexyl-6-(1H-imidazole-1-yl)picolinamide;
[0030] 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide;
[0031] 6-(1H-imidazole-1-yl)-N-phenylpicolineamide;
[0032] 3-(1H-imidazole-1-yl)-N-(2-methoxycyclohexyl)benzamide;
[0033] 3-(1H-imidazole-1-yl)-N-(thiazole-4-yl)benzamide;
[0034] N-cyclohexyl-3-(thiazole-2-yl)benzamide;
[0035] N-(3,5-dimethylphenyl)-2-(1H-imidazole-1-yl)-N-methylisonicotinamide;
[0036] 5-chloro-N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide;
[0037] 5-chloro-N-(2-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide;
[0038] 5-Bromo-N-(4-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide;
[0039] 5-chloro-N-(2-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide;
[0040] 5-chloro-2-(1H-imidazole-1-yl)-N-phenylpyrimidine-4-carboxamide;
[0041] 5-chloro-2-(1H-imidazole-1-yl)-Np-tolylpyrimidine-4-carboxamide;
[0042] 5-bromo-2-(1H-imidazole-1-yl)-N-(3-(trifluoromethyl)phenyl)pyrimidine-4-carboxamide; or
[0043] 6-(1H-imidazole-1-yl)-N-(4-(trifluoromethyl)phenyl)picolinamide.
[0044] In some embodiments, A2 is ; ; ; ; ; ; ; or Selected from;
[0045] Here, A2 is 0 or 1 -OH, -CN, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, isopropoxy, cyclobutoxy, oxetane-3-yloxy, ethinyl, -NH2, -NHCH3, -N(CH3)2, -NHC(O)CH3, , , , , , , It is arbitrarily substituted by.
[0046] In some preferred embodiments, A1 is Cl; ; ; ; ; ; ; ; ; ; ; ; or And; if not Cl, A1 is optionally substituted by one or two methyl or trifluoromethyl groups.
[0047] In some embodiments, A3 is a phenyl having one or two carbon atoms replaced by N. In some embodiments, A3 is a phenyl having one carbon atom replaced by N. In some embodiments, A3 is a phenyl having two carbon atoms replaced by N.
[0048] In some more preferred embodiments, A3 is ; -CH(CH3)2; -C(CH3)3; ; ; ; ; ; ; ; ; ; ; ; ; ; ; or Selected from; where A3 is optionally substituted by zero, one, or two substituents independently selected from -OH, -CN, -OCH2CH2OCH3, 2-methoxypropane-2-yl, 2-hydroxypropane-2-yl, 2-(dimethylamino)ethoxy, -COCH3, -F, -Cl, methyl, trifluoromethyl, methoxy, isopropoxy, cyclopropoxy, piperazine-1-yl, morpholino, or 3-hydroxypyrrolidin-1-yl.
[0049] In some more preferred embodiments, A3 is ; -CH(CH3)2; -C(CH3)3; ; ; ; ; ; ; ; ; ; ; ; ; or Selected from;
[0050] Here, A3 is optionally substituted with zero, one, or two substituents independently selected from -OH, -CN, -OCH2CH2OCH3, -COCH3, -F, -Cl, methyl, trifluoromethyl, methoxy, isopropoxy, cyclopropoxy, hydroxyethoxy, or carboxymethoxy.
[0051] In one embodiment, A2 is ; ; ; or Selected from.
[0052] In a preferred embodiment, A2 is zero or one -CN, methyl, isopropyl, trifluoromethyl, methoxy, cyclobutoxy, oxetane-3-yloxy, -NH2, -NHCH3, -N(CH3)2, , or Arbitrarily substituted by;
[0053] A1 is ; ; ; ; ; ; ; ; or and; A1 is optionally substituted by one or two methyl or trifluoromethyl groups;
[0054] A3 is optionally substituted by zero, one, or two substituents independently selected from -CN, -OCH2CH2OCH3, -COCH3, -F, -Cl, methyl, trifluoromethyl, or methoxy;
[0055] R is H or methyl.
[0056] In another embodiment, A2 is ; ; or Selected from; A2 is 0 or 1 -OH, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, ethinyl, -NH2, , or It is arbitrarily substituted by;
[0057] A1 is ; or and; A1 is optionally substituted by one or two trifluoromethyl groups;
[0058] A3 is ; or and; A3 is optionally substituted by 0, 1, or 2 -F, methyl, or methoxy groups;
[0059] R is H.
[0060] In another embodiment, A2 is and; A2 is optionally substituted by 0 or 1 -F, -NH2 or -NHC(O)CH3;
[0061] A1 is ; or and; A1 is not substituted;
[0062] A3 is and; A3 is arbitrarily substituted by 0, 1, or 2 methoxy groups;
[0063] R is H.
[0064] In an alternative embodiment, A2 is ; ; ; ; ; ; ; or Selected from; A2 is not substituted.
[0065] In one embodiment, A2 is and is not substituted; A3 is and, where k is 0, 1 or 2, preferably k is 0 and the phenyl is -OH; -CN; -OCH2CH2OCH3; -CO-C1-6 Alkyl; halogen; C optionally substituted by 1-3 halogens, methoxy, or hydroxyl groups 1-6 Alkyl; C optionally substituted by NH2 or dimethylamino 1-6 Alkoxy; C 3-6 Cycloalkoxy; or C 3-8 It is substituted by zero, one, or two substituents independently selected from cycloalkyl, wherein C 3-8 Cycloalkyls optionally have one or two carbon atoms replaced by N, O, or S, and 1 to 3 halogens, C 1-6 Alkyl, C 1-6 It is optionally substituted by an alkyl or hydroxyl group.
[0066] In one embodiment, A2 is is optionally substituted by zero or one -CN, methyl, isopropyl, trifluoromethyl, methoxy, cyclobutoxy, oxetane-3-yloxy, -NH2, -NHCH3, -N(CH3)2; preferably substituted by trifluoromethyl; A3 is a phenyl having one or two carbon atoms replaced by N, and preferably A3 is ; ; ; ; or Each of these is optionally substituted by zero, one, or two substituents selected from -CN, -OCH2CH2OCH3, -COCH3, -F, -Cl, methyl, trifluoromethyl, hydroxyethoxy, carboxymethoxy, hydroxy, or methoxy, and preferably substituted by -OCH2CH2OCH3, hydroxyethoxy, carboxymethoxy, hydroxy, or methoxy.
[0067] In one embodiment, R is H.
[0068] In a preferred embodiment, A1 is ; ; ; or And; A1 is not substituted.
[0069] In a more preferred embodiment, A3 is And; A3 is arbitrarily substituted by 0, 1, or 2 methoxy groups.
[0070] In an alternative embodiment, the compound is selected from the following.
[0071] 14,6-di(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 26-chloro-4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 34-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-oxo-1,6-dihydropyridine-2-carboxamide 46-(1H-imidazole-1-yl)-4-methoxy-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 54-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 62-acetamido-N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)benzamide 72-amino-N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)benzamide 82-fluoro-N-((1r,4r)-4-methoxycyclohexyl)-3-(thiazole-5-yl)benzamide 9N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)pyrazine-2-carboxamide 103-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide 116-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 12N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)picolinamide 13N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-pyrazol-5-yl)pyrazine-2-carboxamide 14N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-pyrazol-4-yl)pyrazine-2-carboxamide 156-(isoxazole-4-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 16N-((1r,4r)-4-methoxycyclohexyl)-6-(pyridine-4-yl)pyrazine-2-carboxamide 176-(isoxazol-5-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 18N-((1r,4r)-4-methoxycyclohexyl)-6-(4H-1,2,4-triazole-4-yl)pyrazine-2-carboxamide 19N-((1r,4r)-4-methoxycyclohexyl)-6-(1,3,4-oxadiazole-2-yl)pyrazine-2-carboxamide 205-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 212-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 226-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-(methylamino)pyrimidine-4-carboxamide 236-(dimethylamino)-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 242-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(methylamino)pyrimidine-4-carboxamide 256-amino-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 262-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 273-amino-N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)pyrazine-2-carboxamide 285-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-3-carboxamide 29N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)-1H-indole-7-carboxamide 30N-Cyclohexyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 316-(1H-imidazole-1-yl)-N-isopropylpyrazine-2-carboxamide 326-(1H-imidazole-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide 336-(1H-imidazole-1-yl)-N-(piperidin-4-yl)pyrazine-2-carboxamide 34N-(tert-butyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 356-(1H-imidazole-1-yl)-N-phenylpyrazine-2-carboxamide 366-(1H-imidazole-1-yl)-N-(1-methylpiperidine-4-yl)pyrazine-2-carboxamide 37N-(cyclohexylmethyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 38N-Benzyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 39N-(1-cyclohexylethyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 40N-(1-acetylpiperidine-4-yl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 413-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 423-amino-N-cyclohexyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 435-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-indole-7-carboxamide 446-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxamide 456-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-oxo-2,3-dihydrobenzo[d]oxazole-4-carboxamide 463-(dimethylamino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 476-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-3-(methylamino)pyrazine-2-carboxamide 486-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 49N-Cyclohexyl-6-(1H-imidazole-1-yl)picolinamide 504-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-methylpicolinamide 514-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 526-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-4-methylpicolinamide 536-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-4-(trifluoromethyl)picolinamide 54N-((1r,4r)-4-methoxycyclohexyl)-5-(1H-1,2,3-triazole-1-yl)-1H-indole-7-carboxamide 55N-((1r,4r)-4-methoxycyclohexyl)-5-(2H-1,2,3-triazole-2-yl)-1H-indole-7-carboxamide 565-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-benzo[d]imidazole-7-carboxamide 575-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-indazole-7-carboxamide 585-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 592-amino-5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 603-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 613-amino-N-cyclohexyl-6-(1H-imidazole-1-yl)picolinamide 622-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)isonicotinamide 634-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 646-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 65N-Cyclooctyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 662-(1H-imidazole-1-yl)-N-(pyridin-3-yl)pyrimidine-4-carboxamide 673-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 682-hydroxy-5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 695-amino-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)isonicotinamide 70N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-1,2,4-triazole-1-yl)pyrazine-2-carboxamide 713-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 72N-Cyclohexyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 734-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-2-carboxamide 746-(1H-imidazole-1-yl)-5-methoxy-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 753-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 766-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-methylpicolinamide 775-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 78N-Cyclohexyl-6-(4-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 79N-Cyclohexyl-6-(5-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 80N-Cyclohexyl-6-(2-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 816-(1H-imidazole-1-yl)-N-phenylpicolineamide 822-(1H-imidazole-1-yl)-N-phenylpyrimidine-4-carboxamide 832-(1H-imidazole-1-yl)-N-(o-tolyl)pyrimidine-4-carboxamide 84N-(2-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 85N-(2-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 862-(1H-imidazole-1-yl)-N-(2-methoxyphenyl)pyrimidine-4-carboxamide 872-(1H-imidazole-1-yl)-N-(p-tolyl)pyrimidine-4-carboxamide 88N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 89N-(4-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 902-(1H-imidazole-1-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine-4-carboxamide 91N-(4-cyanophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 922-(1H-imidazole-1-yl)-N-(m-tolyl)pyrimidine-4-carboxamide 93N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 94N-(3-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 952-(1H-imidazole-1-yl)-N-(thiazole-5-yl)pyrimidine-4-carboxamide 96N-Cyclopentyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 97N-Cycloheptyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 982-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 992-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-methylpyrimidine-4-carboxamide 100N-((1r,4r)-4-methoxycyclohexyl)-2-(1H-pyrazole-1-yl)pyrimidine-4-carboxamide 101N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 102N-(3-fluorophenyl)-2-(1H-pyrazole-1-yl)pyrimidine-4-carboxamide 1032-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1046-Cyclobutoxy-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 1052-(1H-imidazole-1-yl)-6-methoxy-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 1066-cyano-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 1072-(1H-imidazole-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)pyrimidine-4-carboxamide 108N-(4,4-dimethylcyclohexyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 1092-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)pyrimidine-4-carboxamide 110N-(4,4-difluorocyclohexyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 1112-(1H-imidazole-1-yl)-N-(pyridin-4-yl)pyrimidin-4-carboxamide 1122-(1H-imidazole-1-yl)-N-(pyridin-2-yl)pyrimidin-4-carboxamide 1132-(1H-imidazole-1-yl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidine-4-carboxamide 114N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-morpholinopyrimidine-4-carboxamide 115N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-5-(piperidin-1-yl)pyrimidine-4-carboxamide 116N-(3-fluorophenyl)-2-(1H-pyrazole-5-yl)pyrimidine-4-carboxamide 117N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-N-methyl-6-(piperidine-1-yl)pyrimidine-4-carboxamide 118N-(2,6-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 119N-Benzyl-2-(1H-imidazole-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxamide 120N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(pyrrolidin-1-yl)pyrimidine-4-carboxamide 1216-Cyclobutoxy-N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 122N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(oxetane-3-yloxy)pyrimidine-4-carboxamide 123N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 124N-(3-chlorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 125N-(3,4-difluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 126N-(3,5-difluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 127N-(4-chloro-3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 1284-(4,4-dimethylpiperidine-1-yl)-N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)picolinamide 129N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-4-(piperidin-1-yl)picolinamide 130N-Cyclohexyl-6-(1H-imidazole-1-yl)-4-(piperidine-1-yl)picolinamide 131N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-4-isopropylpicolinamide 132N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-isopropylpyrimidine-4-carboxamide 133N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-4-(trifluoromethyl)picolinamide 134N-(3,4-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 135N-(2,5-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 136N-(2-chloro-5-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxamide 137N-(5-fluoro-2-methylphenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 138N-(4,4-dimethylcyclohexyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1392-(1H-imidazole-1-yl)-N-(1-methylcyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 140N-Cyclohexyl-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 141N-(tert-butyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 142N-(4,4-dimethylcyclohexyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 1432-(1H-imidazole-1-yl)-N-(1-methylcyclohexyl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 144N-Cyclohexyl-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 145N-(tert-butyl)-2-(1H-imidazole-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxamide 1462-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1472-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 1482-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-morpholinopyrimidine-4-carboxamide 1496-Cyclobutoxy-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)pyrimidine-4-carboxamide 1502-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-(oxetane-3-yloxy)pyrimidine-4-carboxamide 1516-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-3-(trifluoromethyl)picolinamide 1526-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-(trifluoromethyl)picolinamide 153N-((1r,4r)-4-methoxycyclohexyl)-2-(4-(trifluoromethyl)-1H-imidazole-1-yl)pyrimidine-4-carboxamide 154N-((1r,4r)-4-methoxycyclohexyl)-2-(2-(trifluoromethyl)-1H-imidazole-1-yl)pyrimidine-4-carboxamide 155N-((1r,4r)-4-methoxycyclohexyl)-6-(4-(trifluoromethyl)-1H-imidazole-1-yl)picolinamide 156N-((1r,4r)-4-methoxycyclohexyl)-6-(2-(trifluoromethyl)-1H-imidazole-1-yl)picolinamide 1572-(1H-imidazole-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1586-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-4-(trifluoromethyl)picolinamide 159N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-3-(trifluoromethyl)picolinamide 160N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-5-(trifluoromethyl)picolinamide 1612-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-(trifluoromethyl)pyrimidine-4-carboxamide 1622-(1H-imidazole-1-yl)-N-(piperidine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide hydrochloride 1632-(1H-imidazole-1-yl)-N-(tetrahydro-2H-pyran-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 164N-(6-cyanopyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 165N-(4-cyanophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1662-(1H-imidazole-1-yl)-N-(pyridine-3-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 167N-(5-fluoropyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1682-(1H-imidazole-1-yl)-N-(pyridine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 169N-(5-cyanopyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1702-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1712-(1H-imidazole-1-yl)-N-(pyridazine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 172N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 173N-(3,4-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 174N-(3,5-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 175N-(3-fluoro-5-(piperazine-1-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 176N-(3-fluoro-5-morpholinophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1772-(1H-imidazole-1-yl)-N-(3-morpholinophenyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 178(S)-N-(3-fluoro-5-(3-hydroxypyrrolidin-1-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 179N-(3-fluoro-5-(2-methoxypropane-2-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 180N-(3-fluoro-4-(2-hydroxypropane-2-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 181N-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 182N-(3-fluoro-5-(2-methoxyethoxy)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1832-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(pyridine-4-yl)pyrimidine-4-carboxamide 1842-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(2-(trifluoromethyl)pyridine-4-yl)pyrimidine-4-carboxamide 1856-cyano-N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 1866-cyano-2-(1H-imidazole-1-yl)-N-(pyridin-3-yl)pyrimidin-4-carboxamide 1876-cyano-N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 1882-(1H-imidazole-1-yl)-N-(2-(2-methoxyethoxy)pyrimidine-5-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1896-cyano-2-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)pyrimidine-4-carboxamide 1906-(1H-imidazole-1-yl)-N-(pyridine-4-yl)-4-(trifluoromethyl)picolinamide 1916-(1H-imidazole-1-yl)-N-(pyridine-3-yl)-4-(trifluoromethyl)picolinamide 1926-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)-4-(trifluoromethyl)picolinamide 193N-(2-(2-hydroxyethoxy)pyrimidine-5-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 1942-((5-(2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamido)pyrimidine-2-yl)oxy)acetic acid 195N-(2-hydroxypyrimidine-5-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0072] In another aspect, the present invention provides a pharmaceutical composition comprising a compound represented by the above-described formula I or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or excipient.
[0073] In another aspect, the present invention provides the use of a compound or pharmaceutical composition represented by the above-described formula I for the treatment of CD38-mediated diseases.
[0074] Preferably, CD38-mediated diseases are,
[0075] Neurodegenerative diseases selected from dementia, Alzheimer's disease (AD), and Parkinson's disease;
[0076] Tumors selected from glioblastoma, lung cancer, colon cancer, liver cancer, breast cancer, stomach cancer, bladder cancer, and melanoma;
[0077] Autoimmune diseases selected from diabetes mellitus, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE);
[0078] It is an inflammatory disease selected from asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and non-alcoholic fatty liver disease (NASH).
[0079] In another aspect, the present invention provides the use of a compound or pharmaceutical composition represented by the above-described formula I for the production of a drug for treating CD38-mediated diseases.
[0080] Preferably, CD38-mediated diseases are,
[0081] Neurodegenerative diseases selected from dementia, Alzheimer's disease (AD), and Parkinson's disease;
[0082] Tumors selected from glioblastoma, lung cancer, colon cancer, liver cancer, breast cancer, stomach cancer, bladder cancer, and melanoma;
[0083] Autoimmune diseases selected from diabetes mellitus, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE);
[0084] It is an inflammatory disease selected from asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and non-alcoholic fatty liver disease (NASH).
[0085] In another aspect, the present invention provides a method for treating a CD38-mediated disease in a subject in need, said method comprising the step of administering to the subject a therapeutically effective amount of a compound represented by the above-described formula I or a pharmaceutically acceptable salt thereof.
[0086] Preferably, CD38-mediated diseases are,
[0087] Neurodegenerative diseases selected from dementia, Alzheimer's disease (AD), and Parkinson's disease;
[0088] Tumors selected from glioblastoma, lung cancer, colon cancer, liver cancer, breast cancer, stomach cancer, bladder cancer, and melanoma;
[0089] Autoimmune diseases selected from diabetes mellitus, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE);
[0090] It is an inflammatory disease selected from asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and non-alcoholic fatty liver disease (NASH).
[0091] More preferably, the subject is a human.
[0092] In another aspect, the present invention provides a method for inhibiting CD38 function, said method comprising the step of contacting said CD38 with a compound represented by the above-described formula I or a pharmaceutically acceptable salt thereof.
[0093] In one embodiment, the CD38 is in the cell.
[0094] In another embodiment, the contact occurs in a test tube. In yet another embodiment, the contact occurs in the body. Specific details for implementing the invention
[0095] definition
[0096] In the present invention, the following definitions may be applied.
[0097] The phrase “CD38 inhibitor” includes any possible isomers, stereoisomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, and prodrugs of the CD38 inhibitor according to the present invention.
[0098] The article “one (a / an)” is used in the present invention to refer to one or more (i.e., at least one) grammatical objects of the article. For example, “one element” means one or more elements.
[0099] Unless otherwise specified, the term “and / or” is used in the present invention to mean “and” or “or”.
[0100] As used in the present invention, the term “heterocycle” means a cyclic hydrocarbon containing 3 to 10 atoms in which at least one of the atoms is O, N or S, wherein the monocyclic heterocycle may contain up to 2 double bonds. Examples of heterocycles include, but are not limited to, aziridine, oxiran, thiran, azetidine, oxetane, thiethane, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, thiane, imidazolidine, oxazolidine, thiazolidine, dioxolane, dithiolan, piperazine, oxazine, dithiane, and dioxane. In some embodiments, the heterocycle is a pentatonic or hexavalent unsaturated monocyclic heterocycle containing 1 to 3 heteroatoms selected from N, O, and S. In additional embodiments, a pentatonic or hexacyclic unsaturated heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S is aromatic and includes, but is not limited to, imidazolyl, pyrazolil, isoxazolil, oxazolil, isothiazolyl, thiazolil, triazolil, oxadiazolil, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.
[0101] A term “C” used alone or in combination with other chords. 1-6 "Alkyl" refers to a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms. C 1-6 Examples of alkyls include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and neopentyl.
[0102] A term “C” used alone or in combination with other chords. 2-6 “Alkynyl” preferably means an alkynyl having 2 to 6 carbon atoms and at least 1 to 2 alkynyl unsaturated sites, and preferred alkyns include ethinyl (-C≡CH), propargyl (-CH2C≡CH), etc.
[0103] term “C 3-8“Cycloalkyl” means a cyclic hydrocarbon containing 3 to 8 carbon atoms. Examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. It should be understood that any substitutable hydrogen on the cycloalkyl can be substituted by halogens, C1-C3 alkyls, hydroxy, alkoxy, and cyanos. In some embodiments, “C 3-8 “Cycloalkyl” optionally has one or two carbon atoms replaced by N, O, or S. Examples of such cycloalkyls include, but are not limited to, oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomophorinyl.
[0104] A term “C” used alone or in combination with other chords. 1-6 "Alkoxy" means the group R′-O-, where R′ is C 1-6 It is an alkyl. C 1-6 Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, tert-pentyloxy, and hexyloxy.
[0105] A term “C” used alone or in combination with other chords. 3-6 "Cycloalkoxy" means the group R"-O-, where R" is C 3-6 It is a cycloalkyl. C 3-6 Examples of cycloalkoxy include, but are not limited to, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy.
[0106] The term “halogen” or “halo” means fluorine, chlorine, bromine, or iodine. The preferred “halogen” group is fluorine, chlorine, or bromine.
[0107] The term “phenyl” means a group formed by removing one hydrogen from benzene. In some embodiments, phenyl optionally has one or two carbon atoms replaced by N and includes, but is not limited to, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.
[0108] “Anyway” or “at any time” means that the event or situation described below may or may not occur, and that the above description includes cases where the event or situation occurs and cases where the event or situation does not occur.
[0109] The “substituted” group includes an embodiment in which a monoradical substituent is bonded to a single atom of the substituted group (e.g., forming a branched chain), and also includes an embodiment in which the substituent is bonded to two adjacent atoms of the substituted group to form a fused ring in the substituted group.
[0110] Where a given moiety is described in the text as connecting a second moiety and the connection site is not explicitly specified, the given moiety may connect any available site of the second moiety to any available site of the given moiety. For example, “C where the connection site is not clear 1-6 "phenyl substituted by an alkyl group" is C 1-6 It may be to connect any available site of phenyl to any available site of alkyl. In this regard, “available site” is a site of the group where a hydrogen of the group can be replaced by a substituent.
[0111] “Pharmaceuticalally acceptable salts” means salts obtained by reaction with inorganic or organic acids while retaining the biological efficacy and properties of free bases, wherein the inorganic acids are, for example, acids, hydrobromide, sulfuric acid, nitric acid, and phosphoric acid, and the organic acids are, for example, sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, citric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic acid, lactic acid, tartaric acid (e.g., (+) or (-)-tartaric acid or mixtures thereof), amino acids (e.g., (+) or (-)-amino acids or mixtures thereof). Such salts may be prepared by methods known to those skilled in the art. “Pharmaceuticalally acceptable salts” means salts that are suitable for use in contact with tissues of humans and lower animals without excessive toxicity, irritation, allergic reactions, etc., within the scope of reasonable medical judgment, and correspond to a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SMBerge et al. described pharmaceutically acceptable salts in detail in J.PharmaceuticalSciences, 1977, 66, 1-19, and the said literature is cited in the text by reference.
[0112] As used in the present invention, the term “carrier” means a substance, composition, or vehicle such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, comprising a carrier, excipient, and diluent, which is involved in carrying or transporting a drug from one organ or part of the body to another organ or part of the body.
[0113] The phrase “effective amount” means an amount sufficient to achieve a desired effect or result in the context in which the compound according to the present invention is administered or used. Depending on the context, the phrase “effective amount” may include a pharmaceutical effective amount or a therapeutic effective amount, or may be a synonym thereof. The effective amount may be determined by methods known to those skilled in the art.
[0114] Compounds of a given formula (e.g., compounds represented by Formula I) are intended to include the compounds of the present invention, and pharmaceutically acceptable salts, pharmaceutically acceptable esters, isomers, tautomers, solvates, isotopes, hydrates, polymorphs, and prodrugs of such compounds. Additionally, compounds of the present invention may have one or more asymmetric centers and may be produced as racemic mixtures or as individual enantiomers or diastereomers. The number of stereoisomers present in any given compound of a given formula depends on the number of asymmetric centers present (2” stereoisomers may exist, where n is the number of asymmetric centers). Individual stereoisomers may be obtained by decomposing a racemic or non-racemic mixture of intermediates at some appropriate step of the synthesis, or by decomposing the compounds through general methods.
[0115] Unless otherwise specifically stated, individual stereoisomers (including individual enantiomers and diastereomers) and racemic and non-racemic mixtures of stereoisomers are all included within the scope of the present invention, and all of these are intended to be represented by the structures of this specification.
[0116] “Isomers” are different compounds that have the same molecular formula. Isomers include stereoisomers, enantiomers, and diastereomers.
[0117] “Stereoisomers” are isomers that differ only in the spatial arrangement of their atoms.
[0118] “Enantiomers” are a pair of stereoisomers that are mirror images of each other but do not overlap. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. Where appropriate, the term “(±)” is used to denote a racemic mixture.
[0119] “Diastereomers” are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other.
[0120] Some compounds exist in the form of tautomers. Tautomers are in equilibrium with each other. For example, amide-containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is represented and regardless of the equilibrium characteristics between the tautomers, those skilled in the art will understand that these compounds contain amides and imidic acid tautomers. Therefore, amide-containing compounds should be understood to contain their imidic acid tautomers. Furthermore, imidic acid-containing compounds should be understood to contain their amide tautomers.
[0121] The term “polymorph” refers to different crystal structures of crystalline compounds. Different polymorphs may be the result of differences in crystal packing (packing polymorphism) or differences in packing between different form isomers of the same molecule (form polymorphism).
[0122] The term “solvent” refers to a complex formed by a combination of the compound and a solvent of the present invention.
[0123] The term “hydrate” refers to a complex formed by the combination of the compound of the present invention and water.
[0124] The term “prodrug” means a compound of the present invention comprising a chemical group that can be converted in the body and / or separated from the rest of the molecule to provide an active drug, a pharmaceutically acceptable salt thereof, or a biologically active metabolite thereof.
[0125] “Subject” is a mammal, e.g., human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate (e.g., monkey, chimpanzee, baboon, or rhesus), and the terms “subject” and “patient” may be used interchangeably in the present invention.
[0126] The term “inhibition / inhibit / inhibiting” refers to a significant reduction in the baseline activity of a biological activity or process.
[0127] Unless otherwise specified, the term “disease” as used in the present invention means a disorder, a pathology, or a disease, and these terms may be used interchangeably.
[0128] The phrase “neurodegenerative disease” as used in the present invention is used to define a disease characterized by a progressive loss of cognitive function, a progressive loss of motor control, and / or a progressive loss of motor function. Preferably, the neurodegenerative disease is selected from dementia, Alzheimer's disease (AD), multiple infarction dementia (MID), Pick's disease, Parkinson's disease, ALS, TIA, and stroke. More preferably, the neurodegenerative disease is dementia, Alzheimer's disease (AD), or Parkinson's disease.
[0129] As used in the present invention, the term “tumor” refers to the abnormal growth of tissue. A tumor may be benign or malignant. Generally, a malignant tumor is referred to as cancer. Cancer differs from a benign tumor in the ability of malignant cells to invade other tissues, growing directly into adjacent tissues through invasion or transplanting to distant sites through metastasis (i.e., transport via the blood or lymphatic system). Preferably, the tumor is selected from glioblastoma, lung cancer, colon cancer, liver cancer, breast cancer, gastric cancer, bladder cancer, and melanoma.
[0130] As used in the present invention, the phrase “autoimmune disease” refers to a disease resulting from the body’s inappropriate immune response (autoimmunity) to substances and tissues that are generally present in the patient’s body. Symptoms of autoimmune diseases vary from fatigue and mild rashes to rare and severe warning signs such as seizures. Preferably, the autoimmune disease is selected from rheumatoid arthritis (RA), multiple sclerosis (MS), sarcoidosis, psoriasis, Crohn’s disease, systemic lupus erythematosus (SLE), and type 1 diabetes, and more preferably, the autoimmune disease is selected from diabetes mellitus, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE).
[0131] As used in the present invention, the phrase “inflammatory disease” means a disease caused, induced, or resulting from inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory response that induces an overreaction by macrophages, granulocytes, and / or T lymphocytes, leading to abnormal tissue damage and / or apoptosis. Inflammatory disease may be acute or chronic inflammation and may be caused by infectious or non-infectious causes. Inflammatory disease is preferably asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and non-alcoholic steatohepatitis (NASH).
[0132] With respect to subjects, the term “treatment” means improving at least one symptom of the subject’s disease. Treatment may be curing, improving, or at least partially improving the disease.
[0133] As used in the present invention, the term “administer / administering / administration” means directly administering a compound or a pharmaceutically acceptable salt or composition of a compound to a subject, or administering a prodrug derivative or analog of a compound or a pharmaceutically acceptable salt or composition of a compound to a subject, which may form an equivalent amount of the active compound in the subject’s body.
[0134] Pharmaceutical composition and administration
[0135] The present invention further comprises a pharmaceutical composition capable of treating CD38-mediated diseases or inhibiting CD38 function. The composition may be suitable for oral administration and comprises an effective amount of the compound of the present invention as a CD38 inhibitor and a pharmaceutically acceptable carrier. CD38 inhibitors are particularly useful in that they have very low or no systemic toxicity.
[0136] CD38 inhibitors can be administered to subjects in amounts sufficient to treat or prevent cardiovascular and cerebrovascular diseases, neurodegenerative diseases, autoimmune and inflammatory diseases, fibrotic diseases, metabolic disorders, and tumors, or to prevent their development.
[0137] Administration of CD38 inhibitors can be completed through any method of administration of the therapeutic agent. These methods include oral, nasal, parenteral (intravenous), intramuscular, intrathecal, intravitreal, transdermal, subcutaneous, vaginal, buccal, rectal, topical administration, or systemic or local administration such as drug-eluting stents.
[0138] Depending on the expected mode of administration, the composition may be in solid, semi-solid, or liquid dosage forms such as injectables, tablets, suppositories, pills, sustained-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, and suspensions, sometimes in unit doses and in accordance with conventional pharmaceutical practice. Likewise, all of these may be administered intravenously (bolus and infusion), intraperitoneally, intrathecally, intravitreally, subcutaneously, or intramuscularly, as in forms well known to those skilled in the field of pharmacy.
[0139] An exemplary pharmaceutical composition is a tablet and a gelatin capsule, comprising a CD38 inhibitor and a pharmaceutically acceptable carrier, e.g., a) a diluent, e.g., purified water, triglyceride oil (e.g., hydrogenated or partially hydrogenated vegetable oil or a mixture thereof), corn oil, olive oil, sunflower oil, safflower oil, fish oil (EPA or DHA), or esters thereof or triglycerides or a mixture thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and / or glycine; b) a lubricant, e.g., silica, talc, stearic acid, magnesium or calcium salt thereof, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and / or polyethylene glycol; also used in tablets; c) binders, e.g., aluminum magnesium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars (e.g., glucose or β-lactose), corn sweeteners, natural and synthetic gums (acacia, tragacanth, or sodium alginate), waxes and / or polyvinylpyrrolidone (if necessary); d) disintegrants, e.g., starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt or effervescent mixture; e) absorbents, coloring agents, flavoring agents and sweeteners; f) an emulsifier or dispersant, e.g., Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS, or other acceptable emulsifiers; and / or g) an agent that promotes the absorption of the compound, e.g., cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200.
[0140] Liquids, particularly injectable compositions, can be prepared by dissolution, dispersion, etc. For example, CD38 inhibitors are dissolved or mixed in pharmaceutically acceptable solvents (e.g., water, saline solution, aqueous dextrose, glycerol, ethanol, etc.) to form an isotonic solution or suspension for injection. Proteins (e.g., albumin, chylomicron particles, or serum proteins) may be used to dissolve CD38 inhibitors.
[0141] CD38 inhibitors can also be prepared as suppositories that can be manufactured from lipid emulsions or suspensions; and polyalkylene glycol (e.g., propylene glycol) is used as a carrier.
[0142] In additional embodiments, pharmaceutical formulations according to the present invention include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate-release formulations, controlled-release formulations, rapid-melting formulations, delayed-release formulations, extended-release formulations, pulsed-release formulations, multiply particulate formulations, and mixed immediate-release and controlled-release formulations.
[0143] CD38 inhibitors may also be administered in the form of liposome delivery systems (e.g., small monolayer vesicles, large monolayer vesicles, and multilayer vesicles). Liposomes may be formed from various phospholipids, including cholesterol, stearylamine, or phosphatidylcholine. In some embodiments, as described in U.S. Patent No. 5,262,564, a film of lipid components is hydrated with an aqueous solution of the drug to form a lipid layer that encapsulates the drug.
[0144] CD38 inhibitors can be delivered using monoclonal antibodies as individual carriers, and CD38 inhibitors are coupled to said antibodies. CD38 inhibitors can also be coupled to soluble polymers as targetable drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamide-phenol, or polyethylene oxide polylysine substituted with palmitoyl residues. Additionally, CD38 inhibitors may be coupled to a class of biodegradable polymers useful for achieving controlled release of a drug, such as polylactic acid, polyepsilone caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyran, polycyanoacrylates, and hydrogels, or to crosslinked or amphiphilic block copolymers. In one embodiment, the CD38 inhibitor is not covalently bonded to the polymer (e.g., polycarboxylic acid polymer or polyacrylate).
[0145] Parenteral administration is generally used for subcutaneous, intramuscular, or intravenous injections and infusions. Injectables can be prepared in common forms, such as liquid solutions or suspensions, or solid forms suitable for dissolving in liquid prior to injection.
[0146] The composition may each be prepared according to a general mixing, granulation, or coating method, and the pharmaceutical composition of the present invention may contain CD38 inhibitors in an amount of about 0.1% to about 80%, about 5% to about 60%, or about 1% to about 20% by weight or volume.
[0147] The dosage plan for CD38 inhibitors is selected based on various factors, including the patient's type, species, age, weight, sex, race, diet, and medical condition; the severity of the condition to be treated; the route of administration; the patient's renal or hepatic function; and the specific CD38 inhibitor used. Physicians or veterinarians in the field can easily determine and prescribe the effective amount of medication needed to prevent, respond to, or stop the progression of the condition.
[0148] The effective dose of the present invention is in the range of about 0.1 mg to about 5000 mg of the active ingredient per unit dose that can be administered when used for the indicated effect. In one embodiment, the composition is in the form of a scoreable tablet. The appropriate dose of the CD38 inhibitor may be determined as described in Goodman, LS; Gilman, A. The Pharmacological Basis of Therapeutics, 5th edition; MacMillan: New York, 1975, pp. 201–226.
[0149] CD38 inhibitors may be administered once daily, or the total daily dose may be divided into two, three, or four doses per day. Additionally, CD38 inhibitors may be administered intranasally via the topical use of a suitable intranasal vehicle, or via a transdermal route using a transdermal skin patch well known to those skilled in the art. For administration in the form of a transdermal delivery system, dose administration may be continuous rather than intermittent throughout the entire dose regimen. Other exemplary topical formulations include creams, ointments, lotions, aerosol sprays, and gels, wherein the concentration of the CD38 inhibitor is in the range of about 0.1% to about 15% w / w or w / v.
[0150] Uses of compounds and their compositions
[0151] The compounds and compositions described above as CD38 inhibitors may be used to treat or prevent CD38-related diseases. Such diseases include, but are not limited to, neurodegenerative diseases, autoimmune diseases, tumors, or chronic or acute inflammatory diseases. Examples of such diseases or conditions include
[0152] o Neurodegenerative diseases including but not limited to dementia, Alzheimer's disease (AD), Parkinson's disease, ALS, TIA, and stroke;
[0153] o Rheumatic diseases (including but not limited to rheumatoid arthritis, osteoarthritis, and psoriatic arthritis), spondyloarthropathy (including but not limited to ankylosing spondylitis, reactive arthritis, and Reiter's syndrome), pyroarthropathy (including but not limited to gout, pseudogout, and calcium pyrophosphate deposition disease), Lyme disease, polymyalgia rheumatica;
[0154] o Connective tissue diseases including, but not limited to, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, and Sjögren's syndrome;
[0155] o Vasculitis including, but not limited to, nodular polyarteritis, Wegener's granulomatosis, and Churg-Strauss syndrome;
[0156] o Inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), pneumonia, non-alcoholic fatty liver disease (NASH), and the result of trauma or ischemia;
[0157] o Sarcoidosis;
[0158] o Vascular diseases including atherosclerotic vascular disease and infarction, atherosclerosis and vascular occlusive disease (including but not limited to atherosclerosis, ischemic heart disease, myocardial infarction, stroke, and peripheral vascular disease) and vascular stent restenosis;
[0159] o Autoimmune diseases including, but not limited to, diabetes mellitus, thyroiditis, myasthenia gravis, sclerosing cholangitis, primary biliary cirrhosis, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE);
[0160] o Lung diseases including, but not limited to, diffuse interstitial lung disease, pneumoconiosis, fibrotic alveolitis, asthma, bronchitis, bronchiectasis, chronic obstructive pulmonary disease, and adult dyspnea syndrome;
[0161] o Primary or metastatic tumors including, but not limited to, glioblastoma, prostate cancer, colon cancer, lymphoma, lung cancer, liver cancer, gastric cancer, bladder cancer, melanoma, multiple myeloma, breast cancer, stomach cancer, leukemia, cervical cancer, and metastatic cancer;
[0162] o Kidney diseases including glomerulonephritis and interstitial nephritis
[0163] o Disorders of the hypothalamic-pituitary-adrenal axis;
[0164] o Diseases characterized by altered neovascularization (e.g., diabetic retinopathy, rheumatoid arthritis, cancer) and endometrial function (menstruation, implantation, endometriosis);
[0165] o Endotoxic (septic) shock, exotoxic (septic) shock, infectious (true septic) shock, malaria complications, other infectious complications, complications of infectious diseases including pelvic inflammatory disease;
[0166] o Transplant rejection, Graft-versus-host disease;
[0167] o Allergic diseases including allergies, atopic diseases, and allergic rhinitis;
[0168] o Bone diseases (e.g., osteoporosis, Paget's disease);
[0169] o Skin diseases including psoriasis, atopic dermatitis, and UV(B)-induced dermal cell activation (e.g., sunburn, skin cancer); pain, testicular dysfunction, and wound healing
[0170] o Includes gastrointestinal diseases including inflammatory bowel disease (including but not limited to ulcerative colitis and Crohn's disease), peptic ulcer, gastritis, esophagitis, and liver disease (including but not limited to liver cirrhosis and hepatitis).
[0171] Combination therapy
[0172] CD38 inhibitors may be used in combination with one or more other therapeutic agents (e.g., therapeutic compounds, compositions, treatments, regimens, and / or medical procedures). In such combination therapies, the therapeutic agents of the present invention may be formulated with one or more other necessary regimens, or administered simultaneously, prior to, or after. The specific combination of therapies used in combination therapy takes into account the compatibility of the necessary therapeutic agents and / or procedures and the desired therapeutic effect to be achieved. Furthermore, it should be understood that the regimens used may achieve the desired effect for the same pathology, disease, or disorder, or may achieve different effects (e.g., control of any side effects).
[0173] Generally, for therapeutic purposes, the compound according to the text may be used alone, as a mixture of two or more compounds, or in combination with other agents, compounds, and / or drugs. Examples of other agents combined with the compound according to the text include known agents for the treatment of neurodegenerative diseases, inflammatory diseases, autoimmune diseases, or tumors. Other examples of potential agents that may be combined with the compound according to the text include agents for the treatment of different but related or associated symptoms or indications. Depending on the method of administration, the agent may be prepared into a suitable composition that enables easy delivery. Each component of the combination therapy may be prepared according to various methods known in the art. For example, the first agent and the second agent of the combination therapy may be prepared together or separately. The compound and other agents of the present invention may be appropriately administered to a patient at once or over a series of treatments.
[0174] As described in the text, in some embodiments, combination therapy may be proven to provide a “synergistic effect” and “synergistic action,” that is, the effect achieved when active ingredients are used together is greater than the sum of the effects produced by using the compounds separately. A synergistic effect may be obtained when the active ingredients are (1) co-prepared and administered or delivered simultaneously as a combined unit dose formulation; (2) delivered alternately or in parallel as a single formulation; or (3) carried out through some other means. In the case of alternating therapy, a synergistic effect may be obtained when the compounds, drugs, and / or therapeutic agents are administered or delivered sequentially, for example, through different injections in a single syringe. Generally, in alternating therapy, the effective dose of each active ingredient is administered sequentially (i.e., continuously), whereas in combination therapy, the effective dose of two or more active ingredients is administered together. The appropriate dose of any of the said co-administered drugs is the currently used dose and may be reduced due to the combined action (synergistic action) of the compounds of the present invention and other co-administered drugs or treatments.
[0175] As described in the text, each compound of the combination therapy may be prepared according to various methods known in the art. For example, the first and second agents of the combination therapy may be prepared together or separately. Agents prepared individually or separately may be packaged together in a kit. Non-limiting examples include, but are not limited to, kits containing, for example, two pills, a pill and a powder, a suppository, a liquid in a vial, two topical creams, etc. The kit may include optional components to assist in administering a unit dose to a patient, such as a vial for reconstitution of the powder form, an injectable syringe, a custom IV delivery system, or an inhaler. Additionally, the unit dose kit may include instructions for the preparation and administration of the composition. The kit may be prepared as a single-use unit dose for one patient or as a multiple-use for a specific patient (at a constant dose or as the efficacy of a single compound may vary with the progression of treatment); or, the kit may include a multiple-dose (“bulk packaging”) suitable for administration to multiple patients. Kit components can be assembled into boxes, bl-Ver packs, bottles, tubes, etc. Two or more compounds can be mixed together or divided in tablets, capsules, or other vehicles. In one example, the first compound is contained inside a tablet and the second compound is outside, so most of the second compound is released before the first compound is released.
[0176] Persons skilled in the art can select suitable agents for use in combination therapy in accordance with general pharmaceutical principles. By achieving therapeutic efficacy with low doses of each agent, the possibility of side effects can be reduced.
[0177] General synthesis
[0178] Typical embodiments of the compounds according to the present invention can be synthesized using the general reaction scheme described below. It will become apparent from the description in this text that the general scheme can be modified to produce correspondingly different products by replacing the starting materials with other materials having similar structures. The description of synthesis below provides many examples of how the starting materials are modified to provide corresponding products. The starting materials are typically obtained from commercial sources or synthesized using disclosed methods. The compounds of the present invention can be prepared using general synthesis techniques and procedures known to those skilled in the art, starting with commercial starting materials. The following describes reaction schemes suitable for the preparation of such compounds. Further examples can be found in the detailed specific examples below.
[0179] The compounds disclosed in the present invention may have a chiral center, such as a chiral carbon atom. Thus, these compounds comprise a racemic mixture of all stereoisomers (including enantiomers, diastereomers, and rotationally hindered isomers). Additionally, the compounds disclosed in the present invention comprise optical isomers that are enriched or decomposed at any or all asymmetric chiral atoms. That is, the chiral center apparent in the description is provided as a chiral isomer or a racemic mixture. As well as racemic and diastereomer mixtures, individual optical isomers that are separated or synthesized and substantially lack enantiomer or diastereomer partners are all within the scope of the present invention. The racemic mixture may be separated into individual and substantially optically pure isomers through well-known techniques, such as the separation of diastereomer salts formed with an optically active agent (e.g., an acid or a base) followed by conversion back into an optically active substance. The desired optical isomer can also be synthesized through stereospecific reactions starting with an appropriate stereoisomer of the desired starting material.
[0180] Plan 1
[0181]
[0182] In Method 1, I-1 and NHR-A3 or a salt thereof are reacted under appropriate conditions (e.g., using HATU, DIEA, DMF / DCM) to obtain I-2. R and A3 are the same as those described in the present invention; Z1 is a leaving group, e.g., halogen, acetyl, amino, but not limited thereto; It optionally has one or two carbon atoms replaced by nitrogen, and zero or one -OH, -CN, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, isopropoxy, cyclobutoxy, oxetane-3-yloxy, ethinyl, -NH2, -NHCH3, -N(CH3)2, -NHC(O)CH3, , , , , , , It is arbitrarily substituted by.
[0183] Plan 2
[0184]
[0185] In Method 2, I-2 and A1 are reacted under appropriate conditions (e.g., using NaH, THF, or heating) to obtain C. A1, R, and A3 are the same as those described in the present invention; Z1 is a leaving group, e.g., halogen, acetyl, amino, but not limited thereto; It optionally has one or two carbon atoms replaced by nitrogen, and zero or one -OH, -CN, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, isopropoxy, cyclobutoxy, oxetane-3-yloxy, ethinyl, -NH2, -NHCH3, -N(CH3)2, -NHC(O)CH3, , , , , , , It is arbitrarily substituted by.
[0186] Plan 3
[0187]
[0188] In Method 3, III-2 can be prepared from III-1 through a two-step procedure. First, III-1 is converted into a carboxylate under appropriate conditions (e.g., CO, Et3N, Pd(dppf)Cl2, MEOH, using heating). Next, the carboxylate is converted into carboxylic acid III-2 under appropriate conditions (e.g., NaOH, H2O, MeOH, using heating). A1 is the same as described in the present invention; Z2 is a leaving group, e.g., halogen, acetyl, amino, but not limited thereto; It optionally has one or two carbon atoms replaced by nitrogen, and zero or one -OH, -CN, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, isopropoxy, cyclobutoxy, oxetane-3-yloxy, ethinyl, -NH2, -NHCH3, -N(CH3)2, -NHC(O)CH3, , , , , , , It is arbitrarily substituted by.
[0189] Plan 4
[0190]
[0191] In Method 4, III-2 and NHR-A3 or a salt thereof are reacted under appropriate conditions (e.g., CuI, Cs2CO3, DMF, heating, using MW) to obtain C. A1, R and A3 are the same as those described in the present invention; It optionally has one or two carbon atoms replaced by nitrogen, and zero or one -OH, -CN, -F, -Cl, methyl, isopropyl, trifluoromethyl, methoxy, isopropoxy, cyclobutoxy, oxetane-3-yloxy, ethinyl, -NH2, -NHCH3, -N(CH3)2, -NHC(O)CH3, , , , , , , It is arbitrarily substituted by.
[0192] Examples
[0193] The present invention may be better understood according to the following examples. However, those skilled in the art will readily understand that the description in the examples is for the purpose of explaining the invention and is not intended to limit the invention as defined in the claims.
[0194] Unless otherwise specified, compounds of the present invention may be prepared using general synthesis techniques and procedures known to those skilled in the art, starting with commercial starting materials. Chromatographic consumables and instruments may be purchased from companies such as AnaLogix, Inc, Burlington, WI; Analytical Sales and Services, Inc., Pompton Plains, NJ; Teledyne Isco, Lincoln, NE; VWR International, Bridgeport, NJ; and Rainin Instrument Company, Woburn, MA. Chemicals and reagents may be purchased from companies such as Aldrich, Argonaut Technologies, VWR and Lancaster, Invitrogen, Sigma, Promega, Solarbio, Cisbio, Signalchem, and MCE; consumables may be purchased from companies such as Corning, Labcyte, Greiner, and Nunc; and instruments may be purchased from companies such as Labcyte, PerkinElmer, Eppendorf, and ThermoFisher.
[0195] Example 1
[0196] 4,6-di(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 1)
[0197] and
[0198] 6-chloro-4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 2)
[0199]
[0200] A mixture of 6-chloro-4-methoxy-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (150 mg, 0.503 mmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (14.2 mg, 0.10 mmol), imidazole (68.0 mg, 1.00 mmol), CuI (4.7 mg, 0.025 mmol), and DMF (2 mL) containing Cs2CO3 (327 mg, 1.00 mmol) was bubbled with N2 for 3 minutes. The reaction tube was sealed and heated in a microwave reactor at 120°C for 30 minutes. The reaction mixture was cooled and purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, column name: Inertsil ODS-3 10 µm 20*250 nm, mobile phase A: 0.1% HCOOH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min; column temperature: room temperature) to obtain white solid Compound 1 (9.74 mg, 5.3% yield). MS (ESI): m / z 367.1 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 8.76 (s, 1H), 8.64 (d, J = 8.6 Hz, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 8.23 - 8.17 (m, 2H), 7.21 (d, J = 9.0 Hz, 2H), 3.90 - 3.85 (m, 1H), 3.26 (s, 3H), 3.14 (s, 1H), 2.10 - 2.04 (m, 2H), 1.89-1.82 (m, 2H), 1.64 - 1.54 (m, 2H), 1.29 - 1.20 (m, 2H); and white solid compound 2 (34.58 mg, 20.6% yield). MS (ESI): m / z 335.0 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.47 (d, J = 8.3 Hz, 1H), 8.28 (d, J= 1.9 Hz, 1H), 8.20 (d, J = 2.0 Hz, 1H), 8.14 (s, 1H), 7.19 (s, 1H), 3.84 - 3.76 (m, 1H), 3.24 (s, 3H), 3.11 - 3.09 (m, 1H), 2.03 - 2.01 (m, 2H), 1.84 - 1.81 (m, 2H), 1.54 - 1.51 (m, 2H), 1.23 - 1.20 (m, 2H).
[0201] Example 2
[0202] 4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-oxo-1,6-dihydropyridine-2-carboxamide(compound 3)
[0203]
[0204] A mixture of t-BuOH (6 mL) and 50% KOH aqueous solution (2 mL) containing Compound 2 (180 mg, 0.53 mmol) was refluxed for 16 hours. The solution was cooled to room temperature and purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% FA aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (13.49 mg, 7.9% yield). MS (ESI): m / z 335.0 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.88 (s, 1H), 9.51 (s, 1H), 8.33 (s, 1H), 7.70 (s, 1H), 7.20 (s, 1H), 3.80 - 3.70 (m, 1H), 3.25 (s, 3H), 3.18 - 3.10 (m, 1H), 2.02 (dd, J = 12.2, 2.6 Hz, 2H), 1.90 (dd, J = 12.8, 2.2 Hz, 2H), 1.45 - 1.33 (m, 2H), 1.30 - 1.17 (m, 2H).
[0205] Example 3
[0206] 6-(1H-imidazole-1-yl)-4-methoxy-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 4)
[0207]
[0208] A solution of 5 mL of MeOH containing Compound 1 (100 mg, 0.272 mmol) was treated with MeONa (14.0 mg, 0.272 mmol). The resulting reaction mixture was heated in a microwave reactor at 100°C for 1 hour. The solvent was removed under vacuum, and the residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 40 / 1) to obtain the white solid title compound (30.29 mg, 67.2% yield). MS (ESI): m / z 335.5 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.94 (s, 1H), 8.52 (d, J = 8.6 Hz, 1H), 8.26 (s, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.14 (s, 1H), 3.99 (s, 3H), 3.88 - 3.76 (m, 1H), 3.26 (s, 3H), 3.17 - 3.07 (m, 1H), 2.05 (d, J = 10.5 Hz, 2H), 1.83 (d, J = 10.6 Hz, 2H), 1.64 - 1.48 (m, 2H), 1.30 - 1.15 (m, 2H).
[0209] Example 4
[0210] 4-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 5)
[0211]
[0212] A solution of H2O (5 mL) containing Compound 1 (100 mg, 0.273 mmol) was treated with NaOH (22 mg, 0.546 mmol). The resulting reaction mixture was heated in a microwave reactor at 100°C for 1 hour. The reaction mixture was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% aqueous NH4OH, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (3.76 mg, 4.4% yield). MS (ESI): m / z 317.1. [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.80 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.34 (s, 1H), 8.10 (s, 1H), 7.31 (s, 1H), 7.16 (s, 1H), 7.09 (s, 1H), 3.84 - 3.72 (m, 2H), 3.25 (s, 3H), 3.16 - 3.06 (m, 2H), 2.04 (d, J = 11.5 Hz, 2H), 1.81 (d, J = 10.2 Hz, 2H), 1.60 - 1.48 (m, 2H), 1.27 - 1.15 (m, 2H).
[0213] Example 5
[0214] 2-acetamido-N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)benzamide(compound 6)
[0215]
[0216] Step 1. 2-acetamido-5-bromo-N-((1r,4r)-4-methoxycyclohexyl)benzamide.
[0217] TEA (0.51 mL, 3.67 mmol) and AcCl (0.17 mL, 2.45 mmol) were added to a solution of DCM (10 mL) containing 2-amino-5-bromo-N-((1r,4r)-4-methoxycyclohexyl)benzamide (400 mg, 1.22 mmol). The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA = 10 / 1 to 1 / 1) to obtain the title compound as a yellow solid (270 mg, 59.8% yield). MS (ESI): m / z 371.0 [M+H] + .
[0218] Step 2. 2-Acetamido-N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)benzamide
[0219] A mixture of 2-acetamido-5-bromo-N-((1r,4r)-4-methoxycyclohexyl)benzamide (150 mg, 0.41 mmol), thiazole-5-ylboronic acid pinacol ester (128 mg, 0.61 mmol), Pd(PPh3)4 (94 mg, 0.08 mmol), Na2CO3 (112 mg, 0.81 mmol), dioxane (2 mL), and H2O (0.5 mL) was bubbled with argon for 3 minutes. The reaction tube was sealed and heated in a microwave reactor at 120°C for 30 minutes. The obtained mixture was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% HCOOH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (27 mg, 18% yield). MS (ESI): m / z 374.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.13 (s, 1H), 9.09 (s, 1H), 8.65 (d, J = 7.7 Hz, 1H), 8.40 (d, J= 8.7 Hz, 1H), 8.32 (s, 1H), 7.93 (d, J = 2.1 Hz, 1H), 7.78 (dd, J = 8.6, 2.1 Hz, 1H), 3.86 - 3.76 (m, 1H), 3.25 (s, 3H), 3.17 - 3.09 (m, 1H), 2.10 (s, 3H), 2.06 - 2.03 (m, 2H), 1.92 - 1.90 (m, 2H), 1.44 - 1.35 (m, 2H), 1.25 - 1.27 (m, 2H).
[0220] Example 6
[0221] 2-amino-N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)benzamide(compound 7)
[0222]
[0223] A mixture of 2-amino-5-bromo-N-((1r,4r)-4-methoxycyclohexyl)benzamide (150 mg, 0.459 mmol), thiazole-5-ylboronic acid pinacol ester (145 mg, 0.687 mmol), Pd(PPh3)4 (105 mg, 0.090 mmol), Na2CO3 (97.0 mg, 0.92 mmol), dioxane (2 mL), and H2O (0.5 mL) was bubbled with argon for 15 minutes. The reaction tube was sealed and heated in a microwave reactor at 120°C for 30 minutes. The reaction mixture was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% HCOOH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (9.14 mg, 6.0% yield). MS (ESI): m / z 332.2 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.94 (s, 1H), 8.16 (d, J= 7.8 Hz, 1H), 8.10 (s, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.43 (dd, J = 8.5, 2.0 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 6.63 (s, 2H), 3.79 - 3.69 (m, 1H), 3.25 (s, 3H), 3.17 - 3.06 (m, 1H), 2.05 - 2.02 (m, 2H), 1.88 - 1.85 (m, 2H), 1.41 - 1.33 (m, 2H), 1.23 - 1.15 (m, 2H).
[0224] The following compounds were synthesized according to the procedure described for Compound 7.
[0225] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 8 2-fluoro-N-((1r,4r)-4-methoxycyclohexyl)-3-(thiazole-5-yl)benzamide 335.0 9.23 (s, 0.5H), 8.40 (s, 0.5H), 8.38 - 8.36 (m, 0.66H), 8.19 - 8.15 (m, 0.36H), 7.93 - 7.90 (m, 1H), 7.52 - 7.48 (m, 1.5H), 7.36 - 7.32 (m, 0.77H), 7.26 - 7.22 (m, 0.76H), 3.76 - 3.70 (m, 1H), 3.23 (s, 3H), 3.11 - 3.10 (m, 1H), 2.01 - 1.98 (m, 2H), 1.92 - 1.84 (m, 2H), 1.37 - 1.18 (m, 4H). 12 N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)picolinamide 318.5 9.22 (s, 1H), 8.79 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.14 (dd, J = 7.9, 1.1 Hz, 1H), 8.11 - 8.02 (m, 1H), 7.98 - 7.90 (m, 1H), 3.87 - 3.75 (m, 1H), 3.25 (s, 3H), 3.22 - 3.10 (m, 1H), 2.08 - 1.98 (m, 2H), 1.95 - 1.85 (m, 2H), 1.59 - 1.44 (m, 2H), 1.33 - 1.19 (m, 2H).
[0226] Example 7
[0227] N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)pyrazine-2-carboxamide(compound 9)
[0228]
[0229] Step 1: 6-chloro-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide.
[0230] DIEA (1.67 mL, 10.1 mmol), HATU (3.84 g, 10.1 mmol), and 6-chloropyrazine-2-carboxylic acid (1.60 g, 10.1 mmol) were added to a solution of DMF (10 mL) containing trans-4-methoxycyclohexaneamine hydrochloride (1.67 g, 10.1 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with ethyl acetate (50 mL). The organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified using a silica gel column (EA / PE = 1 / 100 to 1 / 50) to obtain the title compound as a white solid (1.80 g, 66.1% yield). MS (ESI): m / z 270.1 [M+H] + .
[0231] Step 2: N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)pyrazine-2-carboxamide.
[0232] A mixture of 6-chloro-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide (100 mg, 371 mmol), thiazole-5-ylboronic acid pinacol ester (117 mg, 0.556 mmol), Pd(PPh3)4 (85.7 mg, 0.074 mmol), dioxane (2 mL) containing Na2CO3 (78.6 mg, 0.742 mmol), and H2O (0.5 mL) was bubbled with argon for 3 minutes. The reaction tube was sealed and heated in a microwave reactor at 120°C for 1 hour. The mixture was cooled to room temperature and diluted with EA (20 mL). The organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% aqueous formic acid, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (21.56 mg, 18.3% yield). MS (ESI): m / z 391.1 [M+H] + . NMR (400 MHZ, DMSO- d 6 ) δ 9.43 (s, 1H), 9.32 (s, 1H), 9.04 (s, 1H), 8.93 (s, 1H), 8.45 (d, J = 8.7 Hz, 1H), 3.84 (s, 1H), 3.25 (s, 3H), 3.13 (d, J = 10.6 Hz, 1H), 2.04 (d, J = 10.2 Hz, 2H), 1.87 (d, J = 10.2 Hz, 2H), 1.55 - 1.48 (m, 2H), 1.29 - 1.20 (m, 2H).
[0233] Example 8
[0234] 3-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide(compound 10)
[0235]
[0236] Step 1. 3-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide
[0237] A mixture of 3,6-dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide (380 mg, 1.25 mmol), imidazole (94.3 mg, 1.38 mmol), and DMF (10 mL) containing K2CO3 (259 mg, 1.87 mmol) was heated at 80°C for 2 hours. The reaction mixture was distributed between CH2Cl2 (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 20 / 1) to obtain a pale yellow solid title compound (90 mg, 21.4% yield). 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.81 (d, J = 7.6 Hz, 1H), 8.70 (s, 1H), 8.43 (s, 1H), 8.11 (t, J = 1.3 Hz, 1H), 7.23 (s, 1H), 3.80 - 3.71 (m, 1H), 3.24 (s, 3H), 3.18 - 3.11 (m, 1H), 2.02 - 1.96 (m, 4H), 1.36 - 1.22 (m, 4H).
[0238] Step 2. 3-((2,4-dimethoxybenzyl)amino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide.
[0239] A mixture of 3-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide (80.2 mg, 0.238 mmol), (2,4-dimethoxyphenyl)methaneamine (70.2 μL) and NMP (5 mL) containing aHCO3 (60.1 mg, 0.715 mmol) was heated at 100°C for 2 hours. The reaction mixture was distributed between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated and dried. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 20 / 1) to obtain a colorless oily substance The title compound (70.1 mg, 63.0% yield) was obtained. MS (ESI): m / z 467.1 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.73 (d, J = 7.6 Hz, 1H), 8.39 (s, 1H), 8.01 (s, 1H), 7.95 (t, J = 5.6 Hz, 1H), 7.86 (s, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.16 (s, 1H), 6.59 (d, J = 2.3 Hz, 1H), 6.47 (dd, J = 8.3, 2.3 Hz, 1H), 4.59 (d, J = 5.5 Hz, 2H), 3.82 (s, 3H), 3.74 (s, 3H), 3.73 - 3.70 (m, 1H), 3.24 (s, 3H), 3.17 - 3.10 (m, 1H), 2.03 (d, J = 12.8 Hz, 2H), 1.91 (d, J = 12.5 Hz, 2H), 1.41 - 1.26 (m, 5H).
[0240] Step 3. 3-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide.
[0241] A solution of TFA (5 mL) containing 3-((2,4-dimethoxybenzyl)amino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-4-carboxamide (70 mg, 0.150 mmol) was heated at 80°C for 2 hours. Volatiles were removed under vacuum, and the residue was distributed between EtOAc (20 mL) and a saturated Na2CO3 solution (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 10 / 1) to obtain the white solid title compound (5.29 mg, 11.1% yield). MS (ESI): m / z 317.1 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.67 (d, J = 7.7 Hz, 1H), 8.39 (s, 1H), 8.00 (s, 1H), 7.86 (s, 1H), 7.16 (d, J = 6.1 Hz, 3H), 3.80 - 3.70 (m, 1H), 3.24 (s, 3H), 3.17 - 3.10 (m, 1H), 2.04 (dd, J = 12.6, 2.7 Hz,2H), 1.92 (dd, J = 13.1, 2.8 Hz, 2H), 1.41 - 1.30 (m, 2H), 1.28 - 1.17 (m, 2H).
[0242] The following compounds were synthesized according to the procedure described for Compound 10.
[0243] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 27 3-amino-N-((1r,4r)-4-methoxycyclohexyl)-6-(thiazole-5-yl)pyrazine-2-carboxamide 334.1 9.09 (s, 1H), 8.78 (s, 1H), 8.57 (s, 1H), 8.18 (d, J = 8.4Hz, 1H), 7.76 (s, 1H), 3.78 (s, 1H), 3.25 (s, 3H), 3.18 - 3.12 (m, 1H), 2.01 (d, J = 10.6 Hz, 1H), 1.86 (d, J = 10.4 Hz, 2H), 1.53 - 1.46 (m, 2H), 1.29 - 1.22 (m, 2H). 41 3-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 317.1 8.74 (s, 1H), 8.68 (s, 1H), 8.47 (d, J = 8.6 Hz, 1H), 8.08 (s, 1H), 7.67 (s, 2H), 7.12 (s, 1H), 3.81 - 7.79 (m, 1H), 3.25 (s, 3H), 3.14 - 3.08 (m, 1H), 2.06 - 2.03 (m, 2H), 1.83 - 1.80 (m, 2H), 1.62 - 1.47 (m, 2H), 1.25 - 1.17 (m, 2H). 42 3-amino-N-cyclohexyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 287.1 8.74 (s, 1H), 8.68 (s, 1H), 8.47 (d, J = 8.7 Hz, 1H), 8.09 (t, J = 1.3 Hz, 1H), 7.67 (s, 2H), 7.12 (t, J = 1.0 Hz, 1H), 3.84 - 3.75 (m, 1H), 1.79 - 1.73 (m, 4H), 1.64 - 1.61 (m, 2H), 1.51 - 1.41 (m, 2H), 1.36 - 1.26 (m, 2H), 1.18 - 1.12 (m, 2H). 46 3-(dimethylamino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 345.5 8.61 (s, 1H), 8.56 (d, J = 7.9 Hz, 1H), 8.38 (s, 1H), 7.83 (s, 1H), 7.11 (s, 1H), 3.76 - 3.66 (m, 1H), 3.24 (s, 3H), 3.15 - 3.08 (m, 1H), 3.03 (s, 5H), 2.06 - 1.97 (m, 2H), 1.93 - 1.83 (m, 2H), 1.43 - 1.31 (m, 2H), 1.28 - 1.16 (m, 2H). 47 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-3-(methylamino)pyrazine-2-carboxamide 331.5 8.79 (s, 1H), 8.67 - 8.60 (m, 2H), 8.51 (d, J = 8.6 Hz, 1H), 8.06 (s, 1H), 7.12 (s, 1H), 3.99 - 3.49 (m, 1H), 3.25 (s, 3H), 3.17 - 2.99 (m, 1H), 2.97 (d, J = 4.9 Hz, 3H), 2.05 (d, J = 10.2 Hz, 2H), 1.82 (d, J = 10.5 Hz, 2H), 1.60 - 1.48 (m, 2H), 1.29 - 1.10 (m, 2H). 59 2-amino-5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 316.1 8.89 (s, 1H), 8.40 (d, J = 2.6 Hz, 1H), 8.24 (d, J = 7.5 Hz, 1H), 8.17 (d, J = 2.6 Hz, 1H), 7.91 (s, 1H), 7.56 (s, 1H), 7.42 (s, 2H), 3.78 - 3.70 (m, 1H), 3.24 (s, 3H), 3.14 - 3.08 (m, 1H), 2.03 (d, J = 10.0 Hz, 2H), 1.88 (d, J = 10.3 Hz, 2H), 1.39 - 1.28 (m, 2H), 1.26 - 1.16 (m, 2H). 60 3-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 316.1 8.66 (s, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.04 (s, 1H), 7.68 (d, J = 8.9 Hz, 1H), 7.35 (d, J = 8.9 Hz, 1H), 7.09 (s, 1H), 6.94 (s, 2H), 3.84 - 3.70 (m, 1H), 3.25 (s, 3H), 3.17 - 3.07 (m, 1H), 2.04 (d, J = 10.6 Hz, 2H), 1.81 (d, J = 10.1 Hz, 2H), 1.52 - 1.48 (m, 2H), 1.26 - 1.16 (m, 2H). 61 3-amino-N-cyclohexyl-6-(1H-imidazole-1-yl)picolinamide 286.2 8.64 (s, 1H), 8.25 (d, J = 8.7 Hz, 1H), 8.02 (s, 1H), 7.68 (d, J = 8.9 Hz, 1H), 7.36 (d, J = 8.9 Hz, 1H), 7.07 (s, 1H), 6.94 (s, 2H), 3.83 - 3.73 (m, 1H), 1.78-1.73(m, 4H), 1.63 (d, J = 12.6 Hz, 1H), 1.53 - 1.41 (m, 2H), 1.36-1.30 (m, 2H), 1.21 - 1.10 (m, 1H). 69 5-amino-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)isonicotinamide 316.2 8.56 - 8.39 (m, 1H), 8.34 (d, J = 7.5 Hz, 1H), 8.04 (s, 1H), 7.98 - 7.78 (m, 1H), 7.72 (s, 1H), 7.26 - 7.12 (m, 1H), 6.51 (s, 2H), 3.80 - 3.70 (m, 1H), 3.25 (s, 3H), 3.17 - 3.08 (m, 1H), 2.09 - 2.01 (m, 2H), 1.95 - 1.87 (m, 2H), 1.44 - 1.30 (m, 2H), 1.28 - 1.16 (m, 2H).
[0244] Example 9
[0245] 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide(compound 11)
[0246]
[0247] Step 1. 6-Bromo-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide
[0248] HATU (225 mg, 0.591 mmol), TEA (0.20 mL, 1.48 mmol), and trans 4-methoxycyclohexanamine hydrochloride (122 mg, 0.739 mmol) were added to a solution of DMF (3 mL) containing 6-bromopyrazine-2-carboxylic acid (100 mg, 0.493 mmol). The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (10 mL) and extracted with EA (10 mL × 3). The combined organic layer was dried with anhydrous Na2SO4, filtered, and the filtrate concentrated. The residue was purified by silica gel column chromatography (PE / EA = 10 / 1 to 1 / 1) to obtain the title compound as a yellow solid (100 mg, 64.6% yield). MS (ESI): m / z 315.9 [M+H] + .
[0249] Step 2. 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide
[0250] A mixture of 6-bromo-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide (100 mg, 0.32 mmol), imidazole (43 mg, 0.64 mmol), CuI (3 mg, 0.016 mmol), Cs2CO3 (207 mg, 0.64 mmol), and trans-N1,N2-dimethylcyclohexane-1,2-diamine (9.0 mg, 0.064 mmol) in DMF (2 mL) was bubbled with argon for 3 minutes. The reaction tube was sealed and heated in a microwave reactor at 110°C for 30 minutes. The reaction mixture was cooled to room temperature and purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, column name: Inertsil ODS-3 10 µm 20*250 nm, mobile phase A: 0.1% NH4OH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min; column temperature: room temperature) to obtain the white solid title compound (43.4 mg, 45.0% yield). MS (ESI): m / z 302.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 9.38 (s, 1H), 9.07 (s, 1H), 9.00 (s, 1H), 8.71 (d, J = 8.5 Hz, 1H), 8.35 (s, 1H), 7.22 (s, 1H), 3.90 - 3.82 (m, 1H), 3.26 (s, 3H), 3.17 - 3.09 (m, 1H), 2.07 - 2.05 (m, 2H), 1.86 - 1.83 (m, 2H), 1.59 - 1.50 (m, 2H), 1.27 - 1.19 (m, 2H).
[0251] The following compounds were synthesized according to the procedure described for Compound 11.
[0252] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d6 ) d 13 N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-pyrazol-5-yl)pyrazine-2-carboxamide 302.1 9.33 (s, 1H), 9.05 (s, 1H), 8.72 (d, J = 4.4 Hz, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.26 (d, J = 2.0 Hz, 1H), 5.50 - 4.50 (brs, 1H), 3.90 - 3.82 (m, 1H), 3.26 (s, 3H), 3.19 - 3.11 (m, 1H), 2.07 (d, J = 10.8 Hz, 2H), 1.90 (d, J = 10.8 Hz, 2H), 1.56 - 1.48 (m, 2H), 1.30 - 1.20 (m, 2H). 14 N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-pyrazol-4-yl)pyrazine-2-carboxamide 302.2 13.31 (s, 1H), 9.18 (s, 1H), 8.89 (s, 1H), 8.73 (s, 1H), 8.54 (d, J = 8.6 Hz, 1H), 8.41 (s, 1H), 3.90 - 3.79 (m, 1H), 3.26 (s, 3H), 3.20 - 3.08 (m, 1H), 2.06 (d, J = 10.4 Hz, 2H), 1.87 (d, J = 10.8 Hz, 2H), 1.63 - 1.48 (m, 2H), 1.32 - 1.15 (m, 2H). 15 6-(isoxazole-4-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide 303.1 8.91 (s, 1H), 8.86 (s, 1H), 8.77 (s, 1H), 8.52 (d, J = 8.2 Hz, 1H), 3.81 - 3.77 (m, 1H), 3.24 (d, J = 1.4 Hz, 3H), 3.16 - 3.10 (m, 1H), 2.07 - 1.97 (m, 2H), 1.92 - 1.75 (m, 2H), 1.53 - 1.41 (m, 2H), 1.30 - 1.18 (m, 2H). 16 N-((1r,4r)-4-methoxycyclohexyl)-6-(pyridine-4-yl)pyrazine-2-carboxamide 313.1 9.59 (s, 1H), 9.22 (s, 1H), 8.81 (d, J = 6.0 Hz, 2H), 8.74 (d, J = 8.5 Hz, 1H), 8.47 - 8.14 (m, 2H), 4.10 - 3.65 (m, 1H), 3.15 - 3.10 (m, 1H), 2.06 (d, J = 10.6 Hz, 2H), 1.88 (d, J = 10.5 Hz, 2H), 1.70 - 1.50 (m, 2H), 1.35 - 1.05 (m, 2H). 30 N-cyclohexyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 272.4 9.38 (s, 1H), 9.07 (s, 1H), 9.00 (s, 1H), 8.72 (d, J = 8.6 Hz, 1H), 8.36 (s, 1H), 7.22 (s, 1H), 3.91 - 3.79 (m, 1H), 1.80 - 1.74 (m, 4H), 1.70 - 1.60 (m, 1H), 1.52 - 1.43 (m, 2H), 1.38 - 1.25 (m, 2H), 1.20 - 1.08 (m, 1H). 31 6-(1H-imidazole-1-yl)-N-isopropylpyrazine-2-carboxamide 232.4 9.39 (s, 1H), 9.08 (s, 1H), 9.00 (s, 1H), 8.74 (d, J = 8.3 Hz, 1H), 8.36 (t, J = 1.3 Hz, 1H), 7.23 (s, 1H), 4.27 - 4.17 (m, 1H), 1.24 (d, J = 6.6 Hz, 6H). 32 6-(1H-imidazole-1-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrazine-2-carboxamide 274.0 9.39 (s, 1H), 9.08 (s, 1H), 9.01 (s, 1H), 8.82 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 7.23 (s, 1H), 4.11 (dd, J = 15.4, 7.4 Hz, 1H), 3.92 (d, J = 11.2 Hz, 2H), 3.45 (s, 2H), 1.88 - 1.65 (m, 4H). 33 6-(1H-imidazole-1-yl)-N-(piperidin-4-yl)pyrazine-2-carboxamide 273.2 9.38 (s, 1H), 9.08 (s, 1H), 9.00 (s, 1H), 8.78 (d, J = 8.5 Hz, 1H), 8.36 (s, 1H), 7.22 (s, 1H), 4.03-3.92 (m, 2H), 2.95 (m, 2H), 2.60 - 2.52 (m, 1H), 1.81 - 1.69 (m, 2H), 1.67 - 1.53 (m, 2H). 34 N-(tert-butyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 246.1 9.38 (s, 1H), 9.08 (s, 1H), 8.93 (s, 1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.23 (s, 1H), 1.45 (s, 9H). 35 6-(1H-imidazole-1-yl)-N-phenylpyrazine-2-carboxamide 266.1 10.58 (s, 1H), 9.46 (s, 1H), 9.21 (s, 1H), 9.07 (s, 1H), 8.43 (s, 1H), 7.86 (q, J = 1.1 Hz, 2H), 7.45-7.41 (m, 2H), 7.25 (s, 1H), 7.23 - 7.17 (m, 1H). 36 6-(1H-imidazole-1-yl)-N-(1-methylpiperidine-4-yl)pyrazine-2-carboxamide 287.2 9.35 (s, 1H), 8.96 (s, 1H), 8.40 (s, 1H), 7.69 (s, 1H), 7.45 (d, J = 7.1 Hz, 1H), 7.33 (s, 1H), 4.08 - 3.99 (m, 1H), 2.84 (d, J = 11.0 Hz, 2H), 2.33 (s, 3H), 2.21 (t, J = 10.8 Hz, 2H), 2.06 (d, J = 10.2 Hz, 2H), 1.73 - 1.63 (m, 2H). 37 N-(cyclohexylmethyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 286.1 9.37 (s, 1H), 8.96 (s, 1H), 8.46 (s, 1H), 7.69 (s, 2H), 7.32 (s, 1H), 3.38 (t, J = 6.5 Hz, 2H), 1.81-1.75 (m, 4H), 1.72 - 1.61 (m, 2H), 1.31-1.17 (m, 3H), 1.08-0.99 (m, 2H). 38 N-benzyl-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 280.0 9.70 (t, J = 6.3 Hz, 1H), 9.42 (s, 1H), 9.11 (s, 1H), 8.98 (s, 1H), 8.36 (s, 1H), 7.38 - 7.31 (m, 4H), 7.28 - 7.23 (m, 1H), 7.22 (s, 1H), 4.57 (d, J = 6.4 Hz, 2H). 39 N-(1-cyclohexylethyl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 300.1 9.38 (s, 1H), 9.05 (s, 1H), 9.01 (s, 1H), 8.76 (d, J = 8.8 Hz, 1H), 8.34 (s, 1H), 7.22 (s, 1H), 4.43 (d, J = 12.8 Hz, 1H), 4.15 - 4.08 (m, 1H), 3.88 (d, J = 12.8 Hz, 1H), 3.16 (t, J = 12.4 Hz, 1H), 2.62 (t, J = 12.8 Hz, 1H), 2.03 (s, 3H), 1.85-1.75 (m, 2H), 1.67- 1.50 (m, 2H). 40 N-(1-acetylpiperidine-4-yl)-6-(1H-imidazole-1-yl)pyrazine-2-carboxamide 315.1 9.39 (s, 1H), 9.09 (s, 1H), 8.98 (s, 1H), 7.69 (s, 1H), 7.45 (d, J = 7.1 Hz, 1H), 7.33 (s, 1H), 4.08 - 3.99 (m, 1H), 2.84 (d, J = 11.0 Hz, 2H), 2.33 (s, 3H), 2.21 (t, J = 10.8 Hz, 2H), 2.06 (d, J = 10.2 Hz, 2H), 1.73 - 1.63 (m, 2H). 48 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 301.1 9.04 (s, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.31 (s, 1H), 8.16 (dd, J = 14.3, 6.4 Hz, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 7.5 Hz, 1H), 7.23 (s, 1H), 3.91 - 3.77 (m, 1H), 3.26 (s, 3H), 3.17 - 3.08 (m, 1H), 2.06 (d, J = 10.8 Hz, 2H), 1.84 (d, J = 10.6 Hz, 2H), 1.63 - 1.51 (m, 2H), 1.28 - 1.17 (m, 2H). 49 N-cyclohexyl-6-(1H-imidazole-1-yl)picolinamide 271.1 8.95 (s, 1H), 8.57 (d, J = 8.7 Hz, 1H), 8.34 - 8.23 (m, 1H), 8.16 (t, J = 7.9 Hz, 1H), 7.97 (dd, J = 16.1, 7.9 Hz, 2H), 7.16 (s, 1H), 3.93 - 3.76 (m, 1H), 1.87 - 1.70 (m, 4H), 1.69 - 1.60 (m, 1H), 1.57 - 1.43 (m, 2H), 1.39 - 1.25 (m, 2H), 1.21 - 1.08 (m, 1H). 50 4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-methylpicolinamide 315.2 8.60 (s, 1H), 8.38 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 8.04 (d, J = 1.3 Hz, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.17 (s, 1H), 3.85 - 3.75 (m, 1H), 3.25 (s, 3H), 3.16 - 3.08 (m, 1H), 2.61 (s, 3H), 2.02 (d, J = 10.5 Hz, 2H), 1.86 (d, J = 10.2 Hz, 2H), 1.50 (td, J = 13.0, 3.0 Hz, 2H), 1.23 (td, J = 13.1, 3.3 Hz, 2H). 51 4-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 335.1 8.99 (s, 1H), 8.65 (d, J = 8.6 Hz, 1H), 8.31 (s, 1H), 8.27 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.17 (s, 1H), 3.83 (dd, J = 8.0, 3.7 Hz, 1H), 3.26 (s, 3H), 3.16 - 3.09 (m, 1H), 2.06 (d, J = 11.1 Hz, 2H), 1.83 (d, J = 10.6 Hz, 2H), 1.57 (q, J = 10.5 Hz, 2H), 1.22 (q, J = 10.4 Hz, 2H). 52 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-4-methylpicolinamide 315.2 9.49 - 9.40 (m, 1H), 8.58 (s, 1H), 8.43 (s, 1H), 7.97 (s, 1H), 7.89 (s, 1H), 7.47 (s, 1H), 3.82 (s, 1H), 3.26 (s, 3H), 3.13 (s, 1H), 2.50 - 2.48 (m, 3H), 2.04 (s, 2H), 1.82 (s, 2H), 1.55 (d, J = 15.2 Hz, 2H), 1.23 (d, J = 12.4 Hz, 2H). 53 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-4-(trifluoromethyl)picolinamide 368.9 9.09 (s, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.11 (s, 1H), 7.20 (s, 1H), 3.95 - 3.80 (m, 1H), 3.26 (s, 3H), 3.15 - 3.08 (m, 1H), 2.07 (d, J = 11.2 Hz, 2H), 1.85 (d, J = 10.8 Hz, 2H), 1.54 (q, J = 10.4 Hz, 2H), 1.23 (q, J = 10.4 Hz, 2H). 58 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 301.1 9.07 (d, J = 2.5 Hz, 1H), 8.93 (d, J = 1.8 Hz, 1H), 8.51 (d, J = 7.5 Hz, 1H), 8.43 - 8.39 (m, 2H), 7.90 (s, 1H), 7.18 (s, 1H), 3.85 - 3.73 (m, 1H), 3.27 - 3.20 (m, 3H), 3.17 - 3.10 (m, 1H), 2.04 (d, J = 12.9 Hz, 2H), 1.92 (d, J = 9.9 Hz, 2H), 1.44 - 1.32 (m, 2H), 1.29 - 1.17 (m, 2H). 62 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)isonicotinamide 301.1 9.03 - 8.93 (br, 1H), 8.64 (d, J = 5.1 Hz, 1H), 8.59 (d, J = 7.5 Hz, 1H), 8.40 - 8.15 (m, 1H), 8.13 (s, 1H), 7.74 (d, J = 5.0 Hz, 1H), 7.53 - 7.42 (m, 1H), 3.80 - 3.60 (m, 1H), 3.25 (s, 2H), 3.17 - 3.10 (m, 1H), 2.04 (d, J = 13.1 Hz, 1H), 1.91 (d, J = 10.3 Hz, 1H), 1.43 - 1.34 (m, 1H), 1.27 - 1.19 (m, 1H). 70 N-((1r,4r)-4-methoxycyclohexyl)-6-(1H-1,2,4-triazole-1-yl)pyrazine-2-carboxamide 303.2 9.99 (s, 1H), 9.31 (s, 1H), 9.19 (s, 1H), 8.74 (d, J = 8.5 Hz, 1H), 8.44 (s, 1H), 4.00 - 3.66 (m, 1H), 3.26 (s, 2H), 3.18 - 3.11 (m, 1H), 2.11 - 2.03 (m, 2H), 1.88 (d, J = 11.1 Hz, 2H), 1.59 - 1.48 (m, 2H), 1.30 - 1.19 (m, 2H). 75 3-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 335.1 8.63 - 8.55 (m, 2H), 8.23 (d, J = 8.7 Hz, 1H), 8.00 (s, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.15 (s, 1H), 3.81 - 3.69 (m, 1H), 3.24 (s, 3H), 3.18 - 3.04 (m, 1H), 2.02 (d, J = 10.4 Hz, 2H), 1.90 (d, J = 10.5 Hz, 2H), 1.43 - 1.32 (m, 2H), 1.29 - 1.17 (m, 2H). 76 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-methylpicolinamide 315.2 8.34 - 8.29 (m, 2H), 8.07 (d, J = 7.8 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.79 (s, 1H), 7.13 (s, 1H), 3.83 - 3.75 (m, 1H), 3.24 (s, 3H), 3.13 - 3.06 (m, 1H), 2.40 (s, 3H), 2.02 (d, J = 10.3 Hz, 2H), 1.82 (d, J = 10.5 Hz, 2H), 1.55 - 1.45 (m, 2H), 1.26 - 1.16 (m, 2H). 77 5-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 335.1 8.45 (d, J = 8.4 Hz, 2H), 8.37 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.92 (br s, 1H), 7.17 (br s, 1H), 3.85 - 3.75 (m, 1H), 3.24 (s, 3H), 3.13 - 3.06 (m, 1H), 2.40 (s, 3H), 2.03 (d, J = 10.0 Hz, 2H), 1.82 (d, J = 10.4 Hz, 2H), 1.55 - 1.45 (m, 2H), 1.26 - 1.16 (m, 2H). 78 N-cyclohexyl-6-(4-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 286.2 9.30 (s, 1H), 9.03 (s, 1H), 8.89 (s, 1H), 8.69 (d, J = 8.4 Hz, 2H), 8.02 (s, 1H), 3.88 - 3.83 (m, 1H), 2.22 (s, 3H), 1.79 (t, J = 12.8 Hz, 4H), 1.65 (d, J = 13.6 Hz, 1H), 1.53 - 1.44 (m, 2H), 1.35- 1.28 (m, 2H), 1.16 (t, J = 12.8 Hz, 1H). 79 N-cyclohexyl-6-(5-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 285.8 9.18 (s, 1H), 9.15 (s, 1H), 8.50 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H), 6.91 (s, 1H), 3.83 (d, J = 8.4 Hz, 1H), 2.44 (s, 3H), 1.85 - 1.72 (m, 4H), 1.61 (d, J = 12.4 Hz, 1H), 1.50- 1.30 (m, 4H), 1.20 - 1.10 (m, 1H). 80 N-cyclohexyl-6-(2-methyl-1H-imidazole-1-yl)pyrazine-2-carboxamide 286.2 9.12 (d, J = 5.0 Hz, 1H), 8.68 (d, J = 8.6 Hz, 1H), 8.40 (d, J = 1.7 Hz, 1H), 7.95 (d, J = 5.0 Hz, 1H), 7.19 (d, J = 1.6 Hz, 1H), 3.88 - 3.79 (m, 1H), 2.81 (s, 3H), 1.85 - 1.71 (m, 4H), 1.67 - 1.59 (m, 1H), 1.52 - 1.42 (m, 2H), 1.40 - 1.27 (m, 2H), 1.22 - 1.11 (m, 1H). 81 6-(1H-imidazole-1-yl)-N-phenylpicolineamide 265.1 10.48 (s, 1H), 9.02 (s, 1H), 8.30 (s, 1H), 8.25 (t, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.20 - 7.15 (m, 2H).
[0253] Example 10
[0254] 6-(isoxazole-5-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 17)
[0255]
[0256] Step 1: 6-Acetyl-N-((1r,4r)-4-methoxycyclohexyl)picolinamide
[0257] HATU (882 mg, 2.31 mmol) and DIEA (0.96 mL, 5.80 mmol) were added to a 15 mL solution of DCM containing 6-acetylpicolinate (800 mg, 1.93 mmol), followed by the addition of trans-4-methoxycyclohexanamine hydrochloride (384 mg, 2.32 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with 300 mL of DCM and washed with water (100 mL). The organic layer was separated, washed with brine (100 mL), dried with anhydrous Na2SO4, and filtered under vacuum. The residue was purified by silica gel column chromatography (EA / PE = 1 / 100 - 3 / 1) to obtain the title compound as a yellow solid (400 mg, 67.4% yield). MS (ESI): m / z 277.1 [M+H] + .
[0258] Step 2: 6-((E)-3-(dimethylamino)acryloyl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide.
[0259] A mixture of 6-acetyl-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (400 mg, 1.30 mmol) and DMF-DMA (10 mL) was stirred at 110°C for 3 hours. The mixture was cooled to room temperature, diluted with EA (100 mL), and washed with saline solution (100 mL). The organic layer was dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (EA / PE = 1 / 100 to 2 / 1) to obtain the title compound as a yellow solid (330 mg, 61.1% yield). LC-MS (ESI): m / z 332.2 [M+H] + .
[0260] Step 3: 6-(isoxazole-5-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide.
[0261] NH2OH·HCl (41.9 mg, 0.603 mmol) was added to a solution of EtOH (5 mL) containing 6-((E)-3-(dimethylamino)acryloyl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (100 mg, 0.302 mmol), and the reaction mixture was stirred at 85°C for 12 hours. The resulting mixture was cooled and purified by preparative HPLC (System: Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 μm 20*250 nm, Mobile Phase A: 0.1% FA aqueous solution, Mobile Phase B: CH3CN, Flow rate: 20 mL / min; Column temperature: Room temperature) to obtain the white solid title compound (29.80 mg, 32.8% yield). MS (ESI): m / z 302.2 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.82 (d, J = 1.9 Hz, 1H), 8.49 (d, J = 8.6 Hz, 1H), 8.20 - 8.08 (m, 3H), 7.53 (d, J = 1.9 Hz, 1H), 3.89 - 3.79 (m, 1H), 3.26 (s, 3H), 3.17 - 3.10 (m, 1H), 2.12 - 1.97 (m, 2H), 1.89 - 1.85 m, 2H), 1.59 - 1.50 (m, 2H), 1.29 - 1.22 (m, 2H).
[0262] Example 11
[0263] N-((1r,4r)-4-methoxycyclohexyl)-6-(4H-1,2,4-triazole-4-yl)pyrazine-2-carboxamide(compound 18)
[0264]
[0265] Step 1: 6-amino-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide
[0266] HATU (983 mg, 2.59 mmol), DIEA (1.07 mL, 6.47 mmol), and trans-4-methoxycyclohexanamine hydrochloride (456 mg, 2.75 mmol) were added to a solution of DCM (15 mL) containing 6-aminopyrazine-2-carboxylic acid (300 mg, 2.16 mmol). The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was diluted with EA (100 mL) and brine (100 mL). The organic layer was separated, dried with anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to obtain the title compound as a yellow solid (200 mg, 37.1% yield).
[0267] Step 2: N-((1r,4r)-4-methoxycyclohexyl)-6-(4H-1,2,4-triazole-4-yl)pyrazine-2-carboxamide.
[0268] A mixture of 6-amino-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide (120 mg, 0.479 mmol), N,N'-bis(dimethylaminomethylene)hydrazine (81.8 mg, 0.575 mmol), and toluene (10 mL) containing TsOH (44.9 mg, 0.623 mmol) was degassed three times with argon. The reaction mixture was stirred at 120°C for 18 hours. The mixture was cooled to room temperature and concentrated. The residue was purified by preparative HPLC (System: Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 µm 20 × 250 nm, Mobile Phase A: 0.1% FA aqueous solution, Mobile Phase B: CH3CN, Flow rate: 20 mL / min; Column temperature: Room temperature) to obtain the title compound as a grayish-white solid (66.1 mg, 45.6% yield). MS (ESI): m / z 303.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ9.73 (s, 1H), 9.43 (s, 0.5H), 9.16 (s, 0.5H), 8.72 (d, J= 8.6 Hz, 0.5H), 8.22 (s, 0.5H), 8.05 (s, 0.5H), 7.96 (d, J = 8.3 Hz, 0.5H), 7.48 (d, J = 8.0 Hz, 0.5H), 7.12 (d, J = 7.8 Hz, 0.5H), 3.94 - 3.65 (m, 1H), 3.25 (d, J = 10.1 Hz, 3H), 3.17 - 3.08 (m, 1H), 2.12 - 1.94 (m, 2H), 1.90 - 1.82 (m, 2H), 1.61 - 1.44 (m, 1H), 1.43 - 1.32 (m, 1H), 1.30 - 1.16 (m, 2H).
[0269] Example 12
[0270] N-((1r,4r)-4-methoxycyclohexyl)-6-(1,3,4-oxadiazole-2-yl)picolinamide(compound 19)
[0271]
[0272] Step 1. Ethyl 6-(((1r,4r)-4-methoxycyclohexyl)carbamoyl)picolinate
[0273] A mixture of 6-bromo-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (1.00 g, 3.19 mmol), triethylamine (0.90 mL, 6.38 mmol), Pd(dppf)Cl2 (230 mg, 0.31 mmol), DMF (10 mL), and EtOH (10 mL) was heated at 80°C under a CO2 atmosphere (1 atm) for 18 hours. The mixture was diluted with EA (50 mL), washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified using a silica gel column (EA / PE = 1 / 100 to 1 / 3) to obtain the title compound as a white solid (667 mg, 68.2% yield). MS (ESI): 307.1 [M+H] + .
[0274] Step 2. 6-(hydrazine carbonyl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide.
[0275] A solution of ethyl 6-(((1r,4r)-4-methoxycyclohexyl)carbamoyl)picolinate (800 mg, 2.61 mmol), MeOH (15 mL), and hydrazine hydrate (0.215 mL, 4.44 mmol) was stirred overnight at 30°C. The reaction mixture was purified using a reverse-phase column (ACN / H2O = 1 / 0 to 30 / 1) to obtain the white solid title compound (120 mg, 15.7% yield), MS (ESI): m / z 293.1 [M+H] + , used in the next step without purification.
[0276] Step 3. N-((1r,4r)-4-methoxycyclohexyl)-6-(1,3,4-oxadiazole-2-yl)picolinamide.
[0277] A mixture of 6-(hydrazine carbonyl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (110 mg, 0.37 mmol), TsOH (64.8 mg, 0.37 mmol), and CH(OEt)3 (2.00 mL, 12.0 mmol) was stirred at 80°C for 4 hours. The mixture was diluted with EA (50 mL), washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% HCOOH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (5.23 mg, 4.6% yield). MS (ESI): m / z 303.4 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 9.51 (s, 1H), 8.38 - 8.32 (m, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.27 - 8.21 (m, 2H), 3.87 - 3.78 (m, 1H), 3.25 (s, 3H), 3.18 - 3.10 (m, 1H), 2.03 (d, J= 10.1 Hz, 2H), 1.89 (d, J = 9.9 Hz, 2H), 1.60 - 1.40 (m, 2H), 1.30 - 1.20 (m, 2H).
[0278] Example 13
[0279] 5-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide(compound 20)
[0280]
[0281] Step 1. 6-Bromo-5-((2,4-Dimethoxybenzyl)amino)-N-((1r,4r)-4-Methoxycyclohexyl)Picolinamide
[0282] A mixture of 6-bromo-5-fluoro-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (120 mg, 0.362 mmol), (2,4-dimethoxyphenyl)methaneamine (0.11 mL, 0.725 mmol), and DMF (2 mL) containing DIEA (0.18 mL, 1.08 mmol) was stirred at 100°C for 2 hours. The reaction mixture was diluted with H2O (20 mL) and extracted with EA (50 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 20 / 1 - 2 / 1) to obtain the title compound (70.2 mg, 40.4% yield), a pale yellow oily substance. LC-MS (ESI): m / z 480.0 [M+H] + .
[0283] Step 2. 5-((2,4-dimethoxybenzyl)amino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide.
[0284] A mixture of 6-bromo-5-((2,4-dimethoxybenzyl)amino)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (70.2 mg, 0.146 mmol), imidazole (11.9 mg, 0.176 mmol), CuI (2.79 mg, 0.015 mmol), Cs2CO3 (95.3 mg, 0.293 mmol), and DMF (3 mL) containing trans-N,N'-dimethylcyclohexane-1,2-diamine (0.003 mL, 0.015 mmol) was bubbled with N2 for 1 minute. The reaction tube was sealed and heated in a microwave reactor at 120°C for 0.5 hours. The reaction mixture was diluted with H2O (20 mL) and extracted with EA (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1 - 40 / 1) to obtain the title compound (45.0 mg, 66.2% yield), a pale yellow oily substance. LC-MS (ESI): m / z 466.1 [M+H] + .
[0285] Step 3. 5-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide.
[0286] A mixture of 5-((2,4-dimethoxybenzyl)amino)-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide (45.0 mg, 0.097 mmol) and TFA (5 mL) was stirred at 80°C for 2 hours. The reaction mixture was diluted with water (20 mL) and then extracted with EA (30 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: H2O solution of 0.1% NH4OH, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (2.34 mg, 0.01 mmol, 7.7% yield). MS (ESI): m / z 316.5 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.17 (s, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.65 (s, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.13 (s, 1H), 5.87 (s, 2H), 3.78 - 3.69 (m, 1H), 3.23 (s, 3H), 3.13 - 3.04 (m, 1H), 2.00 (d, J = 10.4 Hz, 2H), 1.79 (d, J = 10.7 Hz, 2H), 1.46 - 1.38 (m, 2H), 1.24 - 1.14 (m, 2H).
[0287] Example 14
[0288] 2-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide(compound 21)
[0289]
[0290] Step 1: 2-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0291] A mixture of 2,6-dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (1.00 g, 3.29 mmol), imidazole (220 mg, 3.29 mmol), and DMF (10 mL) containing K2CO3 (910 mg, 6.58 mmol) was heated at 80°C for 3 hours. The reaction mixture was cooled to room temperature and distributed between EtOAc (20 mL) and water (40 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 30 / 1) to obtain the title compound as a pale green solid (591 mg, 53.5% yield). MS (ESI): m / z 336.0 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.82 (s, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.38 (s, 1H), 8.16 (t, J = 1.4 Hz, 1H), 7.21 (d, J = 0.7 Hz, 1H), 3.87 - 3.75 (m, 1H), 3.25 (s, 3H), 3.14 - 3.05 (m, 1H), 2.03 (d, J = 10.7 Hz, 2H), 1.82 (d, J = 10.6 Hz, 2H), 1.61 - 1.48 (m, 2H), 1.28 - 1.16 (m, 2H).
[0292] Step 2: 2-amino-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide.
[0293] A mixture of 2-chloro-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (250 mg, 0.744 mmol), diphenylmethaneimine (150 μL, 0.893 mmol), Pd(OAc)2 (16.7 mg, 0.0741 mmol), BINAP (46.4 mg, 0.0741 mmol), and toluene (1.0 mL) containing Cs2CO3 (485 mg, 1.49 mmol) was heated at 100°C under an N2 atmosphere for 16 hours. The mixture was cooled, and the resulting mixture was distributed between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was dissolved in MeOH (5 mL), and then concentrated HCl (384 μL) was added. The resulting mixture was stirred at room temperature for 2 hours. Saturated aqueous Na2CO3 solution (10 mL) was added. The resulting mixture was extracted with CH2Cl2 (20 mL × 2). The combined organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1 - 10 / 1) to obtain the crude product (60 mg), and further purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 um OBD 19*250 mm, mobile phase A: 0.1% NH4OH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the HCl salt of the white solid title compound (13.29 mg, 5.1% yield). MS (ESI): m / z 317.1 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.62 (s, 1H), 8.15 (d, J= 8.2 Hz, 1H), 8.00 (s, 1H), 7.42 (s, 1H), 7.23 (s, 2H), 7.14 (s, 1H), 6.07 (s, 1H), 3.82 - 3.67 (m, 1H), 3.24 (s, 3H), 3.17 - 3.09 (m, 1H), 2.05 - 1.98 (m, 2H), 1.91 - 1.83 (m, 2H), 1.45 - 1.34 (m, 2H), 1.29 - 1.18 (m, 2H); and title compound of white solid (2.98 mg, 1.3% yield) MS (ESI): m / z 317.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.76 (s, 1H), 8.50 (d, J = 8.8 Hz, 1H), 8.03 (s, 1H), 7.66 (s, 2H), 7.09 (s, 1H), 6.96 (s, 1H), 3.83 - 3.74 (m, 1H), 3.26 (s, 3H), 3.16 - 3.07 (m, 1H), 2.07 - 2.03 (m, 2H), 1.82 - 1.76 (m, 2H), 1.58 - 1.48 (m, 2H), 1.25 - 1.16 (m, 2H).
[0294] The following compounds were synthesized according to the procedure described for compound 21.
[0295] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 22 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-(methylamino)pyrimidine-4-carboxamide 331.1 8.72 - 8.62 (m, 1H), 8.30 - 7.93 (m, 2H), 7.63 (s, 1H), 7.39 (s, 1H), 7.13 (s, 1H), 3.75 (s, 1H), 3.24 (s, 3H), 3.18 - 3.09 (m, 1H), 2.92 (s, 3H), 2.01 (d, J = 10.0 Hz, 2H), 1.87 (d, J = 10.4 Hz, 2H), 1.54 - 1.33 (m, 2H), 1.28 - 1.19 (m, 2H). 63 4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 301.4 8.71 (d, J = 5.5 Hz, 1H), 8.66 (s, 1H), 8.59 (d, J = 8.5 Hz, 1H), 8.28 (d, J = 2.1 Hz, 1H), 8.09 (s, 1H), 7.97 (dd, J = 5.5, 2.3 Hz, 1H), 7.19 (s, 1H), 3.86 - 3.75 (m, 1H), 3.25 (s, 3H), 3.16 - 3.06 (m, 1H), 2.02 (d, J = 10.6 Hz, 2H), 1.85 (d, J = 10.4 Hz, 2H), 1.56 - 1.44 (m, 2H), 1.29 - 1.17 (m, 2H). 64 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 302.1 9.19 (d, J = 1.0 Hz, 1H), 8.85 - 8.77 (m, 2H), 8.37 (d, J = 1.0 Hz, 1H), 8.20 (s, 1H), 7.20 (s, 1H), 3.86 - 3.78 (m, 1H), 3.24 (s, 3H), 3.15 - 3.06 (m, 1H), 2.03 (d, J = 10.5 Hz, 2H), 1.83 (d, J = 10.0 Hz, 2H), 1.55 - 1.48 (m, 2H), 1.28 - 1.18 (m, 2H).
[0296] Example 15
[0297] 6-(dimethylamino)-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide(compound 23)
[0298]
[0299] Step 1: 2,6-Dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide.
[0300] DIEA (5.15 mL, 31.1 mmol) and T3P (4.95 mL, 15.5 mmol, 50% EA solution) were added to a solution of DMF (15 mL) containing 2,6-dichloropyrimidine-4-carboxylic acid (1.00 g, 5.18 mmol). The reaction mixture was stirred at room temperature for 30 minutes, and trans-4-methoxycyclohexanamine hydrochloride (1.03 g, 6.22 mmol) was added. The reaction mixture was stirred at room temperature for 1.5 hours. The resulting mixture was diluted with water (150 mL) and extracted with DCM (100 mL × 2). The combined organic layer was washed with brine (150 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 10 / 1 to 2 / 1) to obtain the yellow solid title compound (479 mg, 30.3% yield). MS (ESI): m / z 304.1 [M+H] + .
[0301] Step 2: 2-chloro-6-(dimethylamino)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide.
[0302] Dimethylamine (0.74 mL, 1.48 mmol, 2.0 mol / L THF solution) was added to a solution of DMF (6 mL) containing 2,6-dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (150 mg, 0.49 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with water (60 mL) and extracted with EA (50 mL × 2). The combined organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 50 / 1 to 2 / 1) to obtain the title compound (110.7 mg, 71.8% yield) as a yellow oily substance. MS (ESI): m / z 313.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ8.26 (d, J= 8.4 Hz, 1H), 7.10 (s, 1H), 3.79 - 3.64 (m, 1H), 3.24 (s, 3H), 3.12 (s, 6H), 3.09 - 3.04 (m, 1H), 2.03 - 1.97(m, 2H), 1.82 - 1.75 (m, 2H), 1.54 - 1.44 (m, 2H), 1.25 - 1.16 (m, 2H).
[0303] Step 3: 6-(dimethylamino)-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide.
[0304] A mixture of 2-chloro-6-(dimethylamino)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (110.7 mg, 0.35 mmol), imidazole (28.9 mg, 0.43 mmol), CuI (6.74 mg, 0.035 mmol), Cs2CO3 (231 mg, 0.708 mmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (0.01 mL, 0.035 mmol), and DMF (3 mL) was bubbled with argon for 3 minutes. The reaction tube was sealed and heated in a microwave reactor at 130°C for 1 hour. The mixture was diluted with water (60 mL) and extracted with EA (50 mL × 2). The combined organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% NH4OH aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (62.8 mg, 51.5% yield). MS (ESI): m / z 345.2 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 8.92 (s, 1H), 8.61 (d, J= 8.6 Hz, 1H), 8.20 (s, 1H), 7.15 (s, 1H), 7.13 (s, 1H), 3.91 - 3.84 (m, 1H), 3.40 (s, 3H), 3.32 (s, 3H), 3.24 - 3.15 (m, 4H), 2.11 (d, J = 11.0 Hz, 2H), 1.89 (d, J = 10.7 Hz, 2H), 1.65 - 1.55 (m, 2H), 1.33 - 1.23 (m, 2H).
[0305] The following compounds were synthesized according to the procedure described for compound 23.
[0306] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 24 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(methylamino)pyrimidine-4-carboxamide 331.1 8.87 (s, 1H), 8.49 (d, J = 8.6 Hz, 1H), 8.18 - 8.06 (m, 2H), 7.11 (s, 1H), 7.23 - 6.81 (m, 2H), 6.99 (s, 1H), 3.80 - 3.70 (m, 1H), 3.23 (s, 3H), 3.12 (t, J = 10.6 Hz, 1H), 2.95 (d, J = 4.4 Hz, 3H), 2.05 (d, J = 10.5 Hz, 2H), 1.80 (d, J = 10.4 Hz, 2H), 1.60 - 1.50 (m, 2H), 1.26 - 1.16 (m, 2H). 26 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 385.2 8.85 (s, 1H), 8.53 (d, J = 8.6 Hz, 1H), 8.13 (s, 1H), 7.18 (s, 1H), 7.09 (s, 1H), 3.88 - 3.57 (m, 5H), 3.26 (s, 3H), 3.16 - 3.09 (m, 1H), 2.05 (d, J = 10.1 Hz, 2H), 1.82 (d, J = 10.1 Hz, 2H), 1.69 - 1.49 (m, 8H), 1.26 - 1.17 (m, 2H). 101 N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 367.3 10.51 (s, 1H), 8.93 (s, 1H), 8.21 (s, 1H), 7.84 (dt, J = 11.6, 2.2 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.45 (dd, J = 15.1, 8.2 Hz, 1H), 7.32 (s, 1H), 7.11 (s, 1H), 7.01 (td, J = 8.4, 2.1 Hz, 1H), 3.80 (s, 4H), 1.73-1.55 (m, 6H). 114 N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-morpholinopyrimidine-4-carboxamide 369.2 10.53 (s, 1H), 8.96 (s, 1H), 8.24 (s, 1H), 7.84 (dt, J = 11.6, 2.1 Hz, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.45 (dd, J = 15.1, 8.2 Hz, 1H), 7.35 (s, 1H), 7.12 (s, 1H), 7.02 (td, J = 8.4, 2.2 Hz, 1H), 3.91 - 3.62 (m, 8H). 117 N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-N-methyl-6-(piperidine-1-yl)pyrimidine-4-carboxamide 381.1 8.17 (s, 1H), 7.56 (s, 1H), 7.33-7.27 (m, 2H), 7.15 - 7.01 (m, 3H), 6.99 (s, 1H), 6.93 (s, 1H), 3.67 (s, 4H), 3.37 (s, 3H), 1.64-1.63 (m, 2H), 1.53 (s, 4H). 119 N-benzyl-2-(1H-imidazole-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxamide 363.1 9.55 (t, J = 6.4 Hz, 1H), 8.84 (s, 1H), 8.14 (t, J = 1.3 Hz, 1H), 7.32 (dd, J = 10.2, 2.9 Hz, 4H), 7.28 - 7.23 (m, 1H), 7.22 (s, 1H), 7.10 - 7.08 (m, 1H), 4.53 (d, J = 6.5 Hz, 2H), 1.66 (d, J = 4.6 Hz, 2H), 1.58 (d, J = 3.7 Hz, 4H). 128 4-(4,4-dimethylpiperidine-1-yl)-N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)picolinamide 394.2 10.45 (s, 1H), 8.95 (s, 1H), 8.30 (s, 1H), 7.89 - 7.83 (m, 1H), 7.77 - 7.71 (m, 1H), 7.49 (d, J = 2.1 Hz, 1H), 7.47 - 7.39 (m, 1H), 7.26 (d, J = 2.1 Hz, 1H), 7.12 (s, 1H), 7.03 - 6.94 (m, 1H), 3.60 - 3.53 (m, 4H), 1.48 - 1.40 (m, 4H), 1.00 (s, 6H). 129 N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-4-(piperidin-1-yl)picolinamide 366.1 10.45 (s, 1H), 8.95 (s, 1H), 8.30 (s, 1H), 7.90 - 7.81 (m, 1H), 7.78 - 7.70 (m, 1H), 7.47 (d, J = 1.8 Hz, 1H), 7.46 - 7.37 (m, 1H), 7.25 (d, J = 1.6 Hz, 1H), 7.12 (s, 1H), 7.02 - 6.94 (m, 1H), 3.65 - 3.52 (m, 4H), 1.72 - 1.54 (m, 6H). 130 N-cyclohexyl-6-(1H-imidazole-1-yl)-4-(piperidine-1-yl)picolinamide 354.2 8.89 (s, 1H), 8.40 (d, J = 8.8 Hz, 1H), 8.24 (s, 1H), 7.36 (d, J = 2.2 Hz, 1H), 7.18 (d, J = 2.2 Hz, 1H), 7.12 (s, 1H), 3.88 - 3.73 (m, 1H), 3.60 - 3.48 (m, 4H), 1.86 - 1.70 (m, 4H), 1.70 - 1.53 (m, 7H), 1.53 - 1.40 (m, 2H), 1.40 - 1.25 (m, 2H), 1.23 - 1.06 (m, 1H). 135 N-(2,5-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 385.1 10.46 (s, 1H), 8.81 (s, 1H), 8.12 (t, J = 1.2 Hz, 1H), 7.76 - 7.67 (m, 1H), 7.48 - 7.38 (m, 1H), 7.31 (s, 1H), 7.22 - 7.13 (m, 1H), 7.13 - 7.09 (m, 1H), 3.81 (s, 4H), 1.74 - 1.65 (m, 2H), 1.65 - 1.54 (m, 4H). 137 N-(5-fluoro-2-methylphenyl)-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 381.2 10.31 (s, 1H), 8.81 (s, 1H), 8.13 (s, 1H), 7.67 - 7.53 (m, 1H), 7.41 - 7.26 (m, 2H), 7.18 - 6.97 (m, 2H), 3.98 - 3.64 (m, 4H), 2.39 - 2.24 (m, 3H), 1.77 - 1.52 (m, 6H). 144 N-cyclohexyl-2-(1H-imidazole-1-yl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 355.2 8.86 (s, 1H), 8.53 (d, J = 8.6 Hz, 1H), 8.14 (s, 1H), 7.19 (s, 1H), 7.09 (s, 1H), 3.91 - 3.66 (m, 5H), 1.84 - 1.73 (m, 4H), 1.72 - 1.55 (m, 7H), 1.54 - 1.42 (m, 2H), 1.40 - 1.25 (m, 2H), 1.22 - 1.07 (m, 1H). 145 N-(tert-butyl)-2-(1H-imidazole-1-yl)-6-(piperidin-1-yl)pyrimidine-4-carboxamide 329.1 8.75 (s, 1H), 8.05 (t, J = 1.2 Hz, 1H), 8.00 (s, 1H), 7.20 (s, 1H), 7.08 (s, 1H), 3.75 (s, 4H), 1.74 - 1.64 (m, 2H), 1.63 - 1.52 (m, 4H), 1.42 (s, 9H). 147 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-(piperidine-1-yl)pyrimidine-4-carboxamide 369.2 8.85 (t, J = 1.0 Hz, 1H), 8.51 (d, J = 8.8 Hz, 1H), 8.13 (t, J = 1.3 Hz, 1H), 7.17 (s, 1H), 7.09 - 7.06 (m, 1H), 3.89 - 3.61 (m, 4H), 3.58 - 3.20 (m, 1H), 1.84 - 1.63 (m, 6H), 1.62 - 1.44 (m, 6H), 1.43 - 1.27 (m, 1H), 1.12 - 0.96 (m, 2H), 0.90 (d, J = 6.5 Hz, 3H). 148 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-morpholinopyrimidine-4-carboxamide 371.2 8.88 (s, 1H), 8.54 (d, J = 8.7 Hz, 1H), 8.16 (s, 1H), 7.20 (s, 1H), 7.09 (s, 1H), 3.88 - 3.60 (m, 9H), 1.79-1.68 (m, 4H), 1.59 - 1.45 (m, 2H), 1.42 - 1.26 (m, 1H), 1.14 - 0.96 (m, 2H), 0.94 - 0.87 (m, 3H).
[0307] Example 16
[0308] 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-3-carboxamide (compound 28)
[0309]
[0310] Step 1: 3-chloro-5-(1H-imidazole-1-yl)pyridazine.
[0311] A mixture of 3,5-dichloropyridazine (2.10 g, 14.1 mmol), 1H-imidazole (0.96 g, 14.1 mmol), and DMF (20 mL) containing K2CO3 (3.90 g, 28.2 mmol) was stirred overnight at 40°C. The reaction mixture was diluted with H2O (20 mL) and extracted with EA (50 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1 to 60 / 1) to obtain the white solid title compound (2.40 g, 94.3% yield). MS (ESI): m / z 181.1 [M+H] + .
[0312] Step 2: Methyl 5-(1H-imidazole-1-yl)pyridazine-3-carboxylate.
[0313] A mixture of 3-chloro-5-(1H-imidazole-1-yl)pyridazine (1.02 g, 5.53 mmol), triethylamine (1.54 mL, 11.1 mmol), Pd(dppf)Cl2 (0.41 g, 0.554 mmol), and MeOH (15 mL) was heated in an autoclave at 100°C under a CO2 atmosphere (16 atm) for 5 hours. The resulting mixture was cooled and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1 - 40 / 1) to obtain the title compound as a red solid (340 mg, 30.1% yield). MS (ESI): m / z 205.0 [M+H] + .
[0314] Step 3: 5-(1H-imidazole-1-yl)pyridazine-3-carboxylic acid.
[0315] A mixture of methyl 5-(1H-imidazole-1-yl)pyridazine-3-carboxylate (340 mg, 1.66 mmol), NaOH (133 mg, 3.33 mmol), MeOH (8 mL), and H2O (2 mL) was heated at 50°C for 2 hours. The reaction mixture was cooled to room temperature. The pH of the mixture was adjusted to 2–3 with dilute HCl (1.0 M). The resulting mixture was concentrated under reduced pressure to obtain the title compound as an orange solid (560 mg, 100% yield), MS (ESI): m / z 191.1 [M+H] + , used in the next step without purification.
[0316] Step 4: 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyridazine-3-carboxamide
[0317] Trans-4-methoxycyclohexanamine hydrochloride (105 mg, 0.631 mmol) was added to a mixture of DMF (5 mL) containing 5-(1H-imidazole-1-yl)pyridazine-3-carboxylic acid (100 mg, 0.526 mmol), HATU (239 mg, 0.631 mmol), and DIEA (0.26 mL, 1.578 mmol). The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (50 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1 - 30 / 1) to obtain the white solid title compound (11.5 mg, 7.3% yield). MS (ESI): m / z 302.1 [M+H] + ; 1 H NMR (400 MHz, CDCl3) δ 9.56 (s, 1H), 8.63 - 8.30 (m, 2H), 8.08 (s, 1H), 7.65 - 7.40 (m, 2H), 4.04 (s, 1H), 3.38 (s, 3H), 3.22 (s, 1H), 2.22 - 2.09 (m, 4H), 1.50 - 1.35 (m, 4H).
[0318] Example 17
[0319] N-cyclooctyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide (compound 65)
[0320]
[0321] Step 1. 2-Chloro-N-cyclooctylpyrimidine-4-carboxamide
[0322] A mixture of 2-chloropyrimidine-4-carboxylic acid (200 mg, 1.26 mmol), DIEA (0.63 mL, 3.78 mmol), T3P (0.63 mL, 3.78 mmol, 50% EA solution), and cyclooctylamine (0.17 mL, 1.26 mmol) in DCM (10 mL) was stirred at room temperature for 2 hours. The reaction mixture was diluted with H2O (30 mL), and the resulting mixture was extracted with EA (30 mL × 2). The combined organic layer was washed with brine (30 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 20 / 1-7 / 1) to obtain the title compound as a yellow solid (300 mg, 88.8% yield). MS (ESI): m / z 268.1 [M+H] + .
[0323] Step 2. N-cyclooctyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide
[0324] At 0°C, NaH (59.2 mg, 2.46 mmol, 60%, in oil) was added to a solution of THF (5 mL) containing 2-chloro-N-cyclooctylpyrimidine-4-carboxamide (228 mg, 3.36 mmol), the reaction mixture was heated to room temperature and stirred at this temperature for 0.5 hours. Imidazole (300 mg, 1.12 mmol) was added to the solution, and the mixture was heated at 70°C under an N2 atmosphere for 3 hours. The solution was quenched with H2O at 0°C, and the mixture was extracted with EA (30 mL × 2). The combined organic layer was washed with brine (30 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1-80 / 1) to obtain the white solid title compound (178 mg, 53.2% yield). MS (ESI): m / z 300.0 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 9.06 (d, J= 5.0 Hz, 1H), 8.96 (s, 1H), 8.88 (d, J = 8.4 Hz, 1H), 8.22 (t, J = 1.3 Hz, 1H), 7.90 (d, J = 5.0 Hz, 1H), 7.18 (s, 1H), 4.17 - 4.03 (m, 1H), 1.87 - 1.71 (m, 6H), 1.64 - 1.47 (m, 8H).
[0325] The following compounds were synthesized according to the procedure described for compound 65.
[0326] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 66 2-(1H-imidazole-1-yl)-N-(pyridin-3-yl)pyrimidine-4-carboxamide 267.2 10.89 (s, 1H), 9.16 (d, J = 5.0 Hz, 1H), 9.05 - 9.02 (m, 2H), 8.43 (dd, J = 4.7, 1.3 Hz, 1H), 8.32 (s, 1H), 8.29 - 8.24 (m, 1H), 8.06 (d, J = 5.0 Hz, 1H), 7.50 (dd, J = 8.3, 4.7 Hz, 1H), 7.22 (s, 1H). 72 N-cyclohexyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 272.2 9.06 (d, J = 5.0 Hz, 1H), 8.98 (s, 1H), 8.86 (d, J = 8.6 Hz, 1H), 8.24 (s, 1H), 7.91 (d, J = 5.0 Hz, 1H), 7.18 (s, 1H), 3.91 - 3.79 (m, 2H), 2.55 - 2.46 (m, 8H), 1.88 - 1.72 (m, 4H), 1.65 (d, J = 12.4 Hz, 1H), 1.57 - 1.38 (m, 2H), 1.40 - 1.27 (m, 2H), 1.21 - 1.10 (m, 1H). 73 4-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-2-carboxamide 302.1 9.04 (d, J = 5.6 Hz, 1H), 8.92 (s, 1H), 8.72 (d, J = 8.4 Hz, 1H), 8.23 (t, J = 1.4 Hz, 1H), 8.06 (d, J = 5.6 Hz, 1H), 7.22 (s, 1H), 3.85 - 3.75 (m, 1H), 3.25 (s, 3H), 3.19 - 3.07 (m, 1H), 2.05 (d, J = 10.5 Hz, 2H), 1.85 (d, J = 10.4 Hz, 2H), 1.59 - 1.45 (m, 2H), 1.30 - 1.18 (m, 2H). 82 2-(1H-imidazole-1-yl)-N-phenylpyrimidine-4-carboxamide 266.1 10.70 (s, 1H), 9.14 (s, 1H), 9.04 (s, 1H), 8.31 (s, 1H), 8.05 (s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.45 -7.40 (m, 2H), 7.25 - 7.19 (m, 2H). 83 2-(1H-imidazole-1-yl)-N-(o-tolyl)pyrimidine-4-carboxamide 280.1 10.62 (s, 1H), 9.14 (s, 1H), 8.98 (s, 1H), 8.29 (s, 1H), 8.02 (s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.38 -7.18 (m, 4H), 2.30 (s, 3H). 84 N-(2-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 284.1 10.77 (s, 1H), 9.15 (s, 1H), 8.98 (s, 1H), 8.28 (s, 1H), 8.02 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.40 -7.36 (m, 2H), 7.34 - 7.28 (m, 1H), 7.21 (s, 1H). 85 N-(2-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 300.0 10.77 (s, 1H), 9.17 (s, 1H), 8.90 (s, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.50 -7.33 (m, 2H), 7.21 (s, 1H). 86 2-(1H-imidazole-1-yl)-N-(2-methoxyphenyl)pyrimidine-4-carboxamide 296.2 10.45 (s, 1H), 9.15 (s, 1H), 8.78 (s, 1H), 8.11 (s, 1H), 8.05 (d, J = 7.2 Hz, 1H), 8.03 (s, 1H), 7.26 -7.16 (m, 3H), 7.03 (t, J = 7.2 Hz, 1H), 3.94 (s, 3H). 87 2-(1H-imidazole-1-yl)-N-(p-tolyl)pyrimidine-4-carboxamide 280.1 10.63 (s, 1H), 9.14 (s, 1H), 9.07 (s, 1H), 8.32 (s, 1H), 8.03 (s, 1H), 7.75 (s, 2H), 7.25 -7.22 (m, 3H), 2.32 (s, 3H). 88 N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 284.0 10.75 (s, 1H), 9.14 (s, 1H), 9.03 (s, 1H), 8.30 (s, 1H), 8.03 (s, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.8 Hz, 2H), 7.21 (s, 1H). 89 N-(4-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 300.1 10.78 (s, 1H), 9.14 (s, 1H), 9.03 (s, 1H), 8.30 (s, 1H), 7.92 (s, 2H), 7.51 (d, J = 8.8 Hz, 2H), 7.21 (s, 1H). 90 2-(1H-imidazole-1-yl)-N-(4-(trifluoromethyl)phenyl)pyrimidine-4-carboxamide 334.0 10.93 (s, 1H), 9.17 (s, 1H), 9.04 (s, 1H), 8.31 (s, 1H), 8.14 (d, J = 8.8 Hz, 2H), 8.07 (s, 2H), 7.83 (d, J = 8.8 Hz, 2H), 7.22 (s, 1H). 91 N-(4-cyanophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 291.2 10.95 (s, 1H), 9.17 (s, 1H), 9.05 (s, 1H), 8.31 (s, 1H), 8.13 (d, J = 8.8 Hz, 2H), 8.06 (s, 2H), 7.92 (d, J = 8.8 Hz, 2H), 7.23 (s, 1H). 92 2-(1H-imidazole-1-yl)-N-(m-tolyl)pyrimidine-4-carboxamide 280.1 10.62 (s, 1H), 9.14 (s, 1H), 9.04 (s, 1H), 8.31 (s, 1H), 8.03 (s, 1H), 7.69 (s, 2H),7.32 (t, J = 7.2 Hz, 1H), 7.21 (s, 1H), 7.04 (d, J = 7.6 Hz, 1H), 2.36 (s, 3H). 93 N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 284.2 10.79 (s, 1H), 9.16 (s, 1H), 9.03 (s, 1H), 8.30 (s, 1H), 8.04 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.50 - 7.45 (m, 1H), 7.21 (s, 1H), 7.08 - 7.03 (m, 1H). 94 N-(3-chlorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 300.0 10.78 (s, 1H), 9.15 (s, 1H), 9.04 (s, 1H), 8.31 (s, 1H), 8.03 (s, 2H), 7.89 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.21 (s, 1H). 95 2-(1H-imidazole-1-yl)-N-(thiazole-5-yl)pyrimidine-4-carboxamide 273.1 12.06 (s, 1H), 9.16 (s, 1H), 9.02 (s, 1H), 8.78 (s, 1H), 8.30 (s, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 7.23 (s, 1H). 96 N-cyclopentyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 258.1 9.06 (d, J = 4.8 Hz, 1H), 8.97 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.23 (s, 1H), 7.90 (d, J = 4.8 Hz, 1H), 7.18 (s, 1H), 4.35 - 4.25 (m, 1H), 2.00 - 1.90 (m, 2H), 1.80 - 1.53 (m, 6H). 97 N-cycloheptyl-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 286.2 9.06 (s, 1H), 8.98 (s, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.24 (s, 1H), 7.90 (s, 1H), 7.18 (s, 1H), 4.05 - 3.95 (m, 1H), 2.55 - 2.46 (m, 8H), 1.88 - 1.82 (m, 2H), 1.80 - 1.45 (m, 10H). 98 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 302.1 10.11 (s, 1H), 9.18 (d, J = 5.0 Hz, 1H), 9.03 (d, J = 8.6 Hz, 1H), 8.62 (s, 1H), 8.09 (d, J = 5.0 Hz, 1H), 7.78 (s, 1H), 3.95 - 3.80 (m, 1H), 3.26 (s, 3H), 3.19 - 3.08 (m, 1H), 2.08 (d, J = 11.0 Hz, 2H), 1.86 (d, J = 10.7 Hz, 2H), 1.65 - 1.53 (m, 2H), 1.30 - 1.17 (m, 2H). 99 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-methylpyrimidine-4-carboxamide 316.2 8.94 (s, 1H), 8.89 (d, J = 8.4 Hz, 2H), 8.20 (s, 1H), 7.83 (s, 1H), 7.16 (s, 1H), 3.88 -3.83 (m, 1H), 3.26 (s, 3H), 3.18 - 3.10 (m, 1H), 2.63 (s, 3H), 2.07 (d, J = 10.8 Hz, 2H), 1.84 (d, J = 10.8 Hz, 2H), 1.51 (q, J = 13.2 Hz, 2H), 1.23 (q, J = 13.2 Hz, 2H). 100 N-((1r,4r)-4-methoxycyclohexyl)-2-(1H-pyrazol-1-yl)pyrimidine-4-carboxamide 302.1 9.13 (s, 1H), 9.07 (s, 1H), 8.74 (d, J = 8.4 Hz, 1H), 7.90 (t, J = 4.8 Hz, 2H), 6.67 (s, 1H), 3.88 - 3.80 (m, 1H), 3.25 (s, 3H), 3.16 - 3.10 (m, 1H), 2.06 (d, J = 12.4 Hz, 2H), 1.86 (d, J = 12.0 Hz, 2H), 1.55 - 1.48 (m, 2H), 1.28 - 1.20 (m, 2H). 102 N-(3-fluorophenyl)-2-(1H-pyrazol-1-yl)pyrimidine-4-carboxamide 284.1 10.82 (s, 1H), 9.23 (d, J = 2.4 Hz, 1H), 9.16 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 4.9 Hz, 1H), 7.94 (s, 1H), 7.84 (t, J = 9.0 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.47 (dd, J = 15.1, 8.1 Hz, 1H), 7.05 (td, J = 8.4, 2.1 Hz, 1H), 6.70 (d, J = 1.6 Hz, 1H). 107 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)pyrimidine-4-carboxamide 346.1 9.06 (d, J = 5.0 Hz, 1H), 8.97 (s, 1H), 8.85 (d, J = 8.6 Hz, 1H), 8.23 (t, J = 1.3 Hz, 1H), 7.91 (d, J = 5.0 Hz, 1H), 7.18 (s, 1H), 3.91 - 3.78 (m, 1H), 3.55 (dd, J = 5.8, 3.9 Hz, 2H), 3.43 (dd, J = 5.8, 3.9 Hz, 2H), 3.31 - 3.21 (m, 4H), 2.05 (d, J = 10.6 Hz, 2H), 1.84 (d, J = 10.6 Hz, 2H), 1.65 - 1.50 (m, 2H), 1.34 - 1.18 (m, 2H). 108 N-(4,4-dimethylcyclohexyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 300.4 9.06 (d, J = 5.0 Hz, 1H), 8.98 (s, 1H), 8.84 (d, J = 8.7 Hz, 1H), 8.23 (t, J = 1.3 Hz, 1H), 7.91 (d, J = 5.0 Hz, 1H), 7.20 - 7.18 (m, 1H), 3.86 - 3.71 (m, 1H), 1.80 - 1.58 (m, 4H), 1.43 (d, J = 12.9 Hz, 2H), 1.36 - 1.21 (m, 2H), 0.99 (s, 3H), 0.94 (s, 3H). 109 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)pyrimidine-4-carboxamide 286.2 9.06 (d, J = 5.0 Hz, 1H), 8.98 (s, 1H), 8.85 (d, J = 8.7 Hz, 1H), 8.24 (s, 1H), 7.91 (d, J = 5.0 Hz, 1H), 7.18 (s, 1H), 3.88 - 3.74 (m, 1H), 1.84-1.69 (m, 4H), 1.62 - 1.47 (m, 2H), 1.42 - 1.30 (m, 1H), 0.91 (d, J = 6.5 Hz, 3H). 110 N-(4,4-difluorocyclohexyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 308.3 1 H NMR (400 MHz, DMSO- d 6 ) δ9.07 d, J = 5.0 Hz, 1H), 8.99 - 8.92 (m, 2H), 8.24 (s, 1H), 7.92 (d, J = 5.0 Hz, 1H), 7.18 (s, 1H), 4.16 - 4.02 (m, 1H), 2.16 - 1.92 (m, 4H), 1.91 - 1.75 (m, 4H). 111 2-(1H-imidazole-1-yl)-N-(pyridine-4-yl)pyrimidine-4-carboxamide 267.1 12.29 (s, 1H), 10.76 (s, 1H), 9.35 (d, J = 5.0 Hz, 1H), 8.90 (d, J = 6.8 Hz, 2H), 8.82 (d, J = 7.2 Hz, 3H), 8.31 (d, J = 5.0 Hz, 1H), 7.86 (s, 1H). 112 2-(1H-imidazole-1-yl)-N-(pyridine-2-yl)pyrimidine-4-carboxamide 267.0 1 H NMR (400 MHz, DMSO- d 6 )δ11.08 s, H), .16 d, J = 5.0 Hz, 1H), 9.00 (s, 1H), 8.51 - 8.46 (m, 1H), 8.30 (t, J = 1.3 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.07 (d, J = 5.0 Hz, 1H), 7.97 - 7.91 (m, 1H), 7.30 - 7.25 (m, 1H), 7.20 - 7.18 (m, 1H). 113 2-(1H-imidazole-1-yl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidine-4-carboxamide 286.2 9.07 (d, J = 5.0 Hz, 1H), 8.93 (s, 1H), 8.70 (d, J = 8.1 Hz, 1H), 8.19 (t, J = 1.3 Hz, 1H), 7.91 (d, J = 5.0 Hz, 1H), 7.19 (s, 1H), 3.95 - 3.85 (m, 1H), 1.83-1.76 (m, 3H), 1.63 - 1.53 (m, 4H), 1.47-1.43 (m, 2H), 1.00 (d, J = 7.0 Hz, 3H). 116 N-(3-fluorophenyl)-2-(1H-pyrazole-5-yl)pyrimidine-4-carboxamide 284.0 10.81 (s, 1H), 9.24 (d, J = 2.4 Hz, 1H), 9.16 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 4.9 Hz, 1H), 7.94 (dd, J = 3.0, 2.1 Hz, 1H), 7.85 - 7.80 (m, 1H), 7.73 - 7.70 (m, 1H), 7.51 - 7.44 (m, 1H), 7.08 - 7.01 (m, 1H), 6.70 (dd, J = 2.7, 1.6 Hz, 1H). 125 N-(3,4-difluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 302.0 10.80 (s, 1H), 9.15 (d, J = 5.0 Hz, 1H), 9.02 (s, 1H), 8.29 (t, J = 1.3 Hz, 1H), 8.08 - 7.97 (m, 2H), 7.75 - 7.71 (m, 1H), 7.57 - 7.49 (m, 1H), 7.21 (s, 1H). 126 N-(3,5-difluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 302.1 10.86 (s, 1H), 9.16 (d, J = 5.0 Hz, 1H), 9.02 (s, 1H), 8.29 (t, J = 1.3 Hz, 1H), 8.05 (d, J = 5.0 Hz, 1H), 7.73 (dd, J = 9.6, 2.2 Hz, 2H), 7.22 (s, 1H), 7.12-7.06 (m, 1H). 127 N-(4-chloro-3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 318.0 10.87 (s, 1H), 9.17 (d, J = 5.0 Hz, 1H), 9.07 (s, 1H), 8.31 (s, 1H), 8.05 (dd, J = 8.4, 3.6 Hz, 2H), 7.81 (dd, J = 8.8, 1.6 Hz, 1H), 7.68 (t, J = 8.6 Hz, 1H), 7.25 (s, 1H).
[0327] Example 18
[0328] 3-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide (compound 67)
[0329]
[0330] Step 1. Methyl 6-bromo-3-hydroxypyrazine-2-carboxylate:
[0331] At 0°C, NaNO2 (1.19 g, 17.2 mmol) was added to a solution of concentrated H2SO4 (8.0 mL) containing methyl 3-amino-6-bromopyrazine-2-carboxylate (2.00 g, 8.62 mmol), and the mixture was heated at room temperature for 2 hours. The mixture was diluted with ice and water (50 mL) to obtain a suspension. The mixture was filtered, the filter cake was collected, and dried under vacuum to obtain the title compound as a white solid (1.70 g, 84.6% yield). MS (ESI): m / z 235.0 [M+H] + .
[0332] Step 2. 6-Bromo-3-hydroxypyrazine-2-carboxylic acid:
[0333] LiOH·H2O (270 mg, 6.43 mmol) was added to a solution of MeOH (20 mL) and water (5 mL) containing methyl 3-hydroxy-6-bromopyrazine-2-carboxylate (500 mg, 2.14 mmol). The mixture was heated at 50°C for 4 hours. The reaction mixture was cooled to room temperature. The pH of the mixture was adjusted to 2–3 with concentrated HCl. The resulting mixture was concentrated under reduced pressure to obtain a solid. The solid was filtered, the filter cake was collected, and the mixture was dried under vacuum to obtain a white solid of the title compound (450 mg, 95.8% yield). MS (ESI): 218.9 [M+H] + , used in the next step without purification.
[0334] Step 3. 6-Bromo-3-hydroxy-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide:
[0335] DIEA (1.02 mL, 6.16 mmol), trans-4-methoxycyclohexanamine hydrochloride (340 mg, 2.05 mmol), and HATU (860 mg, 2.26 mmol) were added to a solution of DMF (10 mL) containing 6-bromo-3-hydroxypyrazine-2-carboxylic acid (450 mg, 2.05 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EA (50 mL), washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified using a silica gel column (EA / PE = 1 / 50 to 1 / 1) to obtain the title compound as a white solid (500 mg, 73.7% yield). MS (ESI): m / z 332.0 [M+H] + .
[0336] Step 4. 3-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide.
[0337] A mixture of 6-bromo-3-hydroxy-N-((1r,4r)-4-methoxycyclohexyl)pyrazine-2-carboxamide (150 mg, 0.45 mmol), imidazole (62 mg, 0.90 mmol), CuI (8.7 mg, 0.045 mmol), Cs2CO3 (296.04 mg, 0.90 mmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (6.5 mg, 0.045 mmol), and DMF (4 mL) was bubbled with argon for 3 minutes. The reaction tube was closed and heated in a microwave reactor at 130°C for 1 hour. The reaction mixture was diluted with EA (20 mL) and washed with brine (30 mL × 2). The organic phase was concentrated under reduced pressure. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Inertsil ODS-3 10 µm 20×250 nm, mobile phase A: 0.1% aqueous formic acid, mobile phase B: CH3CN, flow rate: 20 mL / min; column temperature: room temperature) to obtain the white solid title compound (18.08 mg, 12.3% yield). MS (ESI): m / z 318.5 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ13.29 (s, 1H), 9.12 (s, 1H), 8.89 (s, 1H), 8.74 (s, 1H), 8.14 (s, 1H), 7.16 (s, 1H), 3.86 (d, J = 8.7 Hz, 1H), 3.26 (s, 3H), 3.13 (m, 1H), 2.06 (d, J = 10.0 Hz, 2H), 1.87 (d, J = 10.7 Hz, 2H), 1.60 - 1.48 (m, 2H), 1.30 - 1.18 (m, 2H).
[0338] The following compounds were synthesized according to the procedure described for compound 67.
[0339] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 68 2-hydroxy-5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)nicotinamide 317.2 12.98 (s, 1H), 9.76 (d, J = 7.5 Hz, 1H), 8.43 (s, 1H), 8.13 (s, 1H), 8.01 - 7.04 (m, 2H), 3.77 (s, 1H), 3.24 (s, 2H), 3.20 - 3.13 (m, 1H), 2.02 - 1.83 (m, 2H), 1.36 - 1.18 (m, 2H). 71 3-hydroxy-6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 317.2 12.68 (s, 1H), 8.83 (d, J = 8.7 Hz, 2H), 8.18 (s, 1H), 7.95 (d, J = 8.9 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.12 (s, 1H), 3.85 (dd, J = 12.3, 7.8 Hz, 1H), 3.26 (s, 3H), 3.16 - 3.09 (m, 1H), 2.07 (d, J = 10.6 Hz, 2H), 1.85 (d, J = 10.4 Hz, 2H), 1.65 - 1.55 (m, 2H), 1.30 - 1.20 (m, 2H). 74 6-(1H-imidazole-1-yl)-5-methoxy-N-((1r,4r)-4-methoxycyclohexyl)picolinamide 331.1 8.64 (s, 1H), 8.28 (d, J = 8.5 Hz, 1H), 8.12 (s, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.10 (s, 1H), 4.01 (s, 3H), 3.86 - 3.74 (m, 1H), 3.25 (s, 3H), 3.15 - 3.08 (m, 1H), 2.04 (d, J = 10.3 Hz, 2H), 1.82 (d, J = 11.1 Hz, 2H), 1.59 - 1.47 (m, 2H), 1.28 - 1.16 (m, 2H).
[0340] Example 19
[0341] 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide(compound 103)
[0342]
[0343] Step 1: 2,6-Dichloropyrimidine-4-carbonyl chloride
[0344] A solution of POCl3 (50 mL) containing 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid (10 g, 64.06 mmol) was heated overnight at 110°C under an N2 atmosphere in the presence of a catalytic amount of DMF (0.25 mL, 3.20 mmol). Volatiles were removed under vacuum, and the residue was extracted with Et2O (100 mL × 3). The combined organic layer was dried with anhydrous Na2SO4, filtered, concentrated, and dried to obtain the title compound, which was used directly in the next step without further purification.
[0345] Step 2: 2,6-Dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0346] At 0°C, Et2O containing 2,6-dichloropyrimidine-4-carbonyl chloride (1 g, 4.73 mmol) was added to a mixture of DCM (10 mL) containing (1r,4r)-4-methoxycyclohexane-1-amine hydrochloride (0.94 g, 5.68 mmol) and Et3N (4.78 g, 47.29 mmol), and the mixture was stirred under N2 at room temperature for 1 hour. The reaction mixture was diluted with H2O (60 mL), and the resulting mixture was extracted with CH2Cl2 (60 mL × 2). The combined organic layer was washed with brine (60 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 20 / 1-4 / 1) to obtain the white solid title compound (689 mg, 47.9% yield). MS (ESI): m / z 304.0 [M+H] + .
[0347] Step 3: 2-chloro-N-((1r,4r)-4-methoxycyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0348] A mixture of 2,6-dichloro-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (300 mg, 0.99 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.31 mL, 2.47 mmol), and NMP (2 mL) containing CuI (374.78 mg, 1.97 mmol) was heated in a microwave reactor at 100°C for 1.5 hours. The resulting mixture was cooled and distributed between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated and dried. The residue was purified by silica gel chromatography (PE / EA = 20 / 1-1 / 1) to obtain the title compound as a grayish-white solid (120 mg, 36.0% yield). MS (ESI): m / z 338.1 [M+H] + . 1 H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 3.94 - 3.84 (m, 1H), 3.31 (dt, J = 3.2, 1.6 Hz, 1H), 2.16 - 2.10 (m, 2H), 2.03 - 1.93 (m, 3H), 1.60 - 1.47 (m, 3H), 1.32 (qd, J = 13.0, 3.4 Hz, 3H).
[0349] Step 4: 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0350] A mixture of ACN (2 mL) and DMF (2 mL) containing 2-chloro-N-((1r,4r)-4-methoxycyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide (55 mg, 0.16 mmol), 1H-imidazole (33 mg, 0.49 mmol), and K2CO3 (66 mg, 0.49 mmol) was heated at 80°C for 4 hours. The resulting mixture was distributed between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Waters sunfire C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% HCl aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the title compound as a yellow solid (30 mg, 49.9% yield). MS (ESI): m / z 370.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 10.24 (s, 1H), 9.27 (d, J = 8.5 Hz, 1H), 8.60 (s, 1H), 8.37 (s, 1H), 8.37 (s, 1H), 7.78 (s, 1H), 7.78 (s, 1H), 3.96 - 3.84 (m, 1H), 3.26 (s, 3H), 3.20 - 3.09 (m, 1H), 2.08 (d, J = 11.8 Hz, 2H), 1.86 (d, J = 11.0 Hz, 2H), 1.68-1.59 (m, 2H), 1.29-1.20 (m, 2H).
[0351] The following compound was synthesized according to the procedure described for compound 103.
[0352] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 123 N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 352.0 10.92 (s, 1H), 9.09 (s, 1H), 8.33 (s, 1H), 8.29 (s, 1H), 7.86 -7.79 (m, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.50 (dd, J = 15.1, 8.1 Hz, 1H), 7.25 (s, 1H), 7.08 (td, J = 8.5, 2.4 Hz, 1H). 124 N-(3-chlorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 368.0 10.90 (s, 1H), 9.09 (s, 1H), 8.33 (s, 1H), 8.29 (t, J = 1.3 Hz, 1H), 8.03 (t, J = 2.0 Hz, 1H), 7.93- 7.87 (m, 1H), 7.50 (t, J = 8.1 Hz, 1H), 7.31 (dd, J = 8.0, 1.2 Hz, 1H), 7.25 (s, 1H). 133 N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-4-(trifluoromethyl)picolinamide 351.0 10.70 (s, 1H), 9.14 (s, 1H), 8.54 (s, 1H), 8.49 (t, J = 1.4 Hz, 1H), 8.25 (s, 1H), 7.87 - 7.80 (m, 1H), 7.78 - 7.70 (m, 1H), 7.52 - 7.43 (m, 1H), 7.25 - 7.20 (m, 1H), 7.09 - 6.99 (m, 1H). 138 N-(4,4-dimethylcyclohexyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 368.2 9.04 (s, 1H), 8.98 (d, J = 8.6 Hz, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 7.23 (s, 1H), 3.93 - 3.75 (m, 1H), 1.80 - 1.58 (m, 4H), 1.49 - 1.38 (m, 2H), 1.37 - 1.23 (m, 2H), 1.03 - 0.89 (m, 6H). 140 N-cyclohexyl-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 340.0 9.03 (s, 1H), 9.00 (d, J = 8.6 Hz, 1H), 8.22 (t, J = 1.3 Hz, 1H), 8.18 (s, 1H), 7.24 - 7.20 (m, 1H), 3.94 - 3.78 (m, 1H), 1.91 - 1.73 (m, 4H), 1.72 - 1.60 (m, 1H), 1.58 - 1.44 (m, 2H), 1.43 ?- 1.27 (m, 2H), 1.26 - 1.11 (m, 1H). 141 N-(tert-butyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 314.0 9.25 - 9.10 (m, 1H), 8.44 - 8.39 (m, 1H), 8.29 - 8.26 (m, 1H), 8.26 - 8.23 (m, 1H), 7.36 - 7.32 (m, 1H), 1.50 - 1.44 (m, 9H). 146 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 354.0 9.04 (s, 1H), 9.00 (d, J = 8.6 Hz, 1H), 8.23 (t, J = 1.3 Hz, 1H), 8.18 (s, 1H), 7.22 (s, 1H), 3.93 - 3.76 (m, 1H), 1.87 - 1.71 (m, 4H), 1.63 - 1.49 (m, 2H), 1.44 - 1.31 (m, 1H), 1.13 - 0.98 (m, 2H), 0.91 (d, J = 6.5 Hz, 3H). 151 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-3-(trifluoromethyl)picolinamide 369.2 8.70 (s, 1H), 8.61 (d, J = 7.9 Hz, 1H), 8.49 (d, J = 8.7 Hz, 1H), 8.09 (dd, J = 5.0, 3.6 Hz, 2H), 7.19 (s, 1H), 3.79 - 3.69 (m, 1H), 3.24 (s, 3H), 3.17 - 3.08 (m, 1H), 2.02 (dd, J = 12.7, 2.4 Hz, 2H), 1.89 (dd, J = 12.8, 2.9 Hz, 2H), 1.40 -1.19 (m, 4H). 152 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-(trifluoromethyl)picolinamide 369.1 8.64 (d, J = 8.2 Hz, 1H), 8.57 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 7.7 Hz, 1H), 8.18 (s, 1H), 7.65 (s, 1H), 7.15 (s, 1H), 3.87 - 3.76 (m, 1H), 3.24 (s, 3H), 3.13 - 3.04 (m, 1H), 2.02 (d, J = 10.4 Hz, 2H), 1.81 (d, J = 10.5 Hz, 2H), 1.56-1.45 (m, 2H), 1.27 - 1.14 (m, 2H). 153 N-((1r,4r)-4-methoxycyclohexyl)-2-(4-(trifluoromethyl)-1H-imidazole-1-yl)pyrimidine-4-carboxamide 370.1 9.12 (d, J = 5.0 Hz, 1H), 9.09 (s, 1H), 8.90 (d, J = 8.6 Hz, 1H), 8.88 (d, J = 1.3 Hz, 1H), 8.01 (d, J = 5.0 Hz, 1H), 3.90 - .80 (m, 1H), 3.26 (s, 3H), 3.18 -3.10 (m, 1H), 2.08 (d, J = 10.0 Hz, 2H), 1.87 (d, J = 11.2 Hz, 2H), 1.62-1.52 (m, 2H), 1.30 -1.17 (m, 2H). 154 N-((1r,4r)-4-methoxycyclohexyl)-2-(2-(trifluoromethyl)-1H-imidazole-1-yl)pyrimidine-4-carboxamide 370.1 9.18 (d, J = 5.0 Hz, 1H), 8.58 (s, 1H), 8.49 (d, J = 6.6 Hz, 1H), 8.05 (d, J = 5.0 Hz, 1H), 7.38 (s, 1H), 3.89 - .76 (m, 1H), 3.25 (s, 3H), 3.18-3.12 (m, 1H), 2.05 (d, J = 11.0 Hz, 2H), 1.95 - .84 (m, 2H), 1.51-1.42 (m, 2H), 1.30-1.20 (m, 2H). 157 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 414.2 9.02 (s, 1H), 8.99 (d, J = 8.5 Hz, 1H), 8.21 (t, J = 1.4 Hz, 1H), 8.18 (s, 1H), 7.22 (dd, J = 1.4, 0.9 Hz, 1H), 3.91-3.83 (m, 1H), 3.55 (dd, J = 5.8, 3.9 Hz, 2H), 3.43 (dd, J = 5.7, 3.9 Hz, 2H), 3.30 - .24 (m, 4H), 2.06 (d, J = 11.0 Hz, 2H), 1.86 (d, J = 10.6 Hz, 2H), 1.62-1.53(m, 2H), 1.31-1.22 (m, 2H). 158 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)-4-(trifluoromethyl)picolinamide 353.1 9.09 (s, 1H), 8.72 (d, J = 8.5 Hz, 1H), 8.43 (s, 2H), 8.11 (s, 1H), 7.19 (s, 1H), 3.88 - .78 (m, 1H), 1.82-1.72 (m, 4H), 1.61 -1.52 (m, 2H), 1.42 - .32 (m, 1H), 1.12 -0.99 (m, 2H), 0.91 (d, J = 6.5 Hz, 3H). 159 N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-3-(trifluoromethyl)picolinamide 351.1 10.98 (s, 1H), 8.77 (s, 1H), 8.61 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.15 (s, 1H), 7.69 (dt, J = 11.5, 2.1 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.46-7.41 (m, 1H), 7.21 (s, 1H), 7.05 -6.98 (m, 1H). 160 N-(3-fluorophenyl)-6-(1H-imidazole-1-yl)-5-(trifluoromethyl)picolinamide 351.1 10.74 (s, 1H), 8.73 (d, J = 8.2 Hz, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.23 (s, 1H), 7.81 (dt, J = 11.6, 2.3 Hz, 1H), 7.71 (s, 1H), 7.70 - .67 (m, 1H), 7.43 (td, J = 8.2, 7.0 Hz, 1H), 7.19 - .16 (m, 1H), 7.01 (td, J = 8.5, 2.5 Hz, 1H). 161 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-5-(trifluoromethyl)pyrimidine-4-carboxamide 370.1 9.38 (s, 1H), 8.82 (d, J = 7.7 Hz, 1H), 8.73 (s, 1H), 8.05 (s, 1H), 7.22 (s, 1H), 3.83 -3.70 (m, 1H), 3.24 (s, 3H), 3.19 -3.08 (m, 1H), 2.01 (d, J = 10.3 Hz, 2H), 1.90 (d, J = 10.1 Hz, 2H), 1.43 -1.20 (m, 4H). 162 2-(1H-imidazole-1-yl)-N-(piperidine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide hydrochloride 341.1(M-HCl+H + ) 10.14 (s, 1H), 9.56 (d, J = 8.0 Hz, 1H), 9.13-9.04 (m, 2H), 8.57 (s, 1H), 8.37 (s, 1H), 7.70 (s, 1H), 4.23 - 4.14 (m, 1H), 3.35 (d, J = 12.6 Hz, 2H), 3.10 -2.98 (m, 2H), 2.101-1.950 (m, 4H). 163 2-(1H-imidazole-1-yl)-N-(tetrahydro-2H-pyran-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 342.1 9.09 (d, J = 8.3 Hz, 1H), 9.03 (s, 1H), 8.23 (s, 1H), 8.19 (s, 1H), 7.23 (s, 1H), 4.19 - 4.06 (m, 1H), 3.93 (d, J = 10.9 Hz, 2H), 3.42 (td, J = 1.3, 3.5 Hz, 2H), 1.85 - 1.72 (m, 4H). 164 N-(6-cyanopyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 360.1 11.28 (s, 1H), 9.24 (d, J = 2.0 Hz, 1H), 9.07 (s, 1H), 8.56 (dd, J = 8.6, 2.5 Hz, 1H), 8.37 (s, 1H), 8.28 (t, J = 1.3 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.27 - 7.26 (m, 1H). 165 N-(4-cyanophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 359.0 11.08 (s, 1H), 9.08 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.13 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 7.26 (s, 1H). 166 2-(1H-imidazole-1-yl)-N-(pyridine-3-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 334.9 11.00 (s, 1H), 9.09 (s, 1H), 9.04 (d, J = 2.3 Hz, 1H), 8.45 (dd, J = 4.7, 1.3 Hz, 1H), 8.34 (s, 1H), 8.29 (s, 1H), 8.28 - 8.25 (m, 1H), 7.51 (dd, J = 8.2, 4.7 Hz, 1H), 7.26 (s, 1H). 167 N-(5-fluoropyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 352.9 11.15 (s, 1H), 9.08 (s, 1H), 8.96 (t, J = 1.5 Hz, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.35 (s, 1H), 8.29 - 8.24 (m, 2H), 7.26 (dd, J = 1.4, 0.9 Hz, 1H). 168 2-(1H-imidazole-1-yl)-N-(pyridine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 334.9 11.04 (s, 1H), 9.08 (s, 1H), 8.61 (dd, J = 4.8, 1.5 Hz, 2H), 8.35 (s, 1H), 8.29 (t, J = 1.4 Hz, 1H), 7.94 (dd, J = 4.8, 1.5 Hz, 2H), 7.26 (s, 1H). 169 N-(5-cyanopyridine-3-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 360.0 11.21 (s, 1H), 9.32 (d, J = 2.4 Hz, 1H), 9.07 (s, 1H), 8.90 (d, J = 1.8 Hz, 1H), 8.72 (t, J = 2.1 Hz, 1H), 8.36 (s, 1H), 8.28 (s, 1H), 7.27 (s, 1H). 170 2-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 336.0 11.17 (s, 1H), 9.27 (s, 2H), 9.07 (s, 2H), 8.36 (s, 1H), 8.28 (s, 1H), 7.27 (s, 1H). 171 2-(1H-imidazole-1-yl)-N-(pyridazine-4-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 336.0 11.24 (s, 1H), 9.72 (dd, J = 2.6, 0.9 Hz, 1H), 9.23 (d, J = 5.9 Hz, 1H), 9.07 (s, 1H), 8.37 (s, 1H), 8.30 - 8.27 (t, J = 1.2 Hz, 1H), 8.24 (dd, J = 5.9, 2.7 Hz, 1H), 7.28 (s, 1H). 172 N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 352.0 10.88 (s, 1H), 9.09 (s, 1H), 8.32 (s, 1H), 8.29 (t, J = 1.4 Hz, 1H), 7.92 ? 7.87 (m, 2H), 7.34 - 7.28 (m, 2H), 7.25 (d, J = 0.9 Hz, 1H). 173 N-(3,4-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 370.0 10.98 (s, 1H), 9.38 (s, 1H), 8.40 (d, J = 8.1 Hz, 2H), 8.04-7.08 (m, 1H), 7.73-7.71 (m, 1H), 7.59-7.52 (m, 1H), 7.43 (s, 1H). 174 N-(3,5-difluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 370.0 11.00 (s, 1H), 9.08 (s, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 7.72 (d, J = 7.6 Hz, 2H), 7.26 (s, 1H), 7.13 (t, J = 9.1 Hz, 1H).
[0353] Example 20
[0354] 6-Cyclobutoxy-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (Compound 104)
[0355]
[0356] Step 1: 2-chloro-6-cyclobutoxy-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0357] At 0°C, NaH (25.2 mg, 1.05 mmol, 60%, in oil) was added to a mixture of THF (5 mL) containing cyclobutanol (0.04 mL, 0.57 mmol), the reaction mixture was heated to room temperature and stirred at this temperature for 0.5 hours. Then, 2,6-dichloro-N-[(1r,4r)-4-methoxycyclohexyl]pyrimidine-4-carboxamide (160 mg, 0.57 mmol) was added, and the mixture was stirred at room temperature under an N2 atmosphere for 3 hours. The mixture was quenched with H2O at 0°C, and the mixture was extracted with EA (50 mL × 2). The combined organic layer was washed with brine (40 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 20 / 1 - 4 / 1) to obtain the white solid title compound (200 mg, 100% yield). MS (ESI): m / z 340.1 [M+H] + .
[0358] Step 2: 6-Cyclobutoxy-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0359] At 0°C, NaH (42.4 mg, 1.77 mmol, 60%, in oil) was added to a mixture of THF (5 mL) containing 1H-imidazole (80.1 mg, 1.18 mmol), the reaction mixture was heated to room temperature and stirred at this temperature for 0.5 hours. Then, 2-chloro-6-cyclobutoxy-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (200 mg, 0.59 mmol) was added, and the mixture was stirred at 66°C under an N2 atmosphere for 3 hours. The solution was quenched with H2O at 0°C, and the mixture was extracted with EA (50 mL × 2). The combined organic layer was washed with brine (40 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH = 200 / 1-40 / 1) to obtain the white solid title compound (10.7 mg, 4.9% yield). MS (ESI): m / z 372.2 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ8.91 (s, 1H), 8.70 (d, J = 8.6 Hz, 1H), 8.19 (t, J = 1.3 Hz, 1H), 7.17 (s, 1H), 7.16 - 7.15 (m, 1H), 5.38 - 5.27 (m, 1H), 3.86 - 3.75 (m, 1H), 3.25 (s, 3H), 3.16 - 3.07 (m, 1H), 2.22 - 2.10 (m, 2H), 2.06 (d, J = 10.8 Hz, 2H), 1.83 (d, J = 10.6 Hz, 3H), 1.75 - 1.66 (m, 1H), 1.61 - 1.48 (m, 2H), 1.23 (t, J = 11.6 Hz, 2H).
[0360] The following compound was synthesized according to the procedure described for compound 104.
[0361] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 105 2-(1H-imidazole-1-yl)-6-methoxy-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide 332.2 8.95 (s, 1H), 8.72 (d, J = 8.8 Hz, 1H), 8.22 (s, 1H), 7.23 (s, 1H), 7.16 (s, 1H), 4.08 (s, 3H), 3.82 - 3.79 (m, 1H), 3.15 (s, 3H), 3.14 ? 3.09 (m, 1H), 2.05 (d, J = 10.4 Hz, 2H), 1.86 (d, J = 10.4 Hz, 2H), 1.65 - 1.53 (m, 2H), 1.26 - 1.17 (m, 2H). 121 6-Cyclobutoxy-N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 354.1 10.63 (s, 1H), 8.99 (s, 1H), 8.26 (s, 1H), 7.87 - 7.79 (m, 1H), 7.76 - 7.71 (m, 1H), 7.49-7.43 (m, 1H), 7.31 (s, 1H), 7.19 (s, 1H), 7.04 (td, J = 8.4, 2.2 Hz, 1H), 5.43 - 5.32 (m, 1H), 2.58 - 2.51 (m, 2H), 2.26 - 2.12 (m, 2H), 1.86-1.84 (m, 1H), 1.76-1.71 (m, 1H). 149 6-Cyclobutoxy-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methylcyclohexyl)pyrimidine-4-carboxamide 356.3 8.91 (s, 1H), 8.68 (d, J = 8.7 Hz, 1H), 8.19 (t, J = 1.3 Hz, 1H), 7.16 (s, 1H), 7.16 - 7.14 (m, 1H), 5.37 - 5.28 (m, 1H), 3.84 - 3.72 (m, 1H), 2.57 - 2.53 (m, 1H), 2.24 - 2.10 (m, 2H), 1.82-1.69 (m, 6H), 1.59 - 1.46 (m, 2H), 1.43 - 1.29 (m, 1H), 1.11 - 0.96 (m, 2H), 0.90 (d, J = 6.5 Hz, 3H).
[0362] Example 21
[0363] 6-cyano-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (compound 106)
[0364]
[0365] Step 1: 6-chloro-2-(1H-imidazole-1-yl)pyrimidine-4-carboxylic acid
[0366] At 0°C, under an N2 atmosphere, NaH (380 mg, 9.56 mmol, 60%, in oil) was added to a solution of anhydrous THF (50 mL) containing 1H-imidazole (990 mg, 14.49 mmol). At 0°C, under an N2 atmosphere, the obtained solution was added dropwise to a solution of anhydrous THF (50 mL) containing methyl 2,6-dichloropyrimidine-4-carboxylate (3.00 g, 14.49 mmol). The resulting mixture was stirred at 0°C for 1 hour. At the above temperature, the solution was quenched with H2O (1 mL), and the mixture was extracted with EtOAc (20 mL × 3). The combined organic layer was washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (PE / EA = 1 / 1-DCM / MeOH = 100 / 1-30 / 1) to obtain the yellow solid title compound (0.13 g, 3.8% yield). The aqueous layer was acidified to pH = 4 using concentrated HCl (12 N). The resulting mixture was concentrated and dried. The residue was dissolved in a mixture of CH2Cl2 (100 mL) and MeOH (10 mL) to obtain a suspension. The filtrate was concentrated to obtain the title compound (820 mg, 90% yield), which was used directly in the next step without further purification. MS (ESI): m / z 225.1 [M+H] + .
[0367] Step 2: 6-chloro-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0368] At 0°C under an N2 atmosphere, catalytic amounts of DMF (0.03 mL, 0.37 mmol) and (COCl)2 (679.04 mg, 5.48 mmol) were added to a solution of anhydrous CH2Cl2 (5 mL) containing 6-chloro-2-(1H-imidazole-1-yl)pyrimidine-4-carboxylic acid (820 mg, 3.67 mmol). The resulting mixture was stirred at room temperature for 0.5 hours. The solvent was removed under vacuum, and the residue was dissolved in anhydrous CH2Cl2 (5 mL). At 0°C under an N2 atmosphere, the resulting solution was added to a solution of anhydrous CH2Cl2 (5 mL) containing (1r,4r)-4-methoxycyclohexane-1-amine hydrochloride (95.65 mg, 0.63 mmol) and Et3N (739 mg, 7.30 mmol). The obtained reaction mixture was stirred at room temperature for 1 hour. The mixture was distributed between CH2Cl2 (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (20 mL). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1-50 / 1) to obtain the crude product, and further purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Waters sunfire C18 10 um OBD 19*250 mm, mobile phase A: 0.1% HCl aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (58 mg, 4.7% yield). MS (ESI): m / z 336.2 [M+H] + .
[0369] Step 3: 6-Cyano-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide
[0370] A mixture of DMF (2 mL) containing 6-chloro-2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)pyrimidine-4-carboxamide (58 mg, 0.17 mmol), Zn(CN)2 (20.28 mg, 0.17 mmol), dppf (9.75 mg, 0.02 mmol), and Pd2(dba)3 (15.82 mg, 0.02 mmol) was heated at 120°C under an N2 atmosphere for 2 hours. The mixture was distributed between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine (20 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (CH2Cl2 / MeOH = 100 / 1-40 / 1) to obtain the crude product, and further purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Waters sunfire C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% HCl aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the title compound as a yellow solid (10 mg, 16.7% yield). MS (ESI): m / z 327.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 9.98 (s, 1H), 9.16 (d, J = 8.5 Hz, 1H), 8.60 (s, 1H), 8.57 (s, 1H), 7.68 (s, 1H), 3.95 - 3.81 (m, 1H), 3.26 (s, 4H), 3.19 - 3.08 (m, 1H), 2.08 (d, J = 10.7 Hz, 2H), 1.85 (d, J = 10.5 Hz, 2H), 1.66 - 1.54 (m, 2H), 1.30 - 1.19 (m, 2H).
[0371] Example 22
[0372] N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-5-(piperidine-1-yl)pyrimidine-4-carboxamide (compound 115)
[0373]
[0374] Step 1: Methyl 2-(methylthio)-5-(piperidine-1-yl)pyrimidine-4-carboxylate
[0375] A mixture of toluene (30 mL) containing methyl 5-bromo-2-(methylsulfanyl)pyrimidine-4-carboxylate (3 g, 11.41 mmol), piperidine (1.35 mL, 13.71 mmol), Pd2(dba)3 (1.04 mg, 1.14 mmol), RuPhos (0.53 mg, 1.14 mmol), and Cs2CO3 (7.43 mg, 22.80 mmol) was heated at 100°C for 12 hours. The solvent was removed under vacuum, and the residue was distributed between EtOAc (50 mL) and water (50 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (50 mL × 2). The combined organic layer was washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (PE / EA = 10 / 1-5 / 1) to obtain the title compound as a yellow solid (470 mg, 15.4% yield). MS (ESI): m / z 268.2 [M+H] + .
[0376] Step 2: 2-(methylthio)-5-(piperidine-1-yl)pyrimidine-4-carboxylic acid
[0377] LiOH·H2O (148 mg, 3.52 mmol) was added to a solution of THF (5 mL) and H2O (2 mL) containing methyl 2-(methylthio)-5-(piperidin-1-yl)pyrimidine-4-carboxylate (470 mg, 1.76 mmol). The resulting mixture was stirred overnight at room temperature. The solution was divided between EtOAc (20 mL) and water (20 mL). The organic layer was separated, and 1 N HCl solution was added to the aqueous layer to adjust the pH to 4. The resulting mixture was extracted with EtOAc (20 mL × 2). The combined organic layer was washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated to obtain the title compound as a yellow solid (70 mg, 15.7% yield). MS (ESI): m / z 254.2 [M+H] + .
[0378] Step 3: N-(3-fluorophenyl)-2-(methylthio)-5-(piperidine-1-yl)pyrimidine-4-carboxamide
[0379] At 0°C under an N2 atmosphere, a catalytic amount of DMF (1 μ COCl)2 (51.40 mg, 0.41 mmol) was added dropwise to a solution of anhydrous DCM (5 mL) containing 2-(methylthio)-5-(piperidin-1-yl)pyrimidine-4-carboxylic acid (70 mg, 0.28 mmol). The resulting mixture was stirred at room temperature for 0.5 hours. The solvent was removed under vacuum, and the residue was dissolved in anhydrous DCM (5 mL). At 0°C under an N2 atmosphere, the resulting solution was added to a solution of anhydrous DCM (5 mL) containing 3-fluoroaniline (0.03 mL, 0.27 mmol) and Et3N (55.92 mg, 0.55 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The solution was distributed between CH2Cl2 (20 mL) and water (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (20 mL × 2). The combined organic layer was washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated and dried. The residue was purified by silica gel chromatography (PE / EA = 20 / 1-2 / 1) to obtain the title compound as a yellow solid (55 mg, 57.5% yield). MS (ESI): m / z 347.0 [M+H] + .
[0380] Step 4: N-(3-fluorophenyl)-2-(methylsulfonyl)-5-(piperidin-1-yl)pyrimidine-4-carboxamide
[0381] m-CPBA (56.04 mg, 0.33 mmol) was added to a solution of DCM (1 mL) containing N-(3-fluorophenyl)-2-(methylthio)-5-(piperidin-1-yl)pyrimidine-4-carboxamide (45 mg, 0.13 mmol). The resulting mixture was stirred at room temperature for 12 hours. The solution was partitioned between CH2Cl2 (20 mL) and a saturated NaHCO3 solution (20 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (20 mL × 2). The combined organic layer was washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated and dried. The residue was purified by silica gel chromatography (PE / EA = 10 / 1-1 / 1) to obtain the title compound as a yellow solid (35 mg, 71.2% yield). MS (ESI): m / z 379.2 [M+H] + .
[0382] Step 5: N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)-5-(piperidine-1-yl)pyrimidine-4-carboxamide
[0383] A mixture of ACN (4 mL) containing N-(3-fluorophenyl)-2-(methylsulfonyl)-5-(piperidin-1-yl)pyrimidine-4-carboxamide (35 mg, 0.10 mmol), 1H-imidazole (10 mg, 0.14 mmol), and K2CO3 (25.36 mg, 0.18 mmol) was heated at 70°C for 2 hours. Volatiles were removed under vacuum, and the residue was purified by silica gel chromatography (DCM / MeOH = 100 / 1-60 / 1) to obtain the title compound as a yellow solid (16 mg, 47.2% yield). MS (ESI): m / z 367.0 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6) δ 10.89 (s, 1H), 8.77 (s, 1H), 8.55 (s, 1H), 7.94 (s, 1H), 7.75 - 7.67 (m, 1H), 7.52 - 7.41 (m, 2H), 7.14 (s, 1H), 7.03 - 6.97 (m, 1H), 3.16 - 3.09 (m, 4H), 1.63 - 1.55 (m, 4H), 1.54 - 1.47 (m, 2H).
[0384] Substitute compounds
[0385] In addition, the following compounds were synthesized in the present invention.
[0386] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 29 N-((1r,4r)-4-methoxycyclohexyl)-5-(thiazole-5-yl)-1H-indole-7-carboxamide 356.1 11.26 (s, 1H), 9.04 (s, 1H), 8.46 (d, J = 7.9 Hz, 1H), 8.28 (s, 1H), 8.00 (s, 1H), 7.96 (d, J = 1.4 Hz, 1H), 7.39 (t, J = 2.7 Hz, 1H), 6.54 (dd, J = 2.9, 2.0 Hz, 1H), 3.95 - 3.81 (m, 1H), 3.26 (s, 3H), 3.15 (ddd, J = 14.3, 10.5, 3.9 Hz, 1H), 2.08 (d, J = 10.4 Hz, 2H), 1.95 (d, J = 10.9 Hz, 2H), 1.50 - 1.39(m, 2H), 1.30 - 1.18 (m, 2H). 43 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-indole-7-carboxamide 339.2 11.30 (s, 1H), 8.49 - 8.37 (m, 2H), 8.18 (s, 1H), 7.93 (d, J = 1.7 Hz, 1H), 7.86 (d, J = 1.9 Hz, 1H), 7.71 (s, 1H), 7.45 (t, J = 2.8 Hz, 1H), 7.12 (s, 1H), 6.61 - 6.50 (m, 1H), 3.92 - 3.81 (m, 1H), 3.26 (s, 3H), 3.18 - 3.11 (m, 1H), 2.11 - 2.03 (m, 2H), 1.98 - 1.91 (m, 2H), 1.47 - 1.36 (m, 2H), 1.29 - 1.18 (m, 2H). 44 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxamide 356.2 11.14 (s, 1H), 10.52 (s, 1H), 8.30 (d, J = 7.1 Hz, 1H), 7.67 (s, 1H), 7.30 (s, 1H), 3.80 (s, 1H), 3.25 (s, 3H), 3.13 (t, J = 10.4 Hz, 1H), 2.05 (d, J = 11.3 Hz, 2H), 1.91 (d, J = 11.8 Hz, 2H), 1.38 (d, J = 12.6 Hz, 2H), 1.21 (d, J = 12.6 Hz, 2H). 45 6-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-2-oxo-2,3-dihydrobenzo[d]oxazole-4-carboxamide 357.2 8.62 (s, 1H), 8.21 (s, 1H), 7.89-7.68 (m, 3H), 7.12 (s, 1H), 3.79 (dd, J = 7.0, 2.8 Hz, 1H), 3.25 (s, 3H), 3.18 - 3.10 (m, 1H), 2.05 (d, J = 10.5 Hz, 2H), 1.93 (d, J = 10.7 Hz, 2H), 1.38 (dd, J = 24.1, 11.6 Hz, 2H), 1.29-1.18 (m, 2H). 54 N-((1r,4r)-4-methoxycyclohexyl)-5-(1H-1,2,3-triazole-1-yl)-1H-indole-7-carboxamide 340.1 11.40 (s, 1H), 8.75 (d, J = 0.9 Hz, 1H), 8.53 (d, J = 7.8 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.98 (d, J = 1.0 Hz, 1H), 7.49 (t, J = 2.8 Hz, 1H), 6.65 - 6.60 (m, 1H), 3.93 - 3.83 (m, 1H), 3.26 (s, 3H), 3.17 - 3.10 (m, 1H), 2.07 (d, J = 10.6 Hz, 2H), 1.94 (d, J = 11.3 Hz, 2H), 1.49 - 1.38 (m, 2H), 1.29 - 1.18 (m, 2H). 55 N-((1r,4r)-4-methoxycyclohexyl)-5-(2H-1,2,3-triazole-2-yl)-1H-indole-7-carboxamide 340.1 11.32 (s, 1H), 8.66 (d, J = 7.6 Hz, 1H), 8.32 (s, 2H), 8.11 (s, 2H), 7.45 (t, J = 2.8 Hz, 1H), 6.68 - 6.56 (m, 1H), 3.93 - 3.83 (m, 1H), 3.26 (s, 3H), 3.17 - 3.09 (m, 1H), 2.07 (d, J = 10.5 Hz, 2H), 1.97 - 1.88 (m, 2H), 1.52 - 1.41 (m, 2H), 1.29 - 1.17 (m, 2H). 56 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-benzo[d]imidazole-7-carboxamide 340.6 13.28 - 12.67(m, 1H), 9.86 (s, 1H), 8.58 (s, 1H), 8.32 (s, 1H), 7.98 (s, 2H), 7.86 (s, 1H), 7.21 (s, 1H), 3.90 (s, 1H), 3.26 (s, 4H), 2.02 (m, 4H), 1.46 ? 1.28 (m, 4H). 57 5-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-1H-indazole-7-carboxamide 340.4 9.80 (s, 1H), 8.14 (s, 2H), 7.99 (s, 1H), 7.89 (s, 1H), 7.68 (s, 1H), 7.10 (s, 1H), 3.93 - 3.83 (m, 1H), 3.26 (s, 3H), 3.23 - 3.15 (m, 1H), 2.11 - 1.95 (m, 4H), 1.48 - 1.35 (m, 2H), 1.34 - 1.23 (m, 2H).
[0387] Example 23
[0388] N-(3-fluoro-5-(piperazine-1-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0389]
[0390] Step 1. tert-butyl 4-(3-fluoro-5-nitrophenyl)piperazine-1-carboxylate
[0391] Tert-butylpiperazine-1-carboxylate (3.51 g, 18.9 mmol) was added to a solution of DMSO (20 mL) containing 1,3-difluoro-5-nitrobenzene (2.13 mL, 18.9 mmol), and the reaction mixture was stirred at 135 °C for 4 hours. The mixture was diluted with water (300 mL), and the resulting mixture was extracted with EA (150 mL × 3). The organic layers were combined, washed with brine (100 mL), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (PE / EA = 100 / 1 to 20 / 1) to obtain the title compound as a yellow solid (4.50 g, 73.3% yield). LC-MS (ESI): m / z 270.1 [M-55]+ 1 ¹H NMR (400 MHz, DMSO- d 6) δ 7.54 (s, 1H), 7.38 (dt, J = 8.4, 2.0 Hz, 1H), 7.26 (dt, J = 12.2, 2.2 Hz, 1H), 3.52 - 3.39 (m, 6H), 1.43 (s, 9H).
[0392] Step 2. tert-butyl 4-(3-amino-5-fluorophenyl)piperazine-1-carboxylate
[0393] Under N2, 10% Pd / C (400 mg) was added to a solution of MeOH (20 mL) containing tert-butyl 4-(3-fluoro-5-nitrophenyl)piperazine-1-carboxylate (2.00 g, 6.15 mmol). The suspension was degassed under vacuum and purged several times with H2. The resulting mixture was stirred at room temperature under H2 (1 atm) for 36 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under vacuum. The residue was mixed with water (100 mL), and the resulting mixture was extracted with EA (100 mL × 2). The organic layers were combined, washed with brine (100 mL), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain the title compound (1.50 g, 82.6% yield) as a brown oily substance. LC-MS (ESI): m / z 296.0 [M+H] +
[0394] Step 3. tert-butyl 4-(3-(2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamido)-5-fluorophenyl)piperazine-1-carboxylate
[0395] At 0°C under an N2 atmosphere, DMF (0.02 mL, 0.23 mmol) and oxalyl chloride (0.10 mL, 1.16 mmol) were added dropwise to a solution of DCM (20 mL) containing 2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxylic acid (200 mg, 0.78 mmol). The resulting reaction mixture was stirred at room temperature for 0.5 hours. The solvent was removed under vacuum, and the residue was dissolved in anhydrous DCM (3 mL). At 0°C under an N2 atmosphere, the resulting solution was added to a solution of DCM (20 mL) containing tert-butyl 4-(3-amino-5-fluorophenyl)piperazine-1-carboxylate (458 mg, 0.93 mmol, 60% purity) and triethylamine (0.54 mL, 3.87 mmol). The obtained mixture was stirred at room temperature for 1.5 hours. The mixture was mixed with water (100 mL), and the resulting mixture was extracted with EA (80 mL × 2). The organic layers were combined, washed with brine (80 mL), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (PE / EA = 100 / 1 to 3 / 2) to obtain the title compound as a yellow solid (100 mg, 24.1% yield). LC-MS (ESI): m / z 536.2 [M+H] + .
[0396] Step 4. N-(3-fluoro-5-(piperazine-1-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0397] A mixture of tert-butyl 4-(3-(2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamido)-5-fluorophenyl)piperazine-1-carboxylate (100 mg, 0.19 mmol) and HCl / dioxane (4 mL, 4.0 M) was stirred at room temperature for 2 hours. The obtained mixture was evaporated under vacuum, and the residue was slurried with EA (6 mL) to obtain the crude product, the crude substance (60 mg) of the title compound, and further purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Sunfire C18 10 um OBD 19*250 mm, mobile phase A: H2O solution of 0.1% NH4OH, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the yellow solid title compound (6.0 mg, 6.8% yield). LC-MS (ESI): m / z 436.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ10.70 (s, 1H), 9.08 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 7.30 - 7.26 (m, 2H), 7.26 - 7.24 (m, 1H), 6.66 - 6.60 (m, 1H), 3.15 - 3.11 (m, 4H), 2.89 -2.82 (m, 4H).
[0398] The following compound was synthesized according to the procedure described for compound 175.
[0399] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 176 N-(3-fluoro-5-morpholinophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 437.2 10.74 (s, 1H), 9.08 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 7.34 - 7.24 (m, 3H), 6.68 (d, J = 12.6 Hz, 1H), 3.78 - 3.73 (m, 4H), 3.21 - 3.15 (m, 4H). 177 2-(1H-imidazole-1-yl)-N-(3-morpholinophenyl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 419.1 10.68 (s, 1H), 9.10 (s, 1H), 8.32 (s, 1H), 8.30 (t, J = 1.4 Hz, 1H), 7.45 (s, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.25 (s, 1H), 6.84 (dd, J = 8.0, 2.0 Hz, 1H), 3.80 - 3.75 (m, 4H), 3.17 - 3.12 (m, 4H). 178 (S)-N-(3-fluoro-5-(3-hydroxypyrrolidine-1-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 437.0 10.69 (s, 1H), 9.09 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 7.25 (s, 1H), 7.09-7.05 (m, 1H), 6.94 (s, 1H), 6.22 ? J = 3.6 Hz, 1H), 4.42 (s, 1H), 3.43 (dd, J = 10.0, 4.6 Hz, 1H), 3.37 (d, J = 7.1 Hz, 1H), 3.30 (s, 1H), 3.11 (d, J = 10.9 Hz, 1H), 2.07-2.03 (m, 1H), 1.96 - 1.88 (m, 1H).
[0400] Example 24
[0401] N-(3-fluoro-5-(2-methoxypropane-2-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0402]
[0403] Step 1. Methyl 3-(dibenzylamino)-5-fluorobenzoate.BnBr (3.09 mL, 26.0 mmol) and K2CO3 (2.70 g, 19.5 mmol) were added to a solution of DMF (10 mL) containing methyl 3-amino-5-fluorobenzoate (1.10 g, 6.50 mmol). The reaction mixture was stirred at 80°C for 18 hours. The reaction mixture was diluted with EA (100 mL) and brine (100 mL). The organic layer was separated, washed with another brine (100 mL × 3), and concentrated under vacuum. The residue was purified by silica gel column chromatography elution (PE / EA = 1 / 0 to 10 / 1) to obtain the white solid title compound (2.2 g, 96.8% yield). LC-MS (ESI): m / z 350.1 [M+H] + .
[0404] Step 2. 2-(3-(dibenzylamino)-5-fluorophenyl)propan-2-ol
[0405] At 0°C under an N2 atmosphere, MeMgBr (17.2 mL, 17.2 mmol, 1.0 M THF solution) was added dropwise to a solution of THF (50 mL) containing methyl 3-(dibenzylamino)-5-fluorobenzoate (2.00 g, 5.72 mmol). The resulting reaction mixture was stirred at this temperature for 0.5 hours and then stirred at 70°C for 3 hours. The reaction mixture was cooled to room temperature and diluted with EA (100 mL) and brine (100 mL). The organic layer was separated and concentrated under vacuum. The residue was purified by silica gel column chromatography elution (PE / EA = 1 / 0 to 5 / 1) to obtain the title compound as a yellow solid (1.00 g, 50.0% yield). LC-MS (ESI): m / z 350.2 [M+H] + .
[0406] Step 3. N,N-Dibenzyl-3-fluoro-5-(2-methoxypropane-2-yl)aniline.
[0407] At 0°C under an N2 atmosphere, NaH (137 mg, 3.43 mmol, 60%, in oil) was added gradually to a solution of THF (50 mL) containing 2-(3-(dibenzylamino)-5-fluorophenyl)propan-2-ol (400 mg, 1.14 mmol). The resulting mixture was stirred at this temperature for 0.5 hours, and iodomethane (0.21 mL, 3.43 mmol) was added. The reaction mixture was stirred at 70°C for 3 hours, cooled to room temperature, and diluted with EA (30 mL) and brine (30 mL). The organic layer was separated and concentrated under vacuum. The residue was purified by silica gel column chromatography elution (PE / EA = 1 / 0 to 5 / 1) to obtain the title compound as a yellow solid (400 mg, 96.1% yield). LC-MS (ESI): m / z 364.2 [M+H] + .
[0408] Step 4. 3-fluoro-5-(2-methoxypropane-2-yl)aniline.
[0409] Pd / C (100 mg, 10%) was added to a 20 mL solution of MeOH containing N,N-dibenzyl-3-fluoro-5-(2-methoxypropane-2-yl)aniline (500 mg, 1.37 mmol), and the reaction mixture was stirred at 50°C under a H2 atmosphere for 18 hours. The reaction mixture was filtered. The filtrate was concentrated under vacuum to obtain the title compound as a yellow solid (200 mg, 79.3% yield). LC-MS (ESI): m / z 184.1 [M+H] + .
[0410] Step 5. N-(3-fluoro-5-(2-methoxypropane-2-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide.
[0411] DIEA (0.10 mL, 0.49 mmol), 2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxylic acid (42.3 mg, 0.16 mmol), and T3P (159 mg, 0.25 mmol, 50% EA solution) were added to a solution of DMF (4 mL) containing 3-fluoro-5-(2-methoxypropane-2-yl)aniline (30 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% aqueous NH4OH, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the white solid title compound (2.43 mg, 3.5% yield). LC-MS (ESI): m / z 424.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ10.93 (s, 1H), 9.10 (s, 1H), 8.34 (s, 1H), 8.30 (s, 1H), 7.82 - 7.77 (m, 1H), 7.77 - 7.74 (m, 1H), 7.26 (s, 1H), 7.10 - 7.03 (m, 1H), 3.29 (s, 1H), 3.05 (s, 3H), 1.49 (s, 6H).
[0412] The following compounds were synthesized according to the procedure described for compound 179.
[0413] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 180 N-(3-fluoro-4-(2-hydroxypropane-2-yl)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 410.2 10.90 (s, 1H), 9.35 (s, 1H), 8.39 (d, J = 8.0 Hz, 2H), 7.77 - 7.65 (m, 3H), 7.40 (s, 1H), 1.50 (s, 6H).
[0414] Example 25
[0415] N-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0416]
[0417] Step 1. 2-(3-fluoro-5-nitrophenoxy)-N,N-dimethylethanolamine
[0418] At 0°C, under an N2 atmosphere, NaH (360 mg, 15.09 mmol, 60% dispersion in mineral oil) was added in small amounts to a solution of DMF (10 mL) containing 2-(dimethylamino)ethanol (1.12 g, 12.6 mmol). 1,3-difluoro-5-nitrobenzene (2.00 g, 12.6 mmol) was added. The resulting suspension was stirred at room temperature for 2 hours. The reaction mixture was distributed between EtOAc (20 mL) and water (80 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (20 mL × 2). The organic layers were combined, washed with brine (80 mL), dried with anhydrous Na2SO4, filtered, concentrated, and dried to obtain the title compound of a brown oily substance (3.54 g, 80% purity, 100% yield). LC-MS (ESI): m / z 229.0 [M+H] + ;
[0419] Step 2. 3-(2-(dimethylamino)ethoxy)-5-fluoroaniline
[0420] A solution of 2-(3-fluoro-5-nitrophenoxy)-N,N-dimethylethanolamine (1.00 g, 4.38 mmol) in MeOH (10 mL) was hydrogenated at room temperature under hydrogen balloon pressure for 18 hours in the presence of 10% Pd / C (200 mg). The insoluble solid was filtered through Celite, and the filtrate was concentrated to obtain the title compound as a dark oily substance (660 mg, 3.33 mmol, 76.0% yield). LC-MS (ESI): m / z 199.0 [M+H] + ;
[0421] Step 3. N-(3-(2-(dimethylamino)ethoxy)-5-fluorophenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0422] At 0°C under an N2 atmosphere, DMF (1 drop) and (COCl)2 (111 mg, 0.87 mmol) were added dropwise to a solution of DCM (5 mL) containing 2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxylic acid (150 mg, 0.58 mmol). The resulting reaction mixture was stirred at room temperature for 0.5 hours, and then added to a solution of DCM (5 mL) containing 3-(2-(dimethylamino)ethoxy)-5-fluoroaniline (138 mg, 0.70 mmol) and triethylamine (0.38 mL, 2.91 mmol) under an N2 atmosphere at 0°C. The resulting mixture was stirred at room temperature for 1 hour. Volatile products were removed under vacuum, and the residue was purified by silica gel chromatography (DCM / MeOH = 100 / 1 - 10 / 1) to obtain the crude product (110 mg), which was slurried in a mixture of PE and EA (3 mL, PE / EA = 1 / 1). After filtration and drying, the title compound (55 mg, 22.0% yield) was obtained as a pale yellow solid. LC-MS (ESI): m / z 439.1 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ10.82 (s, 1H), 9.09 (s, 1H), 8.32 (s, 1H), 8.28 (t, J = 1.2 Hz, 1H), 7.50 ? J = 10.8 Hz, 1H), 4.16 (t, J = 5.6 Hz, 2H), 2.83 (s, 2H), 2.36 (s, 6H).
[0423] The following compounds were synthesized according to the procedure described for compound 181.
[0424] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 182 N-(3-fluoro-5-(2-methoxyethoxy)phenyl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 426.1 10.81 (s, 1H), 9.09 (s, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.46 (d, J = 10.7 Hz, 1H), 7.41 (s, 1H), 7.25 (s, 1H), 6.75 (d, J = 11.0 Hz, 1H), 4.18 - 4.13 (m, 2H), 3.71 - 3.66 (m, 2H).
[0425] Example 26
[0426] 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(pyridine-4-yl)pyrimidine-4-carboxamide
[0427]
[0428] Step 1. 6-chloro-N-((1r,4r)-4-methoxycyclohexyl)-2-(methylthio)pyrimidine-4-carboxamide
[0429] A mixture of CH2Cl2 (20 mL) containing 6-chloro-2-(methylthio)pyrimidine-4-carbonyl chloride (1.00 g, 4.48 mmol), (1r,4r)-4-methoxycyclohexanamine hydrochloride (0.89 g, 5.38 mmol), and triethylamine (1.86 mL, 13.45 mmol) was stirred at room temperature for 2 hours. The mixture was diluted with water (60 mL) and then extracted with EA (30 mL × 2). The organic layers were combined, washed with brine (50 mL), dried with anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel column chromatography (PE / EA = 100 / 1 - 3 / 1) to obtain the white solid title compound (1.60 g, 80% purity, 100% yield). LC-MS (ESI): m / z 316.1 [M+H] + ;
[0430] Step 2. N-((1r,4r)-4-methoxycyclohexyl)-2-(methylthio)-6-(pyridine-4-yl)pyrimidine-4-carboxamide
[0431] A mixture of acetonitrile (6 mL) and H2O (2 mL) containing 6-chloro-N-((1r,4r)-4-methoxycyclohexyl)-2-(methylthio)pyrimidine-4-carboxamide (200 mg, 0.63 mmol), pyridine-4-ylboronic acid (156 mg, 1.27 mmol), and Cs2CO3 (411 mg, 1.26 mmol) was heated at 95°C under an N2 atmosphere in the presence of Pd(dppf)Cl2 (46.7 mg, 0.063 mmol) for 18 hours. The solvent was removed under vacuum, and the residue was purified by silica gel chromatography (PE / EA = 20 / 1 - 1 / 3) to obtain the title compound as a yellow solid (200 mg, 88.1% yield). LC-MS (ESI): m / z 359.1 [M+H] + ;
[0432] Step 3 N-((1r,4r)-4-methoxycyclohexyl)-2-(methylsulfinyl)-6-(pyridine-4-yl)pyrimidine-4-carboxamide
[0433] A solution of DCM (6 mL) containing N-((1r,4r)-4-methoxycyclohexyl)-2-(methylthio)-6-(pyridine-4-yl)pyrimidine-4-carboxamide (200 mg, 0.56 mmol) was treated with m-CPBA (125 mg, 0.61 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was washed with brine (10 mL), dried with anhydrous Na2SO4, filtered, and concentrated to obtain the title compound as a grayish-white solid (114 mg, 54.6% yield). LC-MS (ESI): m / z 415.1 [M+CH3CN]+;
[0434] Step 4. 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(pyridine-4-yl)pyrimidine-4-carboxamide
[0435] A mixture of ACN (5 mL) containing N-((1r,4r)-4-methoxycyclohexyl)-2-(methylsulfinyl)-6-(pyridine-4-yl)pyrimidine-4-carboxamide (114 mg, 0.30 mmol), imidazole (31 mg, 0.46 mmol), and K2CO3 (84.15 mg, 0.61 mmol) was heated at 70°C for 1 hour. The solvent was removed under vacuum, and the residue was distributed between CH2Cl2 (30 mL) and water (30 mL). The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (30 mL × 2). The organic layers were combined, washed with brine (30 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (DCM / MeOH = 100 / 1 - 20 / 1) to obtain the title product (35.0 mg, 29.2% yield). LC-MS (ESI): m / z 379.2 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ9.12 (s, 1H), 8.90 (d, J = 7.6 Hz, 1H), 8.84 (d, J= 3.6 Hz, 2H), 8.50 (s, 1H), 8.43 - 8.30 (m, 3H), 7.22 (s, 1H), 3.98 - 3.80 (m, 1H), 3.27 (s, 3H), 3.20 - 3.05 (m, 1H), 2.08 (d, J = 10.4 Hz, 2H), 1.88 (d, J = 10.4 Hz, 2H), 1.68 - 1.50 (m, 2H), 1.35 - 1.20 (m, 2H).
[0436] The following compounds were synthesized according to the procedure described for compound 183.
[0437] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 184 2-(1H-imidazole-1-yl)-N-((1r,4r)-4-methoxycyclohexyl)-6-(2-(trifluoromethyl)pyridine-4-yl)pyrimidine-4-carboxamide 447.1 9.16 (s, 1H), 9.02 (d, J = 5.0 Hz, 1H), 8.92 (d, J = 8.4 Hz, 1H), 8.81 (s, 1H), 8.72 (d, J = 4.5 Hz, 1H), 8.68 (s, 1H), 8.44 (s, 1H), 7.22 (s, 1H), 3.91 (s, 1H), 3.27 (s, 3H), 3.15 (s, 1H), 2.08 (d, J = 10.3 Hz, 2H), 1.89 (d, J = 11.6 Hz, 2H), 1.64-1.55 (m, 2H), 1.32 - 1.21 (m, 2H).
[0438] Example 26
[0439] 6-Cyano-N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide
[0440]
[0441] Step 1. 2-chloro-6-cyano-N-(3-fluorophenyl)pyrimidine-4-carboxamide
[0442] At 0°C, DABCO (3.92 mg, 0.035 mmol) and NaCN (20.6 mg, 0.419 mmol) were added simultaneously to a solution of DMF (2 mL) and H2O (0.4 mL) containing 2,6-dichloro-N-(3-fluorophenyl)pyrimidine-4-carboxamide (100 mg, 0.350 mmol). The reaction mixture was stirred at this temperature for 1 hour. The resulting mixture was distributed between EtOAc (30 mL) and water (30 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (30 mL × 2). The organic layers were combined, washed with brine (30 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (PE / EA = 20 / 1 - 4 / 1) to obtain a pale yellow solid title compound (26 mg, 26.0% yield).
[0443] Step 2. 6-Cyano-N-(3-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide
[0444] A mixture of acetonitrile (14 mL) containing 2-chloro-6-cyano-N-(3-fluorophenyl)pyrimidine-4-carboxamide (26 mg, 0.094 mmol), imidazole (9.60 mg, 0.14 mmol), and K2CO3 (25.98 mg, 0.19 mmol) was heated at 70°C for 1 hour. The solvent was removed under vacuum, and the residue was distributed between DCM (30 mL) and water (30 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (30 mL × 2). The organic layers were combined, washed with brine (30 mL), dried with anhydrous Na2SO4, filtered, and concentrated dried. The residue was purified by silica gel chromatography (DCM / MeOH = 100 / 1 - 40 / 1) to obtain the crude product (17 mg), and further purified by preparative HPLC (Waters 2767 / 2545 / 2489 / Qda, Waters sunfire C18 10 um OBD 19*250 mm, mobile phase A: 0.1% HCl aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the yellow solid title compound (20.0% yield). LC-MS (ESI): m / z 349.0 [M+H] + ; 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ11.01 (s, 1H), 9.62 (s, 1H), 8.70 (s, 1H), 8.49 (s, 1H), 7.83 (d, J = 11.4 Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.09 (td, J = 8.4, 2.1 Hz, 1H).
[0445] The following compounds were synthesized according to the procedure described for compound 185.
[0446] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 186 6-cyano-2-(1H-imidazole-1-yl)-N-(pyridin-3-yl)pyrimidine-4-carboxamide 292.1 10.98 (s, 1H), 9.08 (s, 1H), 9.02 (d, J = 2.3 Hz, 1H), 8.60 (s, 1H), 8.47 - 8.42 (m, 1H), 8.30 (s, 1H), 8.28 - 8.23 (m, 1H), 7.51 (dd, J = 8.4, 4.8 Hz, 1H), 7.25 (s, 1H). 187 6-Cyano-N-(4-fluorophenyl)-2-(1H-imidazole-1-yl)pyrimidine-4-carboxamide 309.1 10.85 (s, 1H), 9.07 (s, 1H), 8.57 (s, 1H), 8.30 (d, J = 1.3 Hz, 1H), 7.92 - 7.83 (m, 2H), 7.31 (t, J = 8.9 Hz, 2H), 7.24 (s, 1H). 189 6-cyano-2-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)pyrimidine-4-carboxamide 293.0 11.13 (s, 1H), 9.25 (s, 2H), 9.06 (s, 2H), 8.63 (s, 1H), 8.29 (s, 1H), 7.26 (s, 1H).
[0447] Example 27
[0448] 2-(1H-imidazole-1-yl)-N-(2-(2-methoxyethoxy)pyrimidine-5-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide (Compound 188)
[0449]
[0450] Step 1. 2-(2-methoxyethoxy)-5-nitropyrimidine
[0451] DIEA (3.12 mL, 18.8 mmol) was added to a solution of Compound 1a (6 mL, 75.70 mmol) containing Compound 1 (1 g, 6.27 mmol), and the reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was diluted with EA (100 mL) and brine (100 mL). The organic layer was separated and concentrated under vacuum. The residue was purified by silica gel column chromatography elution (PE / EA = 10 / 1 to 3 / 1) to obtain the yellow solid title compound 2 (300 mg, 1.51 mmol, 24.0%). LC-MS (ESI): m / z N / A
[0452] Step 2. 2-(2-methoxyethoxy)pyrimidine-5-amine
[0453] Pd / C 10% (100 mg, 0.94 mmol) was added to a 10 mL solution of MeOH containing Compound 2 (300 mg, 1.50 mmol), and the reaction mixture was stirred overnight at 50°C under an H2 atmosphere. The reaction mixture was filtered through a Buchner funnel. The filtrate was collected, concentrated and dried under vacuum to obtain the gray solid title compound 3 (250 mg, 1.48 mmol, 98.1% yield, Lot#: N200918-250-R1).
[0454] LC-MS (ESI): m / z 170.0 [M+H] +
[0455] Step 3. 2-(1H-imidazole-1-yl)-N-(2-(2-methoxyethoxy)pyrimidine-5-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0456] Oxalate dichloride (0.10 mL, 1.16 mmol) and DMF (0.01 mL, 0.08 mmol) were added to a solution of DCM (5 mL) containing compound 3a (200 mg, 0.78 mmol), and the reaction mixture was stirred at room temperature for 2 hours. Then, the mixture was added dropwise to a mixture of compound 3 (144 mg, 0.85 mmol), DCM (5 mL), and TEA (0.43 mL, 3.01 mmol), the mixture was stirred at room temperature for 1 hour, and concentrated under vacuum. The residue was purified by preparative HPLC (Waters 2767 / 2545 / 2489, Waters Xbridge C18 10 µm OBD 19*250 mm, mobile phase A: 0.1% NH4HCO3 aqueous solution, mobile phase B: CH3CN, flow rate: 20 mL / min, column temperature: room temperature) to obtain the title compound as a yellow solid (28.71 mg, 0.07 mmol, 9.1% yield, Lot#: N200918-252-P1). LC-MS (ESI): m / z 410.1 [M+H] + . 1 ¹H NMR (400 MHz, DMSO- d 6 ) δ 11.07 (s, 1H), 9.06 (t, 1.2 Hz, 1H), 8.99 (s, 2H), 8.32 (s, 1H), 8.28 (t, 1.2 Hz, 1H), 7.26 (dd, J = 1.4, 0.8 Hz, 1H), 4.49 - 4.43 (m, 2H), 3.73 - 3.67 (m, 2H), 3.32(s, 3H).
[0457] The following compounds were synthesized according to the procedure described for compound 185.
[0458] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 193 N-(2-(2-hydroxyethoxy)pyrimidine-5-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide 396.4 δ 11.06 (s, 1H), 9.06 (s, 1H), 8.98 (s, 2H), 8.32 (s, 1H), 8.28 (s, 1H), 7.26 (s, 1H), 4.91 (t, 4.0 Hz, 1H), 4.37 - 4.34 (m, 2H), 3.77 - 3.33 (s, 2H). 194 2-((5-(2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamido)pyrimidine-2-yl)oxy)acetic acid 410.4 δ 13.01 (s, 1H), 11.06 (s, 1H), 9.06 (s, 1H), 8.98 (s, 2H), 8.34 (s, 1H), 8.27 (s, 1H), 7.24 (s, 1H), 4.48 (s, 2H) 195 N-(2-hydroxypyrimidine-5-yl)-2-(1H-imidazole-1-yl)-6-(trifluoromethyl)pyrimidine-4-carboxamide
[0459] Example 28
[0460] 6-(1H-imidazole-1-yl)-N-(pyridine-4-yl)-4-(trifluoromethyl)picolinamide
[0461]
[0462] Step 1. 6-chloro-N-(pyridin-4-yl)-4-(trifluoromethyl)picolinamide
[0463] At 0°C under an N2 atmosphere, catalytic amounts of DMF (0.01 mL, 0.07 mmol) and (COCl)2 (126 mg, 1.0 mmol) were added dropwise to a solution of DCM (5 mL) containing Compound 1 (150 mg, 0.67 mmol). The resulting reaction mixture was stirred at room temperature for 0.5 hours. After the acid chloride was formed as indicated by TLC, the resulting reaction mixture was added to a solution of DCM (5 mL) containing pyridine-4-amine (75.1 mg, 0.80 mmol) and TEA (0.28 mL, 1.99 mmol) under an N2 atmosphere at 0°C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography (PE / EA = 20 / 1-1 / 2) to obtain a white solid Compound 2 (170 mg, 0.56 mmol, 84.7% yield). LC-MS (ESI): m / z 302.0 [M+H] + ;
[0464] Step 2. 6-(1H-imidazole-1-yl)-N-(pyridine-4-yl)-4-(trifluoromethyl)picolinamide
[0465] At room temperature, NaH (45.1 mg, 1.13 mmol, 60%, in oil) was added to a solution of THF (5 mL) containing 1H-imidazole (57.5 mg, 0.85 mmol), the mixture was stirred at room temperature for 0.5 hours, and Compound 2 (170 mg, 0.564 mmol) was added. The mixture was stirred at 80°C for 2 hours. The reaction mixture was quenched with H2O. The obtained reaction mixture was extracted with EtOAc (20 mL × 2). The organic layers were combined, washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated and dried. The residue was purified by silica gel chromatography (DCM / MeOH = 100 / 1-20 / 1) to obtain the white solid title compound (17 mg, 0.05 mmol, 9.1% yield, Lot#: N200907-302-P1). LC-MS (ESI): m / z 334.0 [M+H] +; 1 ¹H NMR(400 MHz, DMSO- d 6 ) δ10.88 (s, 1H), 9.14 (s, 1H), 8.62-8.58 (m, 2H), 8.56 (s, 1H), 8.49 (s, 1H), 8.27 (s, 1H), 8.01-7.96 (m, 2H), 7.24 (s, 1H).
[0466] The following compounds were synthesized according to the procedure described for compound 185.
[0467] number structure designation MS ESI [M+H] + 1 H NMR (400 MHz, DMSO- d 6 ) d 191 6-(1H-imidazole-1-yl)-N-(pyridine-3-yl)-4-(trifluoromethyl)picolinamide 334.0 10.77 (s, 1H), 9.15 (s, 1H), 9.02 (d, J = 2.4 Hz, 1H), 8.54 (s, 1H), 8.50 (s, 1H), 8.41 (dd, J = 4.7, 1.3 Hz, 1H), 8.29 - 8.23 (m, 2H), 7.48 (dd, J = 8.2, 4.7 Hz, 1H), 7.23 (s, 1H). 192 6-(1H-imidazole-1-yl)-N-(pyrimidine-5-yl)-4-(trifluoromethyl)picolinamide 335.0 10.93 (s, 1H), 9.26 (s, 2H), 9.15 (s, 1H), 9.03 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 8.27 (s, 1H), 7.24 (s, 1H).
[0468] Biological measurements and data
[0469] As described above, the compound represented by Formula I is a CD38 inhibitor and can be used to treat CD38-mediated diseases. The biological activity of the compound represented by Formula I can be determined using any suitable measurement to determine the activity of the candidate compound as a CD38 inhibitor.
[0470] CD38 hydrolase enzyme measurement
[0471] test compound
[0472] A dilution of the test compound was prepared by diluting it four times to the desired final concentration in test compound sucrose buffer (0.25 M sucrose, 40 mM tris base, pH 7.4). Additionally, a blank sample was prepared with 50 μl of sucrose buffer and contained no test compound. The CD38 inhibitor 78c (e.g., disclosed in J. Med. Chem. 2015, 58, 35483571) was used as a control for CD38 activity.
[0473] rhCD38 enzyme powder (10818-H08H, Sino Biological Inc) was stored in rhCD38 enzyme buffer (MES, 25 mM; NaCl, 150 mM) at 50 ng / μl at -80℃. A 2.5-fold rhCD38 enzyme working solution (0.125 ng / μl; BSA, 500 ng / μl) was prepared in sucrose buffer (0.25 M sucrose, 40 mM tris base, pH 7.4). A 2.5-fold substrate working solution (ε-NAD, N2630-25MG, Sigma-Aldrich, 125 μM) was also prepared in sucrose buffer (0.25 M sucrose, 40 mM tris base, pH 7.4).
[0474] The rhCD38 enzyme working solution prepared above was brought into contact with the solution of the test compound disclosed in the text or the control solution prepared above, and dynamic readings were performed on the enzyme marker at 25°C using 300 nm excitation light and 410 nm emission light. The recording of the readings was sustained for a total of 1 hour, and the data were analyzed with a point reading time of 20 min.
[0475] Fluorescence was recorded using a microplate reader. Individual Excel files containing the fluorescence data were produced, the results were plotted for various drug concentrations, and concentration curves were generated by analyzing them in GraphPad Prism 7.0.
[0476] Measurement data
[0477] IC50 from hCD38 enzyme inhibition to measure inhibitory action on hCD38 50 The data is shown in Table 1 below.
[0478] Table 1. In vitro inhibition of human CD38 enzyme compound hCD38 enzyme inhibition IC 50 (nM) 1 29 2 2706 3 >10000 4 40 5 895 6 >10000 7 >10000 8 >10000 9 >10000 10 725 11 32 12 >10000 13 >10000 14 202 15 8051 16 >10000 17 >10000 18 >10000 19 >10000 20 >10000 21 8 22 2755 23 45 24 30 26 46 27 842 28 22470 29 25 30 42 31 394 32 84 33 4079 34 3912 35 4 36 9754 37 348 38 456 39 225 40 96 41 13 42 11 43 106 44 87 45 >10000 46 536 47 38 48 51 49 70 50 >10000 51 9 52 55 53 36 54 6848 55 >10000 56 765 57 114 58 3558 59 >10000 60 17 61 15 62 4976 63 5428 64 >10000 65 17 66 1.7 67 >10000 68 190 69 111 70 >10000 71 73 72 16 73 218 74 4044 75 389 76 >10000 77 2451 78 >10000 79 2194 80 >10000 81 15 82 3 83 132 84 13 85 29 86 696 87 2 88 2 89 2 90 1 91 2 92 2 93 0.3 94 1 95 11 96 30 97 10 98 18 99 9 100 3429 101 17 102 >10000 103 28 104 26 105 20 106 18 107 21 108 24 109 12 110 12 111 2 112 20 113 49 114 5 115 43 116 >10000 117 >10000 121 8 123 5 124 3 125 2 127 2 130 149 135 36 137 >10000 138 76 141 1029 144 46 146 18 147 70 150 16 151 1555 152 >10000 153 >10000 154 >10000 157 49 158 37 159 34 160 317 161 831 162 >10000 163 92 164 4 165 3 166 5 167 4 168 4 169 20 170 13 171 9.8 172 8.2 173 6.8 174 5.4 175 68 176 20 177 38 178 17.3 179 585.7 180 11 181 25.4 182 9.6 183 28 184 28 185 2 186 2 187 2 188 10.7 189 12 190 2.8 191 3.8 192 6.1 193 11 194 30 195 /
[0479] Pharmacokinetics Research
[0480] To study drug-drug interactions, the compounds disclosed in the text were further studied in relation to CYP inhibition.
[0481] 0.1 M K-buffer (K / Mg-buffer) containing 5 mM MgCl2 was preheated to pH 7.4. The test compounds disclosed in the text and the reference inhibitor (2C19:0.99 μM) were serially diluted in a 96-well plate. 8 μL of the 10 mM test compounds were transferred to 12 μL of acetonitrile (ACN). Individual inhibitor spiking solutions of CYP 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, and 3A4 were prepared with 12 μL of ACN and 8 μL of DMSO stock solution. 1:2 serial dilutions of the DMSO:ACN mixture (v / v: 40:60) were prepared.
[0482] A NADPH cofactor (66.7 mg NADPH in 10 mL of 0.1 MK / Mg-buffer (pH 7.4)) was prepared. A substrate (2 mL of isotype sugar) was prepared (HLM was added over ice if necessary). A 0.2 mg / mL HLM solution was prepared (990 μL of 0.1 MK / Mg-buffer in 10 μL of 20 mg / mL). After adding 400 μL of 0.2 mg / mL HLM to the measurement well, 2 μL of the test compound set (serially diluted as above) was added to the designated well. After adding 200 μL of 0.2 mg / mL HLM to the measurement well, 1 μL of the serially diluted reference inhibitor solution prepared above was added to the designated well.
[0483] 30 μL of the 0.2 mg / mL HLM solution containing the test compound and reference compound prepared above, and 15 μL of the substrate solution prepared above were added to a 96-well measurement plate (twice) on ice. The 96-well measurement plate and the NADPH solution were pre-incubated at 37°C for 5 minutes. The reaction was initiated by adding 15 μL of preheated 8 mM NADPH solution to the measurement plate, and the plate was incubated at 37°C for: 5 minutes for 3A4; 10 minutes for 1A2, 2B6, and 2C9; 20 minutes for 2D6 and 2C8; and 45 minutes for 2C19. The reaction was stopped by adding 180 μL of IS-containing ACN. After quenching, the plate was shaken for 10 minutes (600 rpm / min) and centrifuged at 6000 rpm for 15 minutes. Finally, 80 μL of the supernatant from each well was transferred to a 96-well sample plate containing 120 μL of ultrapure water for further analysis.
[0484] According to CYP inhibition studies, the compounds disclosed in the text (where A3 is a substituted phenyl having one or two carbon atoms replaced by N (e.g., pyridinyl or pyrimidinyl)) were found to have no or very weak CYP inhibition, indicating that there is little to no drug-drug interaction.
[0485] It must be understood that if any prior art disclosed invention is mentioned in the text, it is not deemed an acknowledgment that said disclosed invention constitutes part of the common knowledge of the relevant field in all countries.
[0486] All disclosed inventions, patents, patent applications, and disclosed contents of published patent applications mentioned by identifying citation in the text are cited in their entirety by reference in the text.
[0487] Although the invention described above has been explained in detail through examples and illustrations for a clear understanding of the purpose, it is evident to those skilled in the art that some minor changes and modifications can be made. Therefore, the above description and examples should not be understood as limiting the scope of the invention.
Claims
Claim 1 As a compound represented by Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, or solvate thereof, In the above Equation I, A1 is and; where, A1 is unsubstituted or substituted with one or two methyl or trifluoromethyl groups; and A2 is and; where A2 is unsubstituted or substituted with one -CN, methyl, isopropyl, trifluoromethyl, methoxy, cyclobutoxy, oxetane-3-yloxy, -NH2, -NHCH3, or -N(CH3)2; and A3 is and; where A3 is unsubstituted or substituted with one or two substituents independently selected from the group consisting of -CN, -OCH2CH2OCH3, -COCH3, -F, -Cl, methyl, trifluoromethyl, hydroxyethoxy, carboxymethoxy, -OH, or methoxy; and R is H or C 1-6 Alkyl compound. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 A compound according to claim 1, characterized in that A2 is unsubstituted or substituted with trifluoromethyl. Claim 11 delete Claim 12 In paragraph 1, R is a compound of H. Claim 13 delete Claim 14 In paragraph 1, a compound selected from the following. Claim 15 delete Claim 16 A pharmaceutical composition comprising a compound according to any one of claims 1, 10, 12 and 14 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutical composition is used to treat a neurodegenerative disease selected from dementia, Alzheimer's disease (AD), and Parkinson's disease; a tumor selected from glioblastoma, lung cancer, colon cancer, liver cancer, breast cancer, gastric cancer, bladder cancer, and melanoma; an autoimmune disease selected from diabetes mellitus, rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE); and an inflammatory disease selected from asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and non-alcoholic fatty liver disease (NASH). Claim 17 delete Claim 18 delete Claim 19 delete Claim 20 delete Claim 21 delete Claim 22 delete
Citation Information
Patent Citations
Heterobicyclic amides as inhibitors of CD38
US20210032251A1
CD38 inhibitors
KR1020230051425A
Heteroaryl amide inhibitors of CD38
KR1020230106605A
Aryl hydrocarbon receptor antagonists and methods of use
WO2020051207A3
